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Introduction

Introduction 9
The etiology of cardiovascular disorders is complex and involves interaction of genetic, en-
vironmental, metabolic, and physiological factors. A small proportion of all cardiovascular 
cases results from rare single gene defects with strong effects on the phenotype. Biomedical 
research has been extremely successful in the genetic characterization of uncommon, mono-
genic cardiovascular disorders, thereby providing fundamental insights into the pathogen-
esis of cardiovascular disease (CVD). In 1985, Goldstein and Brown have been awarded the 
Nobel Prize for medicine for elucidating the molecular basis of familial hypercholesterolemia 
(FH).1
1.1 Familial hypercholesterolemia
FH is an autosomal dominant disorder of lipid metabolism caused by mutations in the gene 
coding for the low-density lipoprotein (LDL) receptor and leading to accelerated atheroscle-
rosis and CVD at young age.1 The LDL receptor is a transmembrane protein that regulates 
plasma cholesterol levels by uptake of LDL particles from the blood circulation (Figure 1). Mu-
tations in the LDL receptor gene cause insufficient removal of circulating LDL particles, which 
stimulates the hepatic cholesterol production, resulting in raised plasma LDL cholesterol 
Figure 1. A schematic overview of the LDL receptor cycle in the hepatocyte.
Ch
ap
te
r 1
10
concentrations. In the extremely rare (1/million) homozygous form of FH, the LDL receptor 
function is severely reduced or completely absent and plasma LDL cholesterol concentra-
tions up to 26 mmol/L have been reported. Homozygous FH patients develop tendon xan-
thomas in childhood and massive atherosclerosis occurs frequently at a very young age. The 
heterozygous form of FH is considerably more common, with a prevalence of 1/500 persons 
in Western societies. Heterozygous FH patients have partially reduced LDL receptor func-
tion, leading to two- to fourfold elevated plasma LDL cholesterol levels. However, substantial 
variation is seen in the onset of atherosclerotic disease symptoms and cardiovascular death 
among patients with heterozygous FH.2,3 After diagnosis, heterozygous patients are treated 
lifelong with inhibitors of β-hydroxy-β-methylglutaryl coenzyme A reductase (statins) to pre-
vent premature CVD.
1.2 Risk of cardiovascular disease in FH
Approximately 5% of all patients with premature coronary heart disease are heterozygous for 
mutations in the LDL receptor gene. In studies before the widespread use of statins, approxi-
mately 52-85% of male and 32-58% of female heterozygous FH patients had documented 
CVD by the age of 60.4,5 These frequencies are much lower in the present-day, statin-treated 
FH patients.6,7 Typically, the mean age of CVD onset in untreated males was between 40 and 
45 years and in females about ten years later. The burden of heterozygous FH, however, may 
have been preferentially studied in patients and families that presented themselves with 
premature symptoms of atherosclerosis. A mortality study in a large family-tree provided 
insight in the natural course of heterozygous FH, as the persons in the pedigree were not 
selected on the basis of clinical manifestations of FH.2 The excess mortality from untreated 
heterozygous FH varied largely over time and between branches of the pedigree. Mortality 
was not increased in the 19th and early 20th century, rose to a peak in the 1930s to 1960s, and 
decreased thereafter (Figure 2). Interestingly, the mortality of the FH pedigree in the 1800s 
was even lower than in the general population; hypercholesterolemia may have conferred 
a survival advantage when infectious diseases were more prevalent. In multiple pedigrees 
with untreated heterozygous FH patients, it was estimated that 40% of the patients had a 
normal life expectancy whereas 60% suffered from premature death.2,8 This emphasizes that 
this monogenic disorder has a complex burden, which is modified by other genes and envi-
ronmental factors.9
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1.3 Classical risk factors of cardiovascular disease in FH
Traditional cardiovascular risk factors account for most CVD cases in the general population,10 
but the influence of these factors in FH is less straightforward.11 In FH, higher age and male 
gender are also clearly associated with increased CVD susceptibility.12,13 In addition, raised 
levels of plasma high-density lipoprotein cholesterol were protective towards CVD in most 
FH studies.14,15 However, conflicting data were reported about the contribution of other well-
established cardiovascular risk factors such as smoking, diabetes, hypertension, and body 
mass index (BMI), partly due to small study samples.11-14,16-22 The effect of an increased concen-
tration of high-sensitivity C-reactive protein, fibrinogen, lipoprotein(a), and homocysteine on 
CVD risk in FH is still uncertain.11,12,14,18,20,23-31 Raised LDL cholesterol level is the hallmark of FH, 
but variation of plasma LDL cholesterol concentration among FH patients does not predict 
CVD.11,12,13,18,19,21,32
The GIRaFH-study (Genetic Identification of Risk Factors in Familial Hypercholesterolemia) 
provided extensive data on the influence of classical risk factors to the development of CVD 
in FH.33 A total of 2400 unrelated patients with FH, aged 18 years and older, were identified at 
lipid clinics throughout the Netherlands between 1989 and 2002. CVD was defined as coro-
nary, cerebral, and peripheral artery disease. Male gender, smoking, hypertension, diabetes 
mellitus, low HDL cholesterol concentrations, and elevated lipoprotein(a) levels were inde-
pendent predictors of an increased risk of CVD. These six risk factors explained 18.7% of the 
variation in CVD risk. Clearly, other still unknown and possibly genetic factors play a role in 
the development of CVD in FH patients. This thesis focuses on the influence of such genetic 
factors on susceptibility of CVD in individuals with heterozygous FH.
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Figure 2. Mortality from heterozygous FH in a large pedigree according to sex and throughout the ages.(2) SMR indicates standardized 
mortality ratio. The mortality in the pedigree was compared with the mortality in the Dutch population standardized for age, gender, and 
calendar period; the SMR = 1.0 for the Dutch population.
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1.4 LDL receptor mutations
The LDL receptor gene is located on chromosome 19 at 19p13.1-p13.3. More than 800 se-
quence variations have been identified in this gene and the residual LDL receptor activity 
varies considerably among the different mutations.34 LDL receptor mutations can be divided 
into six functional classes based on their phenotypic effects on the protein.35
•	 Class	1	mutations	do	not	synthesize	the	LDL	receptor	protein.
•	 Class	2	mutations	encode	LDL	receptor	protein	that	is	completely	(class	2A)	or	partially	
(class 2B) blocked in its transport between the endoplasmic reticulum and the Golgi 
complex.
•	 Class	3	mutations	produce	LDL	receptor	protein	that	is	effectively	transported	to	the	cell	
surface but does not properly bind with the LDL particles.
•	 Class	4	mutations	lead	to	LDL	receptor	protein	that	successfully	binds	the	LDL	particles,	
but fail to internalize the receptor-LDL complex.
•	 Class	5	mutations	cause	LDL	receptor	protein	that	 fails	to	release	the	 internalized	LDL	
particles in the endosome, a process that is essential for receptor recycling.
•	 Class	6	mutations	encode	rare	LDL	receptor	proteins	that	do	not	bind	properly	to	the	cell	
membrane and, consequently, are released from the cell.
Classes 1 and 2A mutations are referred to as receptor-negative mutations or null alleles, 
whereas classes 2B to 6 mutations are named receptor-defective mutations. Studies in adult 
FH patients that analyzed the genotype-phenotype relationship at the LDL receptor locus 
have yielded conflicting results.3,22,36-43 Selection on specific founder mutations, limited num-
bers of patients, different classifications of the LDL receptor mutation types, and interference 
of environmental factors can all account for these differences in outcome. In this thesis we 
assessed the influence of LDL receptor genotype on lipid concentrations, CVD risk, and re-
sponse to statin therapy in children with FH.
1.5 Candidate genes of cardiovascular disease in FH
A growing number of genetic variants have been implicated in the development of CVD.44 
These genetic markers are not necessarily the cause of the disorder, but may be useful to 
improve risk assessment. Alternatively, genetic markers may provide important clues to 
disease pathophysiology and, therefore, may suggest new opportunities for therapeutic 
intervention.
Candidate gene studies focus on selected genes; they have a specific hypothesis and the 
association between the candidate gene and CVD susceptibility is tested. The variation in 
genes consists mostly of single nucleotide polymorphisms (SNPs). Essentially, candidate SNPs 
are chosen based on combinations of: (a) prior likelihood of being functional, (b) association 
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of the SNP with an atherosclerosis-related phenotype, and (c) technological considerations 
including the availability of high-throughput and lower costs pre-selected SNPs.45 In addi-
tion, candidate gene studies are performed that use haplotypes (based on a set of SNPs that 
Table 1. Candidate genes of cardiovascular disorders in FH
Gene Polymorphism Risk variant N Freq. Phenotype Effect Ref.
ATP binding cassette A1 Arg219Lys K variant 374 0.29 CHD OR 0.63; p<0.05 (47)
Angiotensin-converting 
enzyme
insertion/deletion DD genotype 213 0.33 MI OR 2.57; p=0.02 (48)
CHD OR 2.21; p=0.02 (48)
D allele 112 0.55 CHD NS (49)
DD genotype 228 0.31 CHD NS (12)
Angiotensinogen Met235Thr T variant 112 0.25 CHD NS (49)
Angiotensin II type I 
receptor
A1166C C allele 112 - CHD OR 3.10; p=0.04 (49)
Apolipoprotein E E2/E3/E4 variants E4 allele 706 0.09 CVD NS (50)
E4 allele 236 - CHD NS (14)
E4 allele 93 0.09 CHD NS (51)
Estrogen receptor alpha Haplotype-analysis:
T–1989G GG genotype 295 0.17 CHD OR 4.5; p=0.04 (52)
Cholesteryl ester transfer 
protein
Taq1 RFLP B2/B2 genotype 300 0.20 CVD NS (53)
Lipoprotein lipase Asn291Ser NS+SS variants 1045 0.07 CVD OR 3.89; p=0.003 (54)
Asp9Asn DN+NN variants 2091 0.05 CVD OR 2.2; p=0.04 (55)
Methylenetetrahydro-
folate reductase
C677T TT genotype 199 0.11 age CHD p<0.05 (56)
TT genotype 249 24.5 CHD NS (57)
Paraoxonase1 Leu55Met LL variant 187 0.46 IMT NS (58)
LL variant 197 0.47 CVD NS (59)
Gln192Arg QQ variant 187 0.48 IMT NS (58)
QQ variant 197 0.48 CVD NS (59)
LL/QQ variant 187 - IMT p=0.002 (58)
Haplotype-analysis:
G-824A AA genotype 181 0.10 IMT p=0.03 (60)
Paraoxonase2 Cys311Ser CC+CS variants 197 0.37 CVD p=0.01 (59)
Platelet glycoprotein IIIa C1565T T allele 80 0.23 CHD NS (61)
Abbreviations: CHD, coronary heart disease; MI, myocardial infarction; CVD, cardiovascular disease; IMT, intima-media thickness carotid artery; 
NS, non-significant.
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occur together in the locus) to obtain more detailed information about the genetic variation 
of the locus in relation with CVD. SNP databases such as HAPMAP provide precognition about 
tagging SNPs for haplotyping the gene of interest for different ethnic populations.46
A variety of mostly small-scale single candidate gene association studies among FH popu-
lations have been published (Table 1).12,14,47-61 Bertolini and co-workers assessed the single 
and the combined effects of 11 SNPs in 8 candidate genes involved in lipid metabolism on 
coronary artery disease (CAD) in 221 unrelated FH index cases and 349 FH relatives.62 In these 
Italian FH patients, the fatty acid binding protein-2 54TT variant was an independent predic-
tor of increased CAD risk after adjustment was made for clinically relevant risk factors. The 
219RK and KK variants of the ATP binding cassette A1 were independently associated with 
decreased CAD.
Recently, the contribution to CVD risk of 65 polymorphisms in 36 candidate genes previ-
ously implicated in CVD via their influence on lipid metabolism, blood pressure regulation, 
coagulation and hemostasis, homocysteine metabolism, endothelial function, cell adhesion, 
inflammation, and plaque stability have been tested in the GIRaFH study.63 In 1940 patients 
(80.1%) complete genotypes for all 65 polymorphisms could be obtained. The G20210A 
polymorphism in the prothrombin gene was strongly associated with an increased CVD risk 
(GA versus GG; p<0.001). Furthermore, the Met235Thr variant of angiotensinogen and the 
Thr347Ser variant of apolipoprotein A4 were associated with increased CVD risk, whereas 
the Ser311Cys variant of paraoxonase-2 and the C1100T variant of apolipoprotein C3 were 
associated with decreased CVD risk (P<0.05). In this thesis we investigated the role of three 
additional candidate genes on CVD susceptibility in this large cohort of FH patients.
1.6 Aims and outline of this thesis
Despite the monogenic background of heterozygous FH, the CVD “penetrance” varies enor-
mously, depending only partially on the well-known classical risk factors. The principal aim 
of the studies described in this thesis is to investigate genetic factors that could potentially 
enhance the ability of clinicians to identify FH individuals with severely increased CVD risk, 
who will most likely benefit from targeted therapeutic intervention.
First, we examined the role of variations at the LDL receptor locus. Since LDL receptor 
genotype-phenotype analyses in adult FH patients have revealed conflicting results, we per-
formed our analyses in children with FH. FH children might be better subjects to analyze the 
exact effects of LDL receptor genotypes, because they share a more homogeneous environ-
ment and do not yet have additional lipid disorders. We tested this hypothesis and assessed 
the relationship between the type of LDL receptor mutation and plasma lipid concentrations 
in FH children and the relation with the occurrence of CVD risk in the parents of these chil-
dren. The LDL receptor genotype has also been implicated in the response to statin therapy. 
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After diagnosis, all FH patients are treated with statins but the response shows considerable 
interindividual variation. In this thesis, we studied whether LDL receptor genotype influenced 
the response to statin treatment in children with FH.
The monogenetic background but large variation in CVD risk determines that FH is an ex-
emplary model to analyze candidate genes involved in CVD. In the second part of this thesis, 
we investigated the effect of three candidate genes of CVD based on the correlation with 
an atherosclerosis-related phenotype (complement factor H gene) or their reported associa-
tion with cardiovascular risk factors (adenosine triphosphate binding cassette G8 gene and 
glucocorticoid receptor gene). In the general discussion, the main findings of the studies pre-
sented in this thesis are summarized briefly. In addition, the limitations and potential pitfalls 
when conducting genetic association studies in FH and developing individual prognostic 
models are discussed and directions for future research are provided.
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Abstract
Studies on the clinical consequences of different low-density lipoprotein (LDL) receptor 
genotypes in adult patients have yielded conflicting results. We hypothesized that children 
with familial hypercholesterolemia (FH) provide a better model to perform genotype-phe-
notype analyses than adults. We tested this hypothesis and assessed the effect of LDL recep-
tor genotypes on lipoprotein levels and on parental risk of cardiovascular disease (CVD) in a 
pediatric FH cohort. We identified 75 different LDL receptor mutations in 645 children with 
heterozygous FH; in these children, null alleles were clearly associated with more elevated 
LDL cholesterol levels compared to receptor-defective mutations. Familial factors explained 
50.4% of the variation in LDL cholesterol levels of this pediatric cohort compared to only 9.5% 
in adults. Parental CVD risk was not significantly different between carriers of null alleles and 
receptor-defective mutations (RR, 1.22; 95% CI, 0.76 to 1.95; p=0.4). The N543H/2393del9 mu-
tation was associated with a less deteriorated lipid profile and the parents had less often CVD 
relative to parents with other mutations (RR, 0.39; 95% CI, 0.20 to 0.78; p=0.008). We could 
confirm that children with FH provide a better model to perform genotype-phenotype analy-
ses. In particular, children with null alleles had significantly more elevated LDL cholesterol 
levels than carriers of other alleles but this was not associated with higher risk of CVD in the 
parents. Nonetheless, a specific LDL receptor mutation was associated with less deteriorated 
lipoprotein levels and a milder CVD risk.
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Introduction
Familial hypercholesterolemia (FH) is a common disorder caused by mutations in the low-
density lipoprotein (LDL) receptor gene. FH is characterized by elevated plasma LDL cho-
lesterol (LDL-C) levels, tendinous xanthomas, and premature cardiovascular disease (CVD).1 
Despite the monogenic nature of the disorder, heterozygous FH shows large variability in 
phenotypic expression related to both environmental and genetic factors.2 At present, more 
than 800 sequence variations in the LDL receptor gene have been identified and the residual 
LDL receptor activity varies considerably between mutations.3-4
Previous studies in adult heterozygous FH patients have assessed whether the residual 
LDL receptor function influenced lipoprotein metabolism and, consequently, cardiovascular 
risk. These studies have yielded conflicting results.5-14 Additional familial factors were pro-
posed to have greater influence on the clinical consequences of FH.2,15 In effect, it is not clear 
whether variance of lipoprotein levels and CVD risk could be attributed to variation at the 
LDL receptor locus or to additional familial factors. For instance, adult FH patients referred 
to lipid clinics often suffered from additional lipid disorders.16 Such additional lipid disorders 
are not yet expressed in childhood. Therefore, FH children might be more suited to analyze 
the exact effects of LDL receptor genotypes. Moreover, selection of FH children is not based 
on additional CVD risk factors.
The purposes of this study were (1) to test the hypothesis that children with FH provide 
a better model to perform genotype-phenotype analysis than adults and (2) to assess the 
assumed relationship between LDL receptor genotypes and lipoproteins in a large pediatric 
cohort and their relation with the occurrence of parental CVD.
Methods
Study populations
Our pediatric FH cohort consists of 851 children with FH who were referred consecutively to 
our pediatric Lipid Clinic between July 1989 and January 2003. The general characteristics of 
this pediatric cohort have been previously published.17 At present, in our ongoing molecular 
screening program, a LDL receptor mutation was identified in 655 children. In 8 children, we 
found apolipoprotein B mutations and they were excluded from the analyses, as were 2 chil-
dren with homozygous FH. We performed the lipoprotein analyses in 593 heterozygous FH 
children after exclusion of 52 children on lipid lowering medication. The selection procedure 
is shown in the flow chart of Figure 1. We analyzed the parental risk of CVD in 436 affected 
parents of index children (the first child of a sibship that visited our lipid clinic). The pres-
ence of CVD in the parents was documented and defined as: (1) angina pectoris confirmed 
with electrocardiographic exercise testing, (2) ≥ 70% stenosis on coronary angiography, (3) 
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myocardial infarction assessed by electrocardiography, or a deep and wide Q-wave as an 
electrocardiographic manifestation of an old infarction, or CPK-MB monitoring during the 
acute phase, (4) coronary bypass or percutaneous transluminal coronary angiography, or 
(5) stroke. CVD before the age of 60 years was considered premature CVD. The Institutional 
Review Board approved the study protocol, and informed consent was obtained from all 
children and parents.
The adult FH cohort from our national genetic testing program for FH has been described 
in detail and we presented genotype-phenotype data elsewhere.8 In brief, we studied 399 
untreated adult patients with an identified LDL receptor mutation after exclusion of all 66 
index patients. Their mean age was 31.1 (± (SEM) 0.90) years, mean LDL-C was 5.65 (± 0.07) 
mmol/l, mean high-density lipoprotein cholesterol (HDL-C) was 1.06 (± 0.33), mean triglyc-
erides (TG) was 1.49 (± 0.05), and 16.0 (± 4.0) % had CVD. In the present study, this adult 
FH cohort was used to calculate the sharing of familial factors among adult relatives (see 
statistical analysis).
Type of LDL receptor mutation
We compared lipid profiles between carriers of different types of mutations. Mutations can 
be divided into six functional classes based on their phenotypic effects on the protein. The 
mutation groups for our primary analyses were based on their functional class as reported 
in the literature: (1) the receptor-negative mutations or null alleles group contained all class 
total FH children
n=851
genetically confirmed FH
n=655
heterozygous FH
n=645
FH without medication
n=593
excluding n=196 without LDL receptor mutations
excluding n=10 with apolipoprotein B mutations or homozygous FH
excluding n=52 using lipid lowering medication
Chapter 2_figure 1
Figure 1. Flow chart of the selection procedure for the pediatric FH cohort.
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1 mutations, class 2A mutations, early stop-codons, and nonsense mutations, although the 
latter had often undetermined residual function; (2) the receptor-defective mutations group 
contained class 2B to 6 mutations; (3) the undetermined-receptor-activity mutations group 
contained all remaining mutations with undetermined mutational class. Secondary analyses 
were performed on seven mutations, frequently identified among the children.
Laboratory methods
Fasting plasma concentrations of total cholesterol (TC), TG, and HDL-C were measured using 
commercially available kids (Boehringer, Mannheim, Germany). LDL-C concentrations were 
calculated by the Friedewald formula.18 All children had plasma TG concentrations below 
4.5 mmol/L (398 mg/dL). Apolipoprotein A1 and apolipoprotein B100 were determined on 
a Behring nephelometer, BN 100 (Behring, Marburg, Germany). Lipoprotein (a) [Lp(a)] con-
centrations were measured using the Apo-Tek ELISA (Organon Teknika, Rockville MD, USA). 
Mutational analyses were performed with the use of polymerase chain reaction and restric-
tion enzyme analysis as described previously.19
Statistical analysis
All data were analyzed using SPSS software (version 11.5, SPSS). In a linear mixed model, we 
calculated the intra-class correlations (i.e. the variance in LDL-C levels introduced by familial 
factors) in the pediatric and the adult FH cohort. In the pediatric FH cohort, we compared 
continuous data among specific LDL receptor mutations with one-way ANOVA. Statistical 
testing of TG and Lp(a) levels was performed after logarithmic transformation. We also per-
formed analyses of the lipoproteins restricted to 398 index children without lipid lowering 
medication. Moreover, a sibpair analysis was performed to compare each index child with one 
sibling using the paired t-test. A total of 127 sibships consisted of two children, the remaining 
30 sibships contained at least three children. In the latter, one affected sibling was randomly 
selected for the sibpair analysis. The effect of the nature of the mutation on lipoproteins was 
estimated in a linear mixed model including random familial effects and adjusted for age and 
gender. A total of 239 children were unrelated. The remaining 354 children were brothers 
and sisters and 72 of these sibships were also related in 35 pedigrees. Therefore, we made 
separate categorical variables for sibship and pedigree to adjust for family ties. In effect, we 
adjusted for first degree and higher degree relative.
In an affected-offspring model, we directly compared the parental risk of CVD in carriers 
of null alleles, receptor-defective mutations, and the N543H/2393del9 mutation with Cox 
regression and cumulative event-free survival was analyzed with the Kaplan-Meier method. 
The parental date of birth was used in the Cox regression to adjust for differences in life 
expectancy over calendar periods and adjustment for parental gender and family was made. 
Statistical significance was assessed at the 5% level of probability.
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Results
Additional familial factors
In a linear mixed model, familial factors (intra-class correlation) explained 50.4% of the vari-
ance in LDL-C levels among the FH children. In the adult FH cohort, only 9.5% of the variance 
in LDL-C levels could be explained by familial factors. Table 1 shows the model in both the 
pediatric patients and the adult FH cohort: the LDL-C levels showed a much stronger correla-
tion among related children than in adult siblings.
Table 1. LDL cholesterol levels explained by determinants and familial factors in a mixed linear model
Determinant Effect on LDL-C
FH adults FH children
mmol/L (± 95% CI) mmol/L ± (95% CI)
Mean age 0.25 (-0.18 to 0.67) -0.39 (-0.73 to -0.06)
Male gender -0.16 (-0.46 to 0.14) -0.43 (-0.64 to -0.22)
Null allele 0.51 (-0.21 to 1.23) 1.13 (0.83 to 1.43)
Unexplained 5.69 (5.14 to 6.24) 5.91 (5.50 to 6.31)
Variance explained by
familial factors*
9.5% 50.4%
FH=familial hypercholesterolemia, LDL-C=low-density lipoprotein cholesterol.
* intra-class correlation
LDL receptor gene mutations in FH children
The identified LDL receptor gene mutations are listed in Table 2. A total of 75 different muta-
tions were detected in 645 children with heterozygous FH from 383 apparently unrelated 
families. We found 19 null alleles in 186 children, 26 receptor-defective mutations in 372 
children, and 30 mutations with undetermined residual function in 87 children. Seven LDL 
receptor mutations were discovered in substantial numbers of children: the double mutation 
N543H/2393del9 was found in 141 children; two splice site defects at positions 1359-1 and 
313+1/2 were detected in 106 and 64 children, respectively; the deletion of 2,5 kb at exon 7 
and 8 is a large rearrangement and was found in 26 children; two missense mutations, V408M 
and E207K, were present in 38 and 31 children, respectively; and the W23X nonsense muta-
tion was found in 28 children.
Lipoproteins
A total of 52 FH children were on lipid lowering medication and were excluded from the 
lipoprotein analyses. The characteristics and lipid profiles according to the type of LDL re-
ceptor mutation of the remaining 593 FH children are presented in Table 3. The mean age 
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Table 2. LDL receptor gene mutations in heterozygous FH children
Location Mutation Effect Type Ref. Activity Class Receptor 
protein
n
Exon 1 M-21V Translation initiation signal deleted missense [19] <2% 1 negative 4
M-21L Translation initiation signal deleted missense [21] 1 negative 4
Exon 2 W23X Trp→stop at 23 missense [19] 2-5% 1 negative 28
A29S Ala→Ser at 29 missense [19] 3-6 defective 2
Intron 2 191-2 3’-splice acceptor signal splicing [19] unknown 10
Exon 3 R60C Arg→Cys at 60 missense [19] unknown 1
Intron 3 313+1/2 5’-splice donor signal splicing [19] 2-5% 2 defective 64
314-1 3’-splice acceptor signal splicing [19] unknown 3
Exon 4 C134G Cys→Gly at 134 missense [4] 15-30% 2B defective 1
C146X Cys→stop at 146 nonsense [4] 1 negative 11
C152W Cys→Trp at 519 missense [19] 2B defective 2
C163R Cys→Arg at 163 missense [19] unknown 15
646delTG Stop at 195 frameshift [19] negative 1
653delGGT Gly at 197 deleted frameshift [19] <2% 2B defective 3
D200G Asp→Gly at 200 missense [4] <2% 2B defective 1
C201X Cys→stop at 201 nonsense [3] 1 negative 1
D203V Asp→Val at 203 missense [19] unknown 2
D206E Asp→Glu at 206 missense [19] 5-15% 2B defective 1
E207K Glu→Lys at 207 missense [4] <2% 2B defective 31
Exon 5 E219X Glu→stop at 219 nonsense Novel 1 negative 2
C234R Cys→Arg at 234 missense [19] unknown 1
D245E Asp→Glu at 245 missense [4] 15-30% 2B defective 1
C249X Cys→stop at 249 nonsense Novel 1 negative 1
Exon 6 K273E Lys→Glu at 273 missense [19] unknown 1
S285L Ser→Leu at 285 missense [19] 2-5% 2B defective 15
C292Y Cys→Tyr at 292 missense [19] unknown 2
Exon 7 G314V Gly→Val at 314 missense [19] unknown 3
C317G Cys→Gly at 317 missense [19] 2B defective 2
G322S Gly→Ser at 322 missense [4] 15-30% 2B/5 defective 1
R329X Arg→stop at 329 nonsense [19] 1 negative 6
C331W Cys→Trp at 331 missense [19] 9% unknown 1
Intron 7 1061-8 3’-splice acceptor signal splicing [19] unknown 2
D333G Asp→Gly at 333 missense [4] 15-30% 2B/5 defective 4
Exon 8 I334V Ile→Val at 334 missense [19] unknown 1
E336K Glu→Lys at 336 missense [4] 2B/5 defective 1
C356Y Gly→Tyr at 356 missense [19] unknown 1
C371X Cys→stop at 371 nonsense [19] 1 negative 7
Exon 9 A378D Ala→Asp at 378 missense [19] 3-6 defective 3
R395W Arg→Trp at 395 missense [19] unknown 2
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Location Mutation Effect Type Ref. Activity Class Receptor 
protein
n
N407K Asn→Lys at 407 missense [19] unknown 1
V408M Val→Met at 408 missense [4] <2% 5 defective 38
A410T Ala→Thr at 410 missense [19] 5-15% 3-6 defective 4
D412Y Asp→Tyr at 412 missense [19] unknown 3
V415A Val→Ala at 415 missense [19] 3-6 defective 3
W422C Trp→Cys at 422 missense [19] 5-15% 3-6 defective 1
I430T Ile→Thr at 430 missense [19] unknown 1
Intron 9 1358+1 5’-splice donor signal splicing [19] 1 negative 3
1359-1 3’-splice acceptor signal splicing [19] 1 negative 106
Exon 10 W462R Trp→Arg at 462 missense [20] 2B/5 defective 1
1480del121bp Stop at 486 frameshift Novel negative 4
1486delGG Stop at 513 frameshift [19] negative 2
Exon 11 G525V Gly→Val at 525 missense Novel unknown 2
G528D Gly→Asp at 528 missense [4] <2% 2A negative 2
Exon 12 W556R Trp→Arg at 556 missense [19] unknown 1
1759delA Stop at 643 frameshift [19] negative 1
G571E Gly→Glu at 571 missense [4] 5-15% 5 defective 6
I577L Ile→Leu at 577 missense [19] unknown 1
L590F Leu→Phe at 590 missense [19] 2A negative 1
Exon 13 R612C Arg→Cys at 612 missense [19] 3-6 defective 1
Exon 14 2032del12 Del Gln-Tyr-Leu-Cys at 657-660 frameshift [19] unknown 4
P664L Pro→Leu at 664 missense [4] 15-30% 2B defective 17
P664T Pro→Thr at 664 missense [19] unknown 1
C690S Cys→Ser at 690 missense [19] unknown 3
Exon 15 2204ins13 Stop at 715 frameshift Novel negative 1
Exon 16 2343del5 Stop at 765 frameshift [19] negative 2
Intron 16 2389+1 5’-splice donor signal splicing [19] unknown 4
2390-2 3’-splice acceptor signal splicing [19] unknown 2
Exon 17 2411insG Stop at 795 frameshift [19] negative 2
V806I Val→Ile at 806 missense [4] 15-30% 4A defective 3
Double 
Mutation
K290R/
C292W
Lys→Arg at 290/
Cys→ Trp at 292
missense [19] unknown 3
N543H/
2393del9bp
Asn→ His at 543/
Del Leu-Val-Phe at 778-780
missense [19] 25% 2B defective 141
Large rearrangements Deletion of 2.5kb [4] 2-5% 3&5 defective 26
Insertion of 10kb [19] unknown 9
Insertion of 4,4kb [19] unknown 2
Insertion of 4kb Novel unknown 1
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was 10.6 years in the three groups. The 172 children with null alleles had significantly more 
elevated mean LDL-C levels (difference (± SEM), 1.16 ± 0.13 mmol/L; p<0.001) and higher 
mean TG levels (difference, 0.08 ± 0.04 mmol/L; p=0.03) compared to the 341 children with 
receptor-defective mutations. The carriers of mutations with undetermined receptor activity 
had intermediate LDL-C and TG levels. Mean HDL-C levels were similar in the three groups.
An analysis restricted to index children showed similar relations between lipoproteins and 
LDL receptor genotype (data not shown). A sibpair analysis showed no statistical difference 
in terms of characteristics or lipoprotein levels between index children and affected siblings: 
the mean difference in LDL-C was 0.02 ± 0.11 mmol/L; p=0.9. In Figure 2, a comparison of the 
mean LDL-C levels is shown between the mutation types and between the seven specific 
mutations adjusted for age, gender, and family ties. The mean LDL-C level in carriers of null 
alleles was 6.44 ± 0.22 mmol/L, significantly more elevated than the 5.31 ± 0.37 mmol/L in the 
carriers of receptor-defective mutations (p<0.001).
Table 4 shows lipid profiles of the seven most frequent mutations. Carriers of the 
N543H/2393del9 mutation had significantly less increased mean LDL-C levels (difference, 
1.76 ± 0.12 mmol/L; p<0.001) and mean TG levels (difference, 0.14 ± 0.04 mmol/L; p<0.001) 
and showed a tendency towards higher HDL-C levels (difference, 0.08 ± 0.03 mmol/L; p=0.09) 
compared to carriers of other mutations. In line with our unadjusted results, the carriers of the 
N543H/2393del9 mutation had significantly less increased mean LDL-C levels compared with 
Table 3. Characteristics of FH children with null alleles, receptor-defective mutations, and mutations with undetermined receptor activity
Parameter Undetermined receptor 
activity
Null alleles* Receptor-defective 
mutations
p-value†
(n=80) (n=172) (n=341)
Age, y (range) 10.4 (3.0-18.5) 10.6 (1.4-19.9) 10.6 (1.4-19.3) 1.0
Gender, m / f 38 / 42 79 / 93 170 / 171 0.4
TC (mmol/L) 7.82 ± 0.17 8.04 ± 0.11 6.86 ± 0.08 <0.001
LDL-C (mmol/L) 6.27 ± 0.16 6.40 ± 0.11 5.23 ± 0.07 <0.001
HDL-C (mmol/L) 1.21 ± 0.03 1.26 ± 0.02 1.29 ± 0.02 0.7‡
TC/HDL-C 6.65 ± 0.18 6.65 ± 0.15 5.57 ± 0.09 <0.001
TG (mmol/L) 0.73 ± 0.04 0.82 ± 0.03 0.74 ± 0.02 0.03§
Apo A-I (g/L) 1.23 ± 0.03 1.26 ± 0.02 1.26 ± 0.01 1.0
Apo B100 (g/L) 1.77 ± 0.05 1.75 ± 0.03 1.47 ± 0.02 <0.001
Lipoprotein (a) (mg/L) 184 ± 26 196 ± 19 184 ± 12 0.6§
TC=total cholesterol, LDL=low-density lipoprotein, HDL=high-density lipoprotein, Apo A-I=apolipoprotein A-I, Apo B100=apolipoprotein 
B100, TG=triglyceride, values are given as means ± standard error of the mean (SEM). We observed similar distributions of smoking, BMI, and 
stigmata (data not shown) in the three mutational groups.
*The 5 nonsense mutations that were classified as null alleles had similar distributions of baseline characteristics compared with receptor-
negative mutations (data not shown).
†Comparison between null alleles and receptor-defective mutations.
‡Statistical analysis adjusted for individual serum triglyceride levels did not change the result (data not shown).
§Statistical testing after logarithmic transformation.
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carriers of other alleles (4.49 ± 0.37 mmol/L versus 6.17 ± 0.22 mmol/L; p<0.001). Moreover, 
carriers of the two null alleles, 1359-1 and W23X, had significantly more elevated mean LDL-C 
levels relative to other mutations (6.27 ± 0.44 mmol/L versus 5.42 ± 0.24 mmol/L; p<0.001 
and 6.46 ± 0.57 mmol/L versus 5.55 ± 0.25 mmol/L; p=0.006, respectively). We compared 
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Figure 2. Mean LDL-C according to type of LDL receptor mutations adjusted for age and gender.
* Significant (p<0.001) difference between carriers of the N543H/2393del9 mutation and carriers of other mutations
** Significant (p<0.001) difference between carriers of null alleles and receptor-defective mutations with and without the N543H/2393del9 
mutation
Table 4. Characteristics of 7 most frequent mutations
Parameter N543H/ 
2393del9
313+1/2 V408M E207K 2,5 kb 
deletion
1359-1 W23X p-value*
defective
(n=139)
defective
(n=53)
defective
(n=35)
defective
(n=27)
defective
(n=22)
null allele
(n=100)
null allele
(n=28)
Age, y (range) 10.4
(1.4-19.3)
11.0
(4.5-17.9)
11.7
(2.0-16.6)
10.0
(4.1-18.0)
10.2
(2.5-18.0)
10.5
(1.4-19.9)
11.3
(3.2-18.0)
0.4
Gender, m /f 81 / 58 21 / 32 18 / 17 13 / 14 6 / 16 50 / 50 10 / 18 0.009
TC (mmol/L) 6.04 ± 0.09 7.55 ± 0.19 7.46 ± 0.20 7.73 ± 0.23 8.14 ± 0.33 7.82 ± 0.15 8.24 ± 0.25 <0.001
LDL-C (mmol/L) 4.41 ± 0.08 5.90 ± 0.18 5.94 ± 0.19 6.17 ± 0.22 6.54 ± 0.30 6.21 ± 0.15 6.51 ± 0.26 <0.001
HDL-C (mmol/L) 1.33 ± 0.02 1.30 ± 0.04 1.17 ± 0.05 1.24 ± 0.05 1.17 ± 0.04 1.26 ± 0.03 1.27 ± 0.04 0.09†
TC/HDL-C 4.73 ± 0.10 6.02 ± 0.20 6.70 ± 0.28 6.55 ± 0.37 7.10 ± 0.33 6.47 ± 0.19 6.76 ± 0.34 <0.001
TG (mmol/L) 0.66 ± 0.03 0.76 ± 0.05 0.79 ± 0.06 0.76 ± 0.07 0.98 ± 0.12 0.78 ± 0.04 0.94 ± 0.09 <0.001‡
Apo A-I (g/L) 1.28 ± 0.02 1.25 ± 0.03 1.20 ± 0.04 1.22 ± 0.02 1.23 ± 0.04 1.24 ± 0.02 1.31 ± 0.03 0.08†
Apo B100 (g/L) 1.23 ± 0.02 1.68 ± 0.05 1.71 ± 0.05 1.70 ± 0.07 1.84 ± 0.08 1.70 ± 0.05 1.85 ± 0.09 <0.001
Lipoprotein (a) 
(mg/L)
185 ± 18 147 ± 25 208 ± 42 165 ± 48 227 ± 40 160 ± 21 210 ± 40 0.4‡
TC=total cholesterol, LDL=low-density lipoprotein, HDL=high-density lipoprotein, Apo A-I=apolipoprotein A-I, Apo B100=apolipoprotein 
B100, TG=triglyceride, values are given as means ± standard error of the mean (SEM).
*Comparison between N543H/2393del9 mutation and other mutations.
†Statistical analysis after additional adjusted for individual serum triglyceride (data not shown).
‡Statistical testing after logarithmic transformation.
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the lipoproteins between null alleles and receptor-defective mutations after exclusion of 
the carriers of the N543H/2393del9 mutation (Table 5). Nonetheless, the difference in mean 
LDL-C levels between null alleles and receptor-defective mutations remained significant (dif-
ference, 0.60 ± 0.14 mmol/L; p<0.001). In fact, after adjustment for age, gender, and specific 
family ties, mean LDL-C levels were 6.44 ± 0.24 mmol/L and 5.82 ± 0.40 mmol/L for null alleles 
and receptor-defective mutations, respectively (p<0.001).
Parental history of CVD
We restricted the analyses of the relation between the nature of the mutation and parental 
history of premature CVD to 436 index children with FH. The number of events in FH parents 
was 38 in 5341 person years for null alleles, 44 in 6519 person years for receptor-defective 
mutations (N534H/2393del9 mutation excluded), 24 in 2651 person years for mutations with 
undetermined residual function, and 12 in 3852 person years for the N534H/2393del9 muta-
tion. After exclusion of the carriers of the N534H/2393del9 mutation, the CVD risk was 1.22 of 
parents with null alleles relative to receptor-defective mutations (95% CI, 0.76 to 1.95; p=0.4). 
Strikingly, parents with the N543H/2393del9 mutation had significantly less often CVD than 
the parents with other mutations (RR, 0.39; 95% CI, 0.20 to 0.78; p=0.008). In figure 3, the 
Kaplan-Meier curves show the CVD free survival of parents with null alleles, receptor-defec-
tive mutations, and the N534H/del2393del9 mutation, respectively. CVD free survival was 
significant better in the N543H/2393del9 mutation compared with null alleles and receptor-
negative mutations (log rank test, p=0.02).
Table 5. Null alleles versus receptor-defective mutations without the N543H/2393del9 mutation
Parameter Null alleles Receptor-defective mutations p-value
(n=172) (n=202)
Age, y (range) 10.6 (1.4-19.9) 10.8 (2.0-18.0) 0.7
Gender, m / f 79 / 93 89 / 113 0.7
TC (mmol/L) 8.04 ± 0.11 7.43 ± 0.10 <0.001
LDL-C (mmol/L) 6.40 ± 0.11 5.80 ± 0.09 <0.001
HDL-C (mmol/L) 1.26 ± 0.02 1.27 ± 0.02 1.0*
TC/HDL-C 6.65 ± 0.15 6.14 ± 0.12 0.007
TG (mmol/L) 0.82 ± 0.03 0.80 ± 0.03 0.6†
Apo A-I (g/L) 1.26 ± 0.01 1.25 ± 0.01 0.5
Apo B100 (g/L) 1.75 ± 0.03 1.64 ± 0.03 0.01
Lipoprotein (a) (mg/L) 196 ± 19 182 ± 15 0.5†
TC=total cholesterol, LDL=low-density lipoprotein, HDL=high-density lipoprotein, Apo A-I=apolipoprotein A-I, Apo B100=apolipoprotein 
B100, TG=triglyceride, values are given as means ± standard error of the mean (SEM).
*Adjustment for individual serum triglyceride levels did not change the result (data not shown).
†Statistical testing after logarithmic transformation.
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Discussion
In the present study, we could confirm that FH children provide a better model than adults to 
analyze the relation between the type of LDL receptor mutation and lipoproteins: the LDL-C 
levels among related FH children were strongly correlated compared to a relative weak cor-
relation among adult relatives with the disorder. Likely, children refrain from unfavorable life-
styles and share their environment to a greater extent than related adults.20 The consequenc-
es of LDL receptor genotypes could, therefore, be estimated against a more homogeneous 
background in our pediatric FH cohort. A similar analysis has been reported in genetically 
confirmed FH children, but these children were selected on specific founder mutations.21
In line with most reports, we found that carriers of null alleles had significantly more el-
evated LDL-C levels than carriers of receptor-defective mutations.5-7,9,10,13 In an adult FH co-
hort, we recently observed no difference of LDL-C levels between carriers of null alleles and 
other alleles after exclusion of families with the N543H/2393del9 mutation.8 Exclusion of car-
riers with this mutation, however, did not change the results in our pediatric FH cohort. The 
analyses of lipoprotein levels were performed before the potential onset of additional lipid 
disorders in the children. Such lipid disorders may have influenced our and other analyses in 
adults. Moreover, the present results are in agreement with the only other study in FH chil-
dren that showed significantly lower LDL-C levels in carriers of a receptor-defective mutation 
compared to carriers of two null alleles.21
Contrary to some previous studies, we found no significant differences in CVD risk between 
null and other alleles.5,10-12 The present results are, however, in line with our findings among 
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Figure 3. Kaplan-Meier curves for CVD free survival among parents with different types of LDL receptor mutations. CVD free survival was 
significant better in the N543H/2393del9 mutation compared with null alleles and receptor-negative mutations (log rank test; p=0.02).
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FH adults: in a family study, we excluded all probands to avoid selection on CVD and found 
no difference in CVD risk between carriers of null alleles and other alleles.8 The results of the 
latter studies and two recent mortality studies suggest that additional factors are of greater 
relevance towards the burden of FH than heterogeneity at the LDL receptor locus.2,8,15 Instead 
of further genotype-phenotype analyses, research in FH patients should better focus on the 
identification of these additional risk factors.
The type of mutation did not significantly contribute to variation of CVD risk, but carriers 
of a specific mutation had clearly less increased CVD risk. This N543H/2393del9 mutation is 
a combination of a missense mutation in exon 11 and a deletion of 9 base pairs in exon 17 
linked on the same allele. This allelic combination of mutations reduces the LDL-C uptake by 
75%, suggesting a defect in transport of LDL receptor.22 Recently, we have found in the larger 
group of children with clinical FH that more severely increased LDL-C levels could identify 
the FH children from families at highest risk for CVD.17 In particular, FH children with LDL-C 
levels equal to or above 6.23 mmol/L were 1.7 times more likely to have a parent with FH with 
premature onset of CVD than those with LDL-C levels below 6.23 mmol/L. In this latter study, 
however, the difference in parental CVD risk could be due to the selection of children with 
the N543H/2393del9 mutation. Our present genotype-phenotype analysis was performed in 
a subselection from this earlier report and only 4.3% of the children with this specific muta-
tion had a LDL-C level equal to or above 6.23 mmol/L compared to 44.5% in children with 
other LDL receptor mutations. Therefore, our earlier finding on the LDL-C levels may be based 
on the presence of this specific mutation.17 This finding of relative mild FH in carriers of the 
N543H/2393del9 mutation is in agreement with observations in Spanish FH patients carrying 
the same mutation.23
Limitations of genotype-phenotype analyses in FH include the relatively large group of 
mutations with unknown functional class and residual receptor function. We divided the 
mutations into a null alleles group, a receptor-defective group, and a remaining group with 
undetermined mutational class. These groups were based on the functional class or specific 
properties of a mutation as reported in the literature. This classification has been used in 
several other studies and has resulted in well-defined groups. However, a disadvantage is 
that we excluded a relatively large group of mutations with undetermined receptor function 
from the analyses.
In summary, we conclude that FH children provide a better model to analyze the effects of 
LDL receptor genotypes on the lipid profile than adults. The specific N543H/2393del9 muta-
tion associates with a milder lipid phenotype and less increased parental CVD risk compared 
to other mutations. However, the variation in lipid profile poorly explains the differences in 
CVD risk in carriers of other mutations. Therefore, future research in FH patients should focus 
on the identification of additional risk factors in the pathogenesis of CVD.
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Abstract
Background: The lipid lowering effects of statin therapy show considerable interindividual 
variation in patients with familial hypercholesterolemia (FH). Whether or not the type of low-
density lipoprotein (LDL) receptor mutation predicts the response to statin treatment is not 
yet established. We analyzed the relationship between LDL receptor genotype and response 
to pravastatin treatment in children with FH using carotid intima-media thickness (IMT) to 
measure efficacy.
Methods and Results: In a randomized, placebo-controlled, double-blind, two-year trial with 
pravastatin, 193 children had genetically confirmed FH and were included in the present sub-
study. At baseline, children with null alleles had higher LDL cholesterol levels (difference, 0.94 
± (SEM) 0.19 mmol/L; p<0.001) and a greater carotid IMT (difference, 0.019 ± 0.01 mm; p=0.02) 
compared to children with receptor-defective mutations. The decrease in carotid IMT during 
the trial was not significantly different in children with null alleles and receptor-defective 
mutations (0.018 ± 0.012 mm and 0.012 ± 0.010 mm; two-way covariance analysis p=0.7). 
After two-year treatment, the children with null alleles continued to have greater carotid IMT 
than children with receptor-defective mutations (difference, 0.016 ± 0.01 mm; p=0.02). LDL 
cholesterol-lowering showed a tendency to less reduction in carriers of null alleles compared 
to carriers of receptor-defective mutations (1.30 ± 0.25 mmol/L and 1.85 ± 0.20 mmol/L; two-
way covariance analysis p=0.08).
Conclusions: In FH children, we found that the null allele genotype was associated with a 
greater carotid IMT, higher LDL cholesterol levels, and a non-significant tendency to attenu-
ated LDL cholesterol-lowering, when compared to receptor-defective mutations. Null alleles 
identify FH patients at the highest cardiovascular disease risk who may benefit from more 
aggressive treatment, started in childhood.
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Introduction
Familial hypercholesterolemia (FH) is a common metabolic disorder caused by mutations in 
the low-density lipoprotein (LDL) receptor gene.1 The disorder is characterized by severely 
elevated LDL cholesterol levels from birth onwards. Consequently, FH patients have an in-
creased risk of cardiovascular disease. After diagnosis, heterozygous patients are treated 
lifelong with inhibitors of β-hydroxy-β-methylglutaryl coenzyme A reductase (statins) to 
prevent premature cardiovascular disease.2
The lipid lowering response to statin therapy, however, shows considerable interindividual 
variation.3 In clinical practice, noncompliance with prescribed medication is an important 
cause of variation in statin response.4 In addition, several investigators have assessed wheth-
er specific LDL receptor mutations affect the lipid lowering response to statin therapy.3,5-11 
Understanding this relationship could result in a more individual approach of the treatment 
of FH patients. However, these studies have yielded conflicting results. Selection on specific 
founder mutations, limited numbers of patients, different classifications of the LDL receptor 
mutation types, and a variety of treatment strategies without randomization made it difficult 
to compare the results of these studies. In the present subgroup of a randomized, placebo-
controlled clinical trial with pravastatin in FH children, we analyzed a large number of differ-
ent LDL receptor mutations. Recently, we have found that studying children with FH provide 
more accurate information on genotype-phenotype interactions than studying adults prob-
ably because of a lower chronic exposure to known environmental factors that alter lipid 
levels.12 The randomization was used to reduce the influence of confounding factors. In addi-
tion, our observations were controlled for placebo effects, which enabled us to determine the 
natural course of the specific LDL receptor mutations during the two-year follow-up.
At present, genotype-phenotype studies have focussed on the lipid lowering response to 
statin therapy instead of analyzing the effects of statins on the atherosclerotic process. In 
adults, carotid intima-media thickness (IMT) has been accepted as a validated marker for ath-
erosclerosis and future cardiovascular outcome.13-16 There are clear indications that carotid 
IMT is a marker of the increased atherosclerotic burden in childhood as well.17 In a random-
ized statin trial, we measured both carotid IMT and lipid concentrations and the purpose of 
the present subgroup analysis was to determine whether LDL receptor genotype influenced 
the response to pravastatin treatment in children with heterozygous FH.
Methods
Study design
The FH children in the present subgroup analysis were participants in a single center clinical 
trial carried out in The Netherlands. The study has been described in detail elsewhere.17,18 
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In brief, it was a prospective, randomized, placebo-controlled, double-blind trial to assess 
the effect of two years of treatment with pravastatin on the carotid IMT in 214 children with 
heterozygous FH, aged between 8 and 18 years. After consenting, we randomized children to 
receive pravastatin once daily or matching placebo. In the active treatment group, children 
younger than 14 years of age received 20 mg pravastatin and in those 14 years and older 
pravastatin 40 mg was given. We monitored study drug compliance by tablet counting. In 
the present genotype-phenotype substudy, we included all 193 children whose LDL receptor 
mutation had been identified (Figure 1). The Institutional Review Board approved the study 
protocol, and informed consent was obtained from all children and parents.
214  Randomized Children With Untreated 
Familial Hypercholesterolemia
193  Children With Genetically Confirmed, 
Heterozygous Familial Hypercholesterolemia
3  Lost To Follow-Up
75  Null Alleles
37 Received Pravastatin
38 Received Placebo   
80  Receptor-Defective 
Mutations
41 Received Pravastatin
39 Received Placebo       
38  Undetermined Receptor
Activity Mutations
21 Received Pravastatin
17 Received Placebo       
211  Children With Familial Hypercholesterolemia
Completed Trial
18  Excluded
9  Apolipoprotein B Mutations
9  Without LDL Receptor Mutation
Figure 1. Flow of study participants in the genotype-phenotype substudy.
Type of LDL receptor mutation
We classified the LDL receptor mutations into mutation groups based on their functional 
class as reported in the literature: (a) the receptor-negative mutations or null alleles con-
tained all class 1 mutations, class 2A mutations, large rearrangements (except the 2.5kb dele-
tion which is a class 3 and 5 mutation), mutations resulting in a deletion of the translation 
initiation signal, and early stop-codons; (b) the receptor-defective mutations contained class 
2B to 6 mutations; (c) the undetermined-receptor-activity mutations contained all remain-
ing mutations with undetermined mutational class. A total of 49 different mutations were 
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detected in 193 children with heterozygous FH. We found 17 null alleles in 75 children, 14 
receptor-defective mutations in 80 children, and 18 mutations with undetermined residual 
function in 38 children (Figure 1).
Intima-media thickness
The primary efficacy outcome of this substudy was defined as the difference in change from 
baseline in mean carotid IMT between the placebo and pravastatin group at two years of 
follow-up compared between null alleles and receptor-defective mutations. A single experi-
enced sonographer performed all B-mode ultrasound examinations. The far walls of the left 
and right common carotid artery (CCA), carotid bulb (BULB), and internal carotid artery (ICA) 
were imaged. The digital images were analyzed off-line by one image analyst. For a given seg-
ment, IMT was defined as the average of the left and right IMT measurements. Mean carotid 
IMT was defined as the mean of the CCA, BULB, and ICA far wall segments. The quantitative 
IMT measurements have been described in detail elsewhere.17,18
Laboratory methods
Plasma concentrations of total cholesterol (TC), triglycerides (TG), and high-density lipopro-
tein (HDL) cholesterol were measured using standard (automated) methods after a 12-hour 
overnight fast. LDL cholesterol concentrations were calculated by the Friedewald formula.19 
All children had plasma TG concentrations consistently below 4.0 mmol/L. Mutational analy-
ses were performed with standard methods as described previously.20
Statistical analysis
All statistical analyses were carried out with SPSS software (version 11.5, SPSS). We compared 
children with null alleles and receptor-defective mutations for relevant clinical characteristics, 
lipid concentrations, and carotid IMT. Differences among LDL receptor genotype groups were 
analyzed with Students’ t-test for continuous data. Since TG concentrations had a skewed 
distribution, the analyses were based on log-transformed data. To examine the relationship 
between LDL receptor genotype and baseline carotid IMT, independent of lipid concentra-
tions, we used a multivariate linear regression analysis adjusted for initial LDL cholesterol 
levels.
We have performed a placebo-controlled subgroup analysis to determine the effect of 
genotype on efficacy of pravastatin treatment. First, we calculated for each participant the 
change from baseline in carotid IMT and lipid concentrations during the trial. Secondly, we 
used a linear regression model to analyze the difference between the placebo and pravastatin 
group in carotid IMT and lipids change during the trial for each genotype group separately 
(IMT/lipids change during the trial = β0 + βtreatment group * treatment group). The βtreatment group is the 
difference between the pravastatin group and the placebo group in IMT/lipids change dur-
ing the trial. As a result of randomization for the trial and of randomization by nature of the 
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genotypes, we did not expect differences of age and sex distributions between the genotype 
groups. Nonetheless, we did perform multivariate linear regression analysis to adjust for age 
and sex and found similar results (data not shown). Thirdly, the interaction between geno-
type (null alleles or receptor-defective mutations) and treatment (placebo or pravastatin) 
was statistically tested with two-way covariance analysis. Since LDL receptor genotype was 
associated with baseline lipid levels and carotid IMT, we did not adjust for baseline values in 
multivariate linear regression analysis and two-way covariance analysis. Nonetheless, when 
we adjusted for baseline values, similar trends were found between LDL receptor genotype 
and response to treatment (data not shown). Throughout, a two-tailed P value of less than 
0.05 was interpreted as indicating a statistical significant difference.
Results
Patient characteristics
The baseline characteristics according to the type of LDL receptor mutation are presented 
in Table 1. Study drug compliance was similar among the LDL receptor genotype groups. 
Children with null alleles and receptor-defective mutations were evenly distributed over 
placebo-treated and pravastatin-treated groups. As expected, children with null alleles had 
significantly more elevated mean TC levels (difference (± SEM), 0.94 ± 0.20 mmol/L; p<0.001) 
as well as mean LDL cholesterol levels (difference, 0.97 ± 0.20 mmol/L; p<0.001) compared 
to children with receptor-defective mutations. Moreover, carriers of null alleles had a greater 
mean carotid IMT (difference, 0.020 ± 0.01 mm; p=0.01) and mean IMT of the ICA segment 
(difference, 0.022 ± 0.01 mm; p=0.03) compared to carriers of receptor-defective mutations. 
Mean IMT of the CCA and BULB segments also tended to be higher in children with null alleles 
but this was not significant (difference, 0.021 ± 0.01 mm; p=0.06 and difference, 0.017 ± 0.01 
mm; p=0.08, respectively). Furthermore, after adjustment for baseline LDL cholesterol levels, 
the difference in mean carotid IMT between carriers of null alleles and receptor-defective 
mutations was 0.018 ± 0.01 mm (p=0.04).
Changes in carotid IMT
Figure 2 shows mean differences of the changes in carotid IMT during the trial between the 
placebo and pravastatin group according to the LDL receptor genotype. The decrease of 
mean carotid IMT as well as of mean IMT in the CCA, the BULB, and the ICA segments between 
children who received placebo and pravastatin treatment was not significantly different in 
carriers of null alleles compared to carriers of receptor-defective mutations (two-way covari-
ance analysis; p=0.7, p=0.4, p=0.3, and p=0.7, respectively). The changes in carotid IMT in 
Figure 2 were not adjusted for the changes in LDL cholesterol concentrations. Adjustment 
for changes in LDL cholesterol levels during the trial did not influence the decrease of mean 
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carotid IMT among carriers of null alleles and carriers of receptor-defective mutations: both 
0.014 ± 0.01 mm (two-way covariance analysis; p=0.6). However, after two-year treatment, 
children with null alleles had a consistently greater mean carotid IMT (difference, 0.016 ± 
0.01 mm; p=0.02) and mean IMT of the CCA segment (difference, 0.019 ± 0.01 mm; p=0.04) 
compared to children with receptor-defective mutations. Mean IMT of the BULB and the ICA 
segments after the treatment period tended to be higher in children with null alleles but this 
did not reach significance (difference, 0.017 ± 0.01 mm; p=0.07 for both segments).
Table 1. Baseline characteristics of children with null alleles, receptor-defective mutations, and mutations with undetermined receptor activity
Variable Undetermined
receptor activity
Null alleles Receptor-defective 
mutations
p-value*
(n=38) (n=75) (n=80)
Age, years (range) 12.4 (8.0-18.5) 13.4 (8.4-18.0) 12.6 (8.1-18.5) 0.1
Gender, male/female 16 / 22 33 / 42 44 / 36 0.2
BMI, kg/m2 20.3 ± 0.6 19.5 ± 0.4 18.9 ± 0.4 0.3
Study drug compliance, % 88.5 ± 2.3 89.4 ± 1.8 90.2 ± 1.3 0.7
Lipids in mmol/L
TC 7.98 ± 0.22 8.30 ± 0.16 7.36 ± 0.12 <0.001
LDL cholesterol 6.42 ± 0.21 6.66 ± 0.15 5.70 ± 0.12 <0.001
HDL cholesterol 1.21 ± 0.04 1.23 ± 0.03 1.26 ± 0.03 0.5†
TG 0.78 ± 0.07 0.92 ± 0.06 0.90 ± 0.06 0.9‡
IMT in mm
CCA 0.520 ± 0.01 0.521 ± 0.01 0.501 ± 0.01 0.06
BULB 0.529 ± 0.08 0.532 ± 0.01 0.515 ± 0.01 0.08
ICA 0.429 ± 0.01 0.455 ± 0.01 0.433 ± 0.01 0.03
mean carotid 0.492 ± 0.01 0.503 ± 0.01 0.483 ± 0.01 0.01
IMT in mm§
CCA 0.486 ± 0.07 0.510 ± 0.05 0.503 ± 0.05 0.09
BULB 0.549 ± 0.07 0.513 ± 0.05 0.511 ± 0.04 0.2
ICA 0.430 ± 0.07 0.431 ± 0.05 0.421 ± 0.04 0.08
mean carotid 0.489 ± 0.05 0.485 ± 0.04 0.479 ± 0.03 0.04
BMI=body mass index, TC=total cholesterol, LDL=low-density lipoprotein, HDL=high-density lipoprotein, TG=triglyceride, IMT=intima-media 
thickness, CCA=common carotid artery, BULB=carotid bulb, ICA=internal carotid artery, mean carotid=mean of the CCA, BULB, and ICA. All 
values are given as mean ± standard error of the mean (SEM).
*Comparison between null alleles and receptor-defective mutations.
†Statistical analysis adjusted for individual serum triglyceride levels did not change the result (data not shown).
‡Statistical testing after logarithmic transformation.
§Carotid IMT adjusted for initial LDL cholesterol levels.
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Changes in lipid concentrations
Mean differences of the changes in lipid concentrations during the trial between the placebo 
and pravastatin group according to the LDL receptor genotype are presented in Figure 3. 
Children with null alleles tended to less reduction of TC and LDL cholesterol levels during the 
trial compared to children with receptor-defective mutations, but this did not reach statisti-
cal significance (two-way covariance analysis; both p=0.08). After two-year treatment, mean 
TC in carriers of null alleles was 7.62 ± 0.20 mmol/L and mean LDL cholesterol was 5.94 ± 0.19 
mmol/L, and remained significantly more elevated than the 6.60 ± 0.17 mmol/L and 4.90 ± 
0.17 mmol/L in carriers of receptor-defective mutations (both p<0.001).
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Figure 2. Mean differences of the changes in carotid IMT during the trial between the placebo and pravastatin group in children with null 
alleles and receptor-defective mutations.
IMT=intima-media thickness, CCA=common carotid artery, BULB=carotid bulb, ICA=internal carotid artery, mean carotid=mean of the CCA, 
BULB, and ICA. Error bars indicate standard error of the mean difference. P values for the interaction between genotype (null alleles or receptor-
defective mutations) and treatment (placebo or pravastatin) were calculated using two-way covariance analysis
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Figure 3. Mean differences of the changes in lipid concentrations during the trial between the placebo and pravastatin group in children with 
null alleles and receptor-defective mutations.
TC=total cholesterol, LDL=low-density lipoprotein, HDL=high-density lipoprotein, TG=triglyceride. Error bars indicate standard error of the 
mean difference. P values for the interaction between genotype (null alleles or receptor-defective mutations) and treatment (placebo or 
pravastatin) were calculated using two-way covariance analysis
LDL receptor genotype and response to pravastatin in children 45
Pravastatin increased HDL cholesterol levels and reduced TG levels to a similar extent in both 
LDL receptor genotype groups (two-way covariance analysis; p=0.9 and p=0.7, respectively).
Discussion
In this subgroup study of a randomized, placebo-controlled, two-year trial with pravastatin in 
heterozygous FH children, we showed that LDL receptor genotype was significantly associ-
ated with the carotid IMT, independent of LDL cholesterol levels. Although the reduction of 
LDL cholesterol levels by pravastatin treatment tended to be less in carriers of null alleles, we 
observed no significant difference in change of carotid IMT during the trial between the two 
LDL receptor genotype groups. However, at baseline and after two-year treatment, carotid 
IMT and lipid profile were more unfavorable in children with null alleles compared to children 
with receptor-defective mutations.
Our present analysis is the first genotype-phenotype study in FH that demonstrated the 
influence of statin therapy on carotid IMT. In adults, numerous studies have shown that an 
increase in IMT of the carotid artery is associated with an increased risk of myocardial infarc-
tion and stroke, and that a decrease in carotid IMT due to drug treatment is associated with a 
decrease in the incidence of vascular events.13-16 Therefore, noninvasive B-mode carotid IMT 
has now been accepted as a validated marker for the process of atherosclerosis in adults. 
There are clear indications that carotid IMT is a marker for atherosclerosis in childhood as 
well. Children with FH have a 5-fold more rapid increase of carotid arterial wall IMT during 
childhood than their unaffected siblings.17 This increase led to a significant deviation in terms 
of IMT values from the age of 12 years onwards. Therefore, it might be suggested to measure 
carotid IMT as a marker of the increased atherosclerotic burden in children.
In this placebo-controlled trial, the response to pravastatin treatment on carotid IMT was 
not significantly different between the two genotype groups. Nonetheless, carriers of null 
alleles had a greater carotid IMT than carriers of receptor-defective mutations at baseline and 
this unfavorable difference was largely maintained during treatment. After correction for LDL 
cholesterol levels, the differences in carotid IMT between the LDL receptor genotype groups 
became smaller and less significant. The lower significance may partly be based on loss of 
statistical power as the result of an additional co-variable (LDL cholesterol) in the multivariate 
analysis. The small decrease of the difference in carotid IMT between the genotype groups 
after correction for LDL cholesterol levels, however, suggest that the greater carotid IMT in 
carriers of null alleles was partly but not solely the result of higher LDL cholesterol levels. 
Knowledge of LDL receptor genotype may therefore improve clinical decision-making: un-
treated and treated children carrying null alleles exhibit a more increased risk of cardiovascu-
lar disease that may be partially independent of their more increased LDL cholesterol levels. 
Carriers of null alleles may have to a certain extent irreversible atherosclerosis, but hopefully 
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they just need more aggressive statin treatment. Clearly, the carotid IMT of children with null 
alleles was reduced during pravastatin treatment. Unfortunately, we could not assess the 
relationship between LDL receptor genotype and responses to increasing doses of statins in 
our substudy. In future research, the effect of more aggressive and earlier statin treatment in 
children with null alleles should be investigated. Studies on efficacy and safety in FH children 
of stronger statins and high dosages are starting and some are ongoing. In addition to statin 
treatment, a healthy lifestyle should be advised, because our results suggest that cholesterol 
independent mechanisms affect the carotid IMT and more aggressive lipid lowering may 
have a disappointing effect especially in carriers of null alleles.
In the present study, the reductions of TC and LDL cholesterol levels during pravastatin 
treatment were not significantly different in the two genotype groups. Previous genotype-
phenotype studies in adult FH patients have yielded conflicting results.3,5-11 In a recent study, 
we showed that children with FH are better suited for genotype-phenotype analysis than 
adults.12 In a linear mixed model, we calculated the contribution of familial factors to the 
variance of LDL cholesterol levels in a pediatric and an adult FH cohort (intra-class correla-
tion). Familial factors explained 50.4% of the variance in LDL cholesterol levels among the 
FH children and only 9.5% in adult FH patients. Hence, the LDL cholesterol levels showed a 
much stronger correlation among related children than in adult siblings. Likely, children have 
a lower chronic exposure to known environmental factors that alter lipid levels. Moreover, 
we used placebo-controlled data and, therefore, information was available about the natural 
course of the specific LDL receptor mutation on carotid IMT and lipid profile during the two-
year follow-up. Adjusting for the natural course reduces bias in the analyses of the relation-
ship between LDL receptor genotype and treatment response: placebo effect and secular 
trends did not influence our observations.
Our subgroup analysis had not enough power to observe small differences in the carotid 
IMT responses between the two LDL receptor genotype groups with significance. The ques-
tion arises whether or not we have made a type II error: a difference is not observed with 
statistical significance because of lack of power due to small numbers. However, we did not 
find a difference between the point-estimates. Recently, Schultz and Grimes emphasized 
that methodological rigor to eliminate bias, properly report to avoid misinterpretation, and 
always publish results to avert publication bias is more important than insufficient sample 
size.21 Moreover, the methodological advantages enable that such analyses could ultimately 
be combined in meta-analysis. We have estimated that a meta-analysis to test the results of 
this hypothesis-generating study should be considered when 2600 or more children have 
been included in statin IMT trials. Future studies on genotype effects should also maintain 
the placebo-controlled data of the trial to enable such a meta-analysis.
In summary, we conclude that LDL receptor genotype was significantly associated with 
the carotid IMT before and during treatment with pravastatin in heterozygous FH children, 
independent of LDL cholesterol levels. Selection of null alleles identifies children with the 
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highest cardiovascular disease risk who may benefit by more aggressive as well as earlier lipid 
lowering treatment.
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Abstract
Background: The Y402H polymorphism of complement factor H (CFH) has been strongly and 
consistently related with increased risk of age-related macular degeneration (AMD). Previ-
ous work has suggests that AMD and atherosclerosis share similar pathogenic pathways. 
However, association studies of the CFH variant with cardiovascular disease (CVD) yielded 
conflicting results, probably because they were underpowered.
Methodology and Findings: We determined whether or not the Y402H polymorphism influ-
enced CVD risk in a multicenter cohort study involving 2016 unrelated patients with familial 
hypercholesterolemia (FH), who have an extremely increased susceptibility to CVD. We iden-
tified 261 individuals who were homozygous for the polymorphism (CC genotype; 12.9%), 
929 individuals who were heterozygous (TC genotype; 46.1%), and 826 individuals carried 
the wild type (TT genotype; 41.0%). During 95,115 person years, 644 patients had a cardio-
vascular event. Carriers of the CC genotype had a decreased risk of CVD (relative risk 0.67, 
95% confidence interval 0.51 – 0.87; p = 0.003) relative to the other genotype groups. This as-
sociation was unaltered after adjustment for clinically relevant cardiovascular risk factors or 
age effects. Separate analyses for coronary, cerebral, and peripheral artery disease revealed 
similar decreased risk estimates for the CC genotype.
Conclusion: Among patients with FH, the Y402H CFH variant was associated with less suscep-
tibility to CVD. This suggests that the inconsistencies about this relationship are the result 
of context dependent expression. The studies with significant findings are in balance and it 
cannot be excluded that it were all chance findings. Therefore, adequately powered replica-
tion studies should be performed to dissect the association with CVD.
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Introduction
Age-related macular degeneration (AMD) is a progressive late-onset disease affecting central 
vision and is the leading cause of irreversible blindness in the elderly Western population.1 
Recently, three independent genomic studies identified the Y402H (rs 1061170) polymor-
phism of complement factor H (CFH) that may account for almost half of all AMD cases.2-4 
Several replication studies established the association of this CFH variant with increased risk 
of AMD in different ethnic populations and different clinical subtypes of the disease.5-10
Epidemiologic, genetic, and pathological evidence suggest that similar pathways may be 
involved in the etiologies of AMD and atherosclerosis.11 Atherosclerosis is a chronic inflam-
matory disorder and its initiation and progression are thought to be influenced by activation 
of the complement system.12,13 The complement system is the innate component of the im-
mune response and consists of a cascade of plasma and membrane-bound proteins that (i) 
protects the host from invading microorganisms, (ii) removes debris and damaged tissues, 
and (iii) enhances cell mediated inflammatory reactions.14 A number of studies have convinc-
ingly shown that, although complement activation is nearly absent in normal arteries, it is 
extensively activated in atherosclerotic lesions.15-17
During complement activation, host cells are protected from being damaged as innocent 
bystanders by regulatory proteins, including CFH.18 Immunohistochemical studies have de-
tected CFH in early human coronary artery lesions.19 Interestingly, CFH was exclusively lo-
cated in the superficial layer of the arterial intima, suggesting that it may protect the arterial 
wall from damage by excess complement activation. Several variants in the CFH gene have 
been identified, but the Y402H polymorphism is of particular interest because it is located 
within the binding site for heparin and C-reactive protein.18 It is proposed that the replace-
ment of tyrosine for histidine at position 402 in exon 9 may affect the binding properties 
of CFH on host surfaces, potentially influencing complement activation, immune responses, 
and inflammation.20
To date, three studies have been conducted on potential associations between the Y402H 
polymorphism and cardiovascular disease (CVD).21-23 In contrast with the strong and con-
sistent findings in AMD, however, they have yielded conflicting results. This inconsistency 
may be due to heterogeneity in the cardiovascular phenotype and variations in population 
and study design. An alternative reason for these variable findings, though, is false negative 
results because subsequent studies were underpowered. Consequently, we postulate that 
the association between this CFH variant and CVD should be assessed in a population at 
increased risk of CVD with the matching high power to detect potential small effects of the 
genetic modifier.
Patients with heterozygous familial hypercholesterolemia (FH) have severely elevated low-
density lipoprotein (LDL) cholesterol levels and as a result they belong to those at highest 
risk of CVD.24 The atherosclerotic burden of FH shows, however, large variation and many 
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untreated patients reach a normal life span. 25 The disorder is considered to be an exemplary 
model to analyze secondary (or modifier) genes as well as environmental factors involved in 
CVD.26
We hypothesized that the Y402H polymorphism in CFH influences susceptibility to CVD. 
Therefore, we assessed the relationship between this CFH variant and risk of CVD in a large 
cohort of patients with heterozygous FH. Furthermore, we determined the influence of the 
polymorphism on the risk of coronary, cerebral, and peripheral arterial events separately.
Methods
Study design and patients
The study population and data collection of the FH cohort have been described in detail 
elsewhere.27 In brief, lipid clinics throughout The Netherlands submitted DNA samples 
of clinically suspected patients with FH to a central laboratory for LDL receptor mutation 
analysis. From this database, we randomly selected a cohort of 4000 out of 9300 patients, 
who were collected between 1989 and 2002. We excluded subjects with secondary causes of 
hypercholesterolemia and those with hypercholesterolemia caused by other genetic defects, 
such as familial defective apolipoprotein B. A total of 2400 unrelated patients, aged 18 years 
and older, fulfilled the diagnostic criteria for FH as they were previously published.27 DNA was 
available of 2016 patients with heterozygous FH for the present analyses. Of these patients, 
over 99% were Caucasian and 1055 (52.3%) individuals had a documented LDL receptor 
mutation. The Institutional Review Board of each participating hospital approved the study 
protocol and informed consent was obtained from all patients.
We assessed cardiovascular risk factors using the following definitions. Smoking was de-
fined as ever smoking. Hypertension was defined as systolic blood pressure >140 mmHg 
or diastolic blood pressure >90 mmHg at three consecutive office visits. Patients on anti-
hypertensive medication were only added to the hypertension group, when a documented 
diagnosis was available. Diabetes mellitus was defined as patients using anti-diabetic medi-
cation or fasting plasma glucose >6.9 mmol/L. Lipid levels were determined in fasting pa-
tients not using lipid-lowering medication for at least 6 weeks. Total cholesterol, high-density 
lipoprotein (HDL) cholesterol and triglycerides were measured by standard methods. LDL 
cholesterol was calculated with the Friedewald equation.
Cardiovascular disease
The primary clinical endpoint of the present genetic association study was CVD, defined as 
fatal or non-fatal CVD using internationally accepted criteria. Cardiovascular disease was 
defined as: (I) myocardial infarction, proven by at least two of the following: (a) classical 
symptoms >15 minutes, (b) specific electrocardiographic abnormalities, (c) elevated cardiac 
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enzymes (>2 times upper limit of normal); (II) percutaneous coronary intervention or other 
invasive procedures; (III) coronary artery bypass grafting; (IV) angina pectoris, defined as clas-
sical symptoms in combination with at least one unequivocal result of one of the following: 
(a) exercise test, (b) nuclear scintigram, (c) dobutamine stress ultrasound, (d) a more than 
70 percent stenosis on a coronary angiogram; (V) ischaemic stroke, demonstrated by CT- or 
MRI scan; (VI) documented transient ischaemic attack; (VII) peripheral arterial bypass graft-
ing; (VIII) peripheral percutaneous transluminal angioplasty or other percutaneous invasive 
intervention; (IX) intermittent claudication, defined as classical symptoms with at least one 
unequivocal result of one of the following: (a) ankle/arm index <0.9 or (b) a stenosis >50 per-
cent on an angiogram or duplex scan. Secondary endpoints of the study were coronary heart 
disease, cerebral artery disease, and peripheral artery disease. Coronary heart disease was 
defined as: (i) myocardial infarction, (ii) percutaneous coronary intervention or other inva-
sive procedures, (iii) coronary artery bypass grafting, and (iv) angina pectoris. Cerebral artery 
disease was defined as: (i) ischaemic stroke and (ii) documented transient ischaemic attack. 
Peripheral artery disease was defined as: (i) peripheral arterial bypass grafting, (ii) peripheral 
percutaneous transluminal angioplasty or other percutaneous invasive intervention, and (iii) 
intermittent claudication.
Molecular analysis
Genomic DNA was extracted from peripheral blood leukocytes according to standard proto-
cols.28 Considering the concordance of previous association studies for CFH Y402H in AMD 
populations, we investigated specifically this polymorphism. The Y402H polymorphism in 
CFH was detected with molecular analysis of the CFH gene with the standard protocol of the 
7900HT Taqman (Applied Biosystems, Foster City, USA). Two oligonucleotide primers were 
used to identify the replacement of thymine (T) by cytosine (C) on position 1277.2
Statistical analyses
All data were analyzed using SPSS for Windows software package version 11.5.0 (SPSS Inc., 
Chicago, IL, USA). Deviations of the genotype distribution from that expected for a popula-
tion in Hardy-Weinberg equilibrium were tested using chi-square statistics with one degree 
of freedom. Genotype and allele frequencies among patients with and without history of 
CVD were compared with the chi-square test. Differences between CFH genotypes were 
tested with chi-square statistics for dichotomous variables and independent sample t-test 
for continuous variables. If dependent variables were not normally distributed, logarithmic 
transformations were applied. To adjust statistical tests for age and gender, we used multiple 
linear regression analysis.
Cox proportional hazard regression analysis was used to determine the association be-
tween the CFH variant and the occurrence of CVD. The proportional hazards assumption 
was tested by drawing log minus log plots of the survival function and was met for all Cox 
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proportional hazard models. Follow-up started at birth and ended at the first occurrence of 
established fatal or non-fatal CVD. Patients without CVD were censored at the date of the 
last lipid clinic visit or at the date of death attributable to other causes. CFH genotype was 
analysed according to an additive, dominant or recessive genetic model, respectively. The 
recessive genetic model (homozygous carriers relative to heterozygous and wild type carri-
ers) had the highest log-likelihood and was used in the present analyses (data not shown). 
The cumulative CVD free survival, without adjustment for co-variables, was illustrated with 
the Kaplan-Meier method. Initially, we adjusted in the multiple Cox regression analysis for 
variables that are independent of the polymorphism: year of birth, gender, and smoking. 
Additionally, adjustment was made for all other variables that were significant risk factors 
of CVD in Cox regression analysis. The presence of the homozygous CFH variant in young 
patients, who did not yet express their high cardiovascular risk, could potentially have led to 
lower risk estimates. Therefore, we tested the effect of age by separate analyses of age tertiles 
and by adjusting for age tertiles in the Cox regression analysis. Statistical significance was 
assessed at the 5% level.
Results
Genotype and allele frequencies
We observed homozygosity for the Y402H polymorphism in 261 (CC genotype; 12.9%) pa-
tients, heterozygosity in 929 (TC genotype; 46.1%) patients, and 826 (TT genotype; 41.0%) 
patients carried the wild type. Genotype distributions in the total cohort and in the patients 
with and without history of CVD were in Hardy-Weinberg equilibrium (p>0.18).
To compare our results with previous case-control studies, we reported all genotype and 
allele frequencies in Table 1. The distribution of CFH genotypes was significantly different 
between patients with and without history of CVD (p=0.003) as a result of higher frequency 
of the CC genotype in patients without history of CVD (p=0.001).
Table 1. Genotype and allele frequencies for the T→C variation in CFH gene coding for Y402H variant
Genotype or Allele Patients with CVD Patients without CVD
N (frequency) N (frequency)
TT 270 (0.419) 556 (0.405)
TC 314 (0.488) 615 (0.448)
CC 60 (0.093) 201 (0.147)
T allele 854 (0.663) 1727 (0.629)
C allele 434 (0.337) 1017 (0.371)
CFH denotes complement factor H; CVD denotes history of cardiovascular disease.
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Table 2. Characteristics of 2016 patients with familial hypercholesterolemia according to the genotypes of the CFH Y402H polymorphism
Characteristic TT genotype TC genotype CC genotype p-value*
(n=826) (n=929) (n=261)
Age at first lipid clinic visit (years) 45.2 (± 0.4) 44.7 (± 0.4) 43.9 (± 0.8) 0.2
Age at last lipid clinic visit (years) 50.3 (± 0.4) 49.8 (± 0.4) 48.9 (±0.9) 0.2
Males (%) 47.3 (± 1.7) 48.5 (± 1.6) 44.8 (± 3.1) 0.3
Smoking, ever (%) 73.5 (± 1.6) 74.1 (± 1.5) 67.5 (± 3.0) 0.05†
Hypertension (%) 9.9 (± 1.0) 8.4 (± 0.9) 7.7 (± 1.7) 0.7†
Diabetes (%) 5.6 (± 0.8) 6.2 (± 0.8) 5.4 (± 1.4) 0.9†
Body mass index (kg/m2) 25.1 (± 0.1) 25.1 (± 0.1) 24.9 (± 0.2) 0.5†
Total cholesterol (mmol/L) 9.44 (± 0.07) 9.60 (± 0.07) 9.47 (± 0.13) 0.8†
Low-density lipoprotein cholesterol 
(mmol/L)
7.30 (± 0.08) 7.40 (± 0.07) 7.42 (± 0.13) 0.6†
High-density lipoprotein cholesterol 
(mmol/L)
1.22 (± 0.01) 1.23 (± 0.01) 1.19 (± 0.02) 0.07†
Triglycerides (mmol/L) 1.80 (± 0.04) 1.81 (± 0.04) 1.66 (± 0.07) 0.02†‡
CFH denotes complement factor H.
Values are given as means ± standard error of the mean (SEM).
*Comparison between the CC genotype and other genotypes.
†Adjusted for age and gender.
‡Statistical testing after logarithmic transformation.
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Figure 1. Kaplan-Meier curves for cardiovascular disease free survival among familial hypercholesterolemia patients with the CC genotype 
and TT/TC genotypes of complement factor H gene. Carriers of the CC genotype had a decreased risk of CVD compared with carriers of other 
genotypes (RR 0.67, 95% CI 0.51 – 0.87; p=0.003).
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Characteristics of patients
Comparisons of general characteristics among the genotypes are presented in Table 2. 
Patients with the CC genotype had significant lower plasma triglyceride levels (difference 
(±SEM), 0.14 ± 0.07 mmol/L; p=0.01). We found no significant differences in demographics, 
the presence of smokers, hypertension, and diabetes mellitus, body mass index (BMI), and 
other plasma lipid concentrations between the CC genotype and other genotypes.
CFH genotype and CVD
During 95,115 person years, 644 patients had their first cardiovascular event. Mean age of 
onset of CVD was 48.5 ± 10.7 years. In Figure 1, the Kaplan-Meier curves show the CVD free 
survival of patients with the CC genotype and TT/TC genotype. Without adjustment for co-
variables, carriers of the CC genotype had a decreased risk of CVD compared with carriers 
of other genotypes (RR 0.67, 95% CI 0.51 – 0.87; p=0.003). As shown in Table 3, year of birth, 
male sex, smoking, the presence of diabetes, higher BMI, lower levels of HDL cholesterol, and 
higher triglyceride levels were significantly associated with an increased cardiovascular risk 
Table 3. Relative risk of cardiovascular disease estimated with Cox regression analyses in 2016 patients with familial hypercholesterolemia
Variables Relative Risk (95% CI) p-value
Analyses of single variables
Year of birth 1.07 (1.06 to 1.08) <0.001
Males 2.96 (2.51 to 3.48) <0.001
Smoking 1.90 (1.54 to 2.34) <0.001
Diabetes mellitus 1.31 (1.03 to 1.66) 0.03
Hypertension 1.13 (0.91 to 1.40) 0.3
Body mass index 1.03 (1.00 to 1.06) 0.03
Low-density lipoprotein cholesterol 0.97 (0.92 to 1.01) 0.1
High-density lipoprotein cholesterol 0.37 (0.27 to 0.49) <0.001
Triglycerides 1.23 (1.08 to 1.39) 0.001
CC genotype of CFH gene 0.67 (0.51 to 0.87) 0.003
Analyses of CC genotype of CFH gene adjusted for
Year of birth, gender, and smoking 0.68 (0.51 to 0.89) 0.005
Year of birth, gender, smoking, diabetes, body mass index, high-
density lipoprotein cholesterol, triglycerides
0.54 (0.36 to 0.79) 0.002
Analyses of CC genotype of CFH gene and age tertiles*
19 – 43 years 1.12 (0.57 to 2.18) 0.7
44 – 55 years 0.50 (0.29 to 0.86) 0.01
56 – 86 years 0.74 (0.51 to 1.06) 0.1
CFH denotes complement factor H.
*Multiple Cox regression analyses of CC genotype of CFH gene adjusted for year of birth, gender, and smoking according to the age tertiles in the 
cohort.
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in univariate analyses. In Cox regression analysis with adjustment for year of birth, gender, 
and smoking, the CC genotype was significantly associated with 0.68 decreased risk of CVD 
(p=0.005; Table 3). Additional adjustment for other risk factors did not change the effect of CC 
genotype on the decreased susceptibility to CVD in our population (p=0.002). Furthermore, 
we found similar results among men and women (data not shown).
Age effects
The average (± SD) age at end of follow-up of patients without CVD was 46.6 ± 12.8 years 
and this was significantly lower than the mean age (48.5 ± 10.7 years) at onset of CVD in the 
other group. The presence of the homozygous CFH variant in young patients, who did not 
yet express their high cardiovascular risk, could potentially have led to lower risk estimates. 
To test for effects of the CC genotype on CVD risk with age, we stratified the cohort by age 
tertiles and performed separate Cox regression analyses in these three age strata. The results 
of these analyses are shown in Table 3. In the lower age tertile, the CC genotype was not 
associated with CVD. The point-estimates of the relative risks in the two upper age tertiles 
were similar to the findings in the total cohort. Actually, we may have underestimated the 
cardioprotective effect of the CC genotype in our total cohort as a result of the presence of 
young patients. Therefore, we performed an analyses restricted to the upper two age tertiles 
adjusting for year of birth, gender, and smoking and found a relative risk of 0.63 (95% CI, 0.47 
to 0.86; p=0.003). Finally, we performed a Cox regression analysis with adjustment for year of 
birth, gender, smoking, and age tertiles: patients with the CC genotype had 0.68 (95% CI, 0.52 
to 0.89; p=0.006) times less frequent CVD relative to patients with the other genotypes.
CFH genotype and secondary outcomes
As expected, coronary heart disease was the most prevalent cardiovascular event in the pop-
ulation: in 549 (85.2%) of the FH patients with a history of CVD the first event was coronary 
heart disease, in 39 (6.1%) patients the first event was cerebral artery disease, and periph-
eral artery disease was the first event in 56 (8.7%) patients. The relationship between the CC 
genotype of the CFH gene and these three major cardiovascular events has been shown in 
Figure 2. The CC genotype was significantly associated with decreased risk of coronary heart 
disease (RR 0.69, 95% CI 0.52 – 0.93; p=0.01). Although we found no significant association 
between the CC genotype and other major cardiovascular events, probably as a result of 
lower prevalence in our cohort, the relative risk of carriers with the CC genotype was 0.39 
for cerebral artery disease (95% CI, 0.14 – 1.06; p=0.07) and 0.69 for peripheral artery disease 
(95% CI, 0.33 – 1.42; p=0.3).
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Figure 2. Effects of CC genotype of complement factor H gene on cardiovascular disease, coronary heart disease, cerebral artery disease, and 
peripheral artery disease in patients with familial hypercholesterolemia.
Discussion
In this large, multicenter cohort study of high-risk patients with heterozygous FH, we dem-
onstrated that the CC genotype of the CFH gene, present in ~13% of the population, was 
significantly associated with a 2-fold decreased risk of CVD. Adjustment for clinically relevant 
cardiovascular risk factors and age effects did not influence the effect. We also analyzed the 
risk of coronary, cerebral, and peripheral events separately and found similar decreased rela-
tive risks in carriers of the CC genotype.
Atherosclerosis is characterized by a strong inflammatory component.12 Data is accumulat-
ing that activation of the complement system is an important link between inflammation and 
atherogenesis.13 Complement activation can arise through the classical, alternative, or lectin 
pathway.14 All three pathways initiate activation of a C3 convertase enzyme which leads to 
the production of C3a and C3b and then to the terminal C5b-9 membrane attack complex, 
causing cell lysis. Complement activation is nearly absent in normal arteries, but is consider-
ably active in atherosclerotic lesions as demonstrated by C5b-9 depositions in atherosclerotic 
plaques;15 the extent of deposition was correlated with the severity of the lesion.16 Further-
more, the expression of messenger RNA for complement proteins was up regulated in vas-
cular cells of atherosclerotic lesions,17 and elevated levels of activated complement products 
were found in plasma and atherosclerotic plaques of patients with myocardial infarction.29
During complement activation, host cells are protected from being damaged by CFH. CFH 
modulates the complement cascade initiated by the alternative pathway: it inhibits the ac-
tivation of C3 to C3a and C3b and inactivates existing C3b, thereby preventing uncontrolled 
complement activation.18 CFH was also present in human coronary artery lesions but was 
exclusively located in the superficial layer of the arterial intima, suggesting that CFH may 
protect the arterial wall from damage by excess complement activation.19
CFH is encoded by a member of the Regulator of Complement Activation (RCA) gene clus-
ter, a group of closely linked genes located on chromosome 1q32 coding for several of the 
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complement regulatory proteins. Mutations in the CFH gene are extremely rare and are asso-
ciated with renal diseases like glomerulonephritis and atypical hemolytic uremic syndrome. 
A large number of polymorphisms have been identified in CFH, but their potential influence 
on the level of expression or function of CFH are unknown.19 Interestingly, the Y402H poly-
morphism is located within the binding site for heparin and C-reactive protein. Recently, 
it has been demonstrated that the wild type and the 402H variant differentially recognize 
heparin in vitro.30 This functional alteration may affect binding of CFH to the proteoglycan 
layer on the arterial intima, potentially influencing complement activation and inflammation 
in the atherosclerotic plaque.
Three previous studies also assessed the relationship between this CFH variant and cardio-
vascular events, but they have yielded conflicting results.21-23 In the Physicians’ Health Study 
cohort, no association of the CFH Y402H polymorphism with risk of incident myocardial 
infarction and ischaemic stroke was observed.21 In addition, the authors examined the rela-
tionship between the CFH variant and plasma C-reactive protein levels in a subpopulation. 
Although they found no significant association, the C-reactive protein concentrations were 
lowest in individuals with the CC genotype (median mg/L: TT, 1.39; TC, 1.10; CC, 1.00). In the 
second case-control study, Goverdhan et al. reported no significant association between the 
CFH variant and coronary artery disease.22 In contrast, in the Rotterdam Study, a prospective 
population-based cohort study in the elderly, carriers of the CC genotype had a hazard ratio 
of 1.77 (95% CI 1.23 to 2.55) for myocardial infarction.23 All these previous studies, however, 
were performed in populations that were on average 20 years older than individuals in our 
study. Our patients had much more severely increased LDL cholesterol levels: such values 
were hardly or not present at all in the other studies. Moreover, most studies were underpow-
ered to detect the modest effects that are expected for genetic susceptibility for a complex 
disorder such as CVD.
The strength of the present study lies in the availability of a well-documented, large cohort 
of patients with severe hypercholesterolemia resulting in a 8.5 times increased CVD risk.24 
However, the risk shows considerable variation among patients with FH: 40% of untreated 
patients reach a normal life span whereas excess mortality caused by CVD occurs in the re-
maining 60%.25 Clearly secondary genetic factors and life style determine the burden from 
this monogenic disorder.31 The monogenic background and the large variation of CVD risk 
offer a unique opportunity to analyze secondary genes involved in CVD.26
A limitation of our study is that the influence of the Y402H polymorphism on potential 
intermediate traits such as C-reactive protein levels and other inflammation markers could 
not be determined. In addition, we were unable to replicate our findings in a second inde-
pendent sample of patients with FH. To our knowledge, however, the present FH cohort is 
the only one with well-documented clinical outcome measures. The cardioprotective effect 
of the CFH variant may be restricted to hypercholesterolemic patients. Furthermore, associa-
tion studies would ideally be performed using haplotype-based analysis in stead of single 
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nucleotide polymorphism-based analysis. The CFH Y402H polymorphism, however, was the 
only genetic variant consistently associated with AMD in previous reports and therefore we 
restricted our analysis to this polymorphism. An advantage of this single nucleotide polymor-
phism-based approach is that we had no problems regarding multiple testing, as is often the 
case in genetic association studies.
Interestingly, individuals with the Y402H polymorphism in CFH have an increased suscep-
tibility to AMD,2-10 but homozygous carriers of the CFH variant had a decreased risk of CVD in 
our FH subjects. Differences in angiogenesis may be a possible explanation for this opposite 
effects of the CFH variant in cardiovascular disease and AMD. Insufficient collateral blood 
vessel formation increases the burden of ischemic vascular diseases,32 whereas neovascu-
larisation clearly increases the severity of AMD.1 It is, therefore, tempting to hypothesize that 
CFH is involved in the process of neovascularisation. 
The exact reason for the conflicting results on the polymorphism in CVD research is un-
known. The expression of the CFH variant may be context dependent, but it cannot be ex-
cluded that the significant results so far were based on chance findings. Obviously, future 
research is warranted to acquire more detailed characterization of the CFH gene and to es-
tablish the functional consequences of the CFH Y402H variant and its impact on complement 
activation, neovascularisation, and complex diseases such as AMD and atherosclerosis.
In conclusion, this large cohort study shows a significant 2-fold decreased risk of CVD, as 
well as coronary heart disease, in severe hypercholesterolemic patients homozygous for the 
CC genotype of CFH gene. The association was not explained by known cardiovascular risk 
factors such as age, gender, smoking, diabetes, and cholesterol levels, suggesting that the CC 
genotype is a modifier gene of CVD.
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Abstract
Background: Elevated plasma plant sterol concentrations may be a risk factor of cardiovascu-
lar disease (CVD). Polymorphisms in the ABCG8 gene have been identified that contribute to 
the variation in plasma concentrations of plant sterols. However, data on the direct relation-
ship of ABCG8 gene polymorphisms with CVD are lacking.
Methodology and Findings: Therefore, we examined associations between the D19H and 
T400K polymorphisms in the ABCG8 gene and cardiovascular events in a large, multicenter, 
cohort study of 2012 patients with heterozygous familial hypercholesterolemia (FH). A total 
of 253 individuals carried one or two alleles of the D19H variant and 580 individuals the 
T400K variant. During 94,809 person years, 648 (32.2%) subjects developed CVD. We de-
fined CVD as coronary (n=553), cerebral (n=37), or peripheral artery disease (n=58). In a Cox 
proportional hazard regression model adjusted for year of birth, gender, and smoking, the 
D19H polymorphism was not associated with total CVD risk (p>0.1). However, after additional 
adjustment for plasma HDL cholesterol and triglycerides levels there was evidence of an as-
sociation with higher risk of coronary heart disease (RR 1.40 confidence interval 1.03–1.92; 
p=0.03). We observed no relationship between the T400K polymorphism and cardiovascular 
endpoints (p>0.1).
Conclusion: In conclusion, our data suggest that these genetic variations in the ABCG8 gene 
are not a major contributor for differences in CVD risk among patients with FH.
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Introduction
Increased plasma cholesterol levels are among the most important risk factors of cardiovas-
cular disease (CVD). Cholesterol is the most common sterol of animal origin and its levels 
are regulated by cholesterol absorption and synthesis. Sterols of plant origin are structurally 
similar to cholesterol but they cannot be synthesized endogenously and are completely de-
rived from the diet. The major plant sterols, sitosterol and campesterol, are normally present 
in very low amounts in the blood and are at least 100-fold less abundant than cholesterol.1
The accumulation of plant sterols is actively prevented by two members of the adenosine 
triphosphate binding cassette (ABC) transporter family, ABCG5 and ABCG8.2,3 Both proteins 
are expressed in the intestine and in the liver, where they dimerize to form active membrane 
transporters. They function to limit the intestinal absorption of dietary sterols by effluxing 
sterols from enterocytes to the small intestinal lumen and promote the excretion of sterols 
from the liver into the bile. Mutations in either one of the two genes that encode for these 
transporters cause sitosterolemia. This is a rare autosomal recessive disorder characterized 
by increased intestinal absorption and markedly impaired biliary secretion of plant sterols.4 
Patients with sitosterolemia have plasma and tissue levels of plant sterols that are >50-fold 
increased and they develop CVD at a young age.5,6
High plasma concentrations of plant sterols have been suggested to increase CVD risk also 
in nonsitosterolemic subjects. Elevated plasma sitosterol and campesterol levels and/or their 
ratios to cholesterol have been associated with a personal or family history of CVD in both 
hypercholesterolemic and normocholesterolemic individuals.7-10 Moreover, the higher the 
ratio of sitosterol and campesterol to cholesterol in serum, the higher was their ratio also in 
the carotid artery wall of individuals undergoing carotid endarterectomy.11
Plasma plant sterol concentrations vary over a 5- to 10-fold range among individuals, but 
are very stable within individuals and they are highly heritable.12 It was found that common 
DNA sequence polymorphisms in the ABCG8 gene contributed to the variation in plasma con-
centrations of plant sterols such as sitosterol and campesterol.12-14 In addition, ABCG8 gene 
variants were also associated with plasma total cholesterol and LDL cholesterol levels.13-16 
Although plant sterol concentrations have been related to CVD and common polymorphisms 
in ABCG8 have been identified that associated with plant sterol levels, the direct influence of 
ABCG8 polymorphisms on atherosclerotic diseases is yet unknown.
The effect of a single polymorphism on genetic susceptibility for a complex disorder such 
as CVD is a priori expected to be modest.17 The association between ABCG8 variants with CVD 
should, therefore, preferably be examined in a population at increased risk of CVD with the 
matching high power to detect potential small effects of the genetic variant. Patients with 
heterozygous familial hypercholesterolemia (FH) have severely elevated plasma low-density 
lipoprotein (LDL) cholesterol levels, leading to accelerated atherosclerosis and an increased 
risk of premature CVD.18,19 Despite the monogenic cause, the cardiovascular morbidity and 
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mortality of FH shows considerable variation related to both environmental and genetic 
factors.20-22 The disorder is considered to be an exemplary model to analyze secondary (or 
modifier) genes involved in CVD.23
We hypothesized that the presence of common polymorphic variants in the ABCG8 gene 
may effect variation in CVD risk. We therefore examined the relationship between polymor-
phisms in the ABCG8 gene and plasma cholesterol concentrations as well as susceptibility to 
CVD in patients heterozygous for FH.
Methods
Study design and study population
The exact selection procedure and data collection of the FH cohort have been previously 
published.24 In brief, lipid clinics throughout The Netherlands submit DNA samples from 
clinically suspected FH patients to a central laboratory for LDL receptor mutation analysis. Be-
tween 1989 and 2002, a total of 9300 DNA samples were collected and we randomly selected 
a cohort of 4000 subjects from this database. FH was diagnosed according to internationally 
established criteria.25 A total of 2400 unrelated patients, aged 18 years and older, fulfilled 
the diagnostic criteria for heterozygous FH. Of these patients, over 99% were Caucasian. The 
Institutional Review Board of each participating hospital approved the study protocol and 
informed consent was obtained from all patients.
Data collection
Phenotypic data were obtained by reviewing the patient’s medical records by a trained team 
of data collectors.26 Smoking was classified as ever having smoked. Body mass index (BMI) 
was calculated from height and length (kg/m2). Hypertension was defined as a systolic blood 
pressure >140 mmHg or a diastolic blood pressure >90 mmHg at three consecutive office 
visits or patients with a documented diagnosis and using antihypertensive medication. Dia-
betes mellitus was defined as patients with fasting plasma glucose >6.9 mmol/L or patients 
using anti-diabetic medication.
All laboratory parameters, as stated in the medical record, were determined in fasting pa-
tients not using lipid-lowering medication for at least 6 weeks. Total cholesterol, high-density 
lipoprotein (HDL) cholesterol and triglyceride levels were measured by standard enzymatic 
methods. LDL cholesterol concentrations were calculated with the Friedewald formula.
Cardiovascular disease
Primary outcome of the study was fatal or non-fatal CVD. CVD was defined as coronary, cere-
bral, or peripheral artery disease using internationally accepted criteria as published before.24 
Secondary endpoints of the study were coronary heart disease, cerebral artery disease, and 
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peripheral artery disease. Coronary heart disease was defined as: (i) myocardial infarction, (ii) 
percutaneous coronary intervention or other invasive procedures, (iii) coronary artery bypass 
grafting, and (iv) angina pectoris. Cerebral artery disease was defined as: (i) ischaemic stroke 
and (ii) documented transient ischaemic attack. Peripheral artery disease was defined as: (i) 
peripheral arterial bypass grafting, (ii) peripheral percutaneous transluminal angioplasty or 
other percutaneous invasive intervention, and (iii) intermittent claudication.
Molecular analysis
Genomic DNA was extracted from peripheral blood leukocytes according to a standard pro-
tocol.27 We decided to analyse only those ABCG5 and/or ABCG8 polymorphisms that showed 
most consistently associations with plasma plant sterol and cholesterol concentrations in 
earlier studies among Caucasian populations.12-16 This resulted in the selection of two poly-
morphisms in ABCG8: D19H (substitution of histidine for aspartic acid at amino acid 19 in 
exon 1) and T400K (substitution of thyrosine for lysine at amino acid 400 in exon 8). Genotype 
determination was performed using fluorescence-based assay-by-design allelic discrimina-
tion method using Taqman Universal PCR master mix (Applied Biosystems, Foster City, USA), 
Taqman SNP Genotyping Assays, and a Taqman ABI Prism 7900 Sequence Detection System 
(Applied Biosystems). Taqman SNP Genotyping Assay ID for the D19H was C_26135643_10 
and for the T400K C_375061_10 (Applied Biosystems). Reaction components and amplifica-
tion parameters were based on the manufacturer’s instructions using an annealing tem-
perature of 60º. Results were scored blinded for CVD status. From the 2400 heterozygous 
FH patients who comprised the study cohort, complete ABCG8 genotypes were available of 
2012 individuals.
Statistical analysis
All data were analyzed using SPSS for Windows software package version 11.5.0 (SPSS Inc., 
Chicago, IL, USA). Genotype and allele frequencies were compared with values predicted by 
Hardy-Weinberg equilibrium using the chi-square test. Because of the limited number of indi-
viduals homozygous for the ABCG8 polymorphisms, heterozygous and homozygous carriers 
of the minor allele were combined in the analyses. Chi-square test was applied to evaluate 
differences in genotype distributions between individuals without and with a history of CVD. 
Differences in plasma cholesterol concentrations and patient characteristics among ABCG8 
genotypes were analyzed with chi-square statistics. Statistical testing of triglyceride concen-
trations was performed after logarithmic transformation because of its skewed distribution. 
Multiple linear regression analysis was used to adjust statistical tests for the effects of age, 
gender, and smoking.
The association between the D19H and T400K polymorphisms in ABCG8 and the occurrence 
of fatal or non-fatal CVD was assessed using a Cox proportional hazard regression analysis. 
Follow-up started at birth and ended at the first occurrence of established fatal or non-fatal 
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CVD. Patients without CVD were censored at the date of the last lipid clinic visit or at the 
date of death attributable to other causes than CVD. Initially, we adjusted for variables that 
are independent of the polymorphisms in ABCG8: year of birth, age, and smoking. Polymor-
phisms might express their effects via for example hypertension, diabetes mellitus, obesity, 
or dyslipidemia. To evaluate the influence of the polymorphisms in ABCG8 on intermediate 
CVD traits, we additionally adjusted for variables that were significant risk factors of CVD in 
the Cox regression analysis. A two-tailed p-value of less than 0.05 was considered a statistical 
significant result.
Results
Patient characteristics and genotype frequencies
Characteristics of all 2012 subjects with heterozygous FH are shown in Table 1. Table 2 shows 
ABCG8 genotype and allele frequencies. For the D19H polymorphism, we observed homozy-
gosity (HH) in 9 (0.4%) patients, heterozygosity (DH) in 244 (11.8%) patients, and 1812 (87.7%) 
patients were homozygous for the wild type allele (DD). For the T400K polymorphism, 48 
(2.3%) patients were homozygous (KK), 532 (25.9%) patients were heterozygous (TK), and in 
1473 (71.7%) patients the homozygous wild type allele (TT) was detected. Genotype distri-
butions in the total cohort and in patients without and with a history of CVD were in Hardy-
Weinberg equilibrium for both ABCG8 genotypes (p > 0.2).
Using chi-square analyses, ABCG8 genotype distributions were similar between individuals 
without and with a history of CVD (D19H, p = 0.9; T400K, p = 0.1)
Table 1. Characteristics of 2012 individuals with heterozygous FH
Characteristic
Age at first lipid clinic visit (years) 44.8 (± 0.3)
Age at last lipid clinic visit (years) 49.8 (± 0.3)
Males (%) 48.7 (± 1.1)
Smoking, ever (%) 73.2 (± 1.0)
Hypertension (%) 9.0 (± 0.6)
Diabetes (%) 5.8 (± 0.5)
Body mass index (kg/m2) 25.1 (± 0.1)
Total cholesterol (mmol/L) 9.50 (± 0.05)
Low-density lipoprotein cholesterol (mmol/L) 7.33 (± 0.05)
High-density lipoprotein cholesterol (mmol/L) 1.22 (± 0.01)
Triglycerides (mmol/L) 1.81 (± 0.03)
Values are given as means ± standard error of the mean (SEM).
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Table 2. Genotype and allele distributions for D19H and T400K polymorphisms in ABCG8
D19H T400K
CVD – CVD + CVD – CVD +
N (%) N (%) N (%) N (%)
Genotypes
Wild type 1198 (87.8) 570 (88.0) 965 (70.7) 479 (73.9)
Heterozygous 161 (11.8) 76 (11.7) 372 (27.3) 151 (23.3)
Homozygous 5 (0.4) 2 (0.3) 27 (2.0) 18 (2.8)
Total 1364 (100.0) 648 (100.0) 1364 (100.0) 648 (100.0)
Alleles
Wild type allele 2557 (93.7) 1216 (93.8) 2302 (84.4) 1109 (85.6)
Minor allele 171 (6.3) 80 (6.2) 426 (15.6) 187 (14.4)
Total 2728 (100.0) 1296 (100.0) 2728 (100.0) 1296 (100.0)
CVD indicates history of cardiovascular disease.
ABCG8 genotypes and plasma cholesterol concentrations
Plasma cholesterol concentrations according to D19H genotypes are illustrated in Figure 1 
and among T400K genotypes in Figure 2. We found no significant differences in plasma lipid 
concentrations among D19H and T400K genotypes. Additional adjustment for year of birth, 
gender, and smoking did not change the results. Patients homozygous or heterozygous for 
the T400K polymorphism had significantly less often hypertension compared to carriers of 
the wild type alleles (7.0% vs. 9.8%; p = 0.03). In addition, demographics, gender, BMI, the 
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Figure 1. Mean plasma cholesterol concentrations ± standard deviation in the different genotypes of the ABCG8 D19H polymorphism. 
Cholesterol levels are expressed in mmol/L.
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presence of smokers and diabetes mellitus were comparable among the ABCG8 genotype 
groups (data not shown).
ABCG8 genotypes and risk of CVD
During 94,809 person years, 648 (32.2%) FH individuals had their first cardiovascular event. 
Mean age of onset of CVD was 48.4 ± 10.9 years. Separate analyses of a number of variables, 
which may act as confounder or intermediate trait in the relationship between the ABCG8 
variants and CVD susceptibility, are presented in Table 3. Year of birth, male gender, smok-
ing, diabetes, lower plasma HDL cholesterol concentrations, and higher plasma triglyceride 
levels were significantly associated with increased CVD risk. As shown in Table 4, we found no 
evidence for associations of the D19H or T400K polymorphisms with total CVD risk.
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Figure 2. Mean plasma cholesterol concentrations ± standard deviation in the different genotypes of the ABCG8 T400K polymorphism. 
Cholesterol levels are expressed in mmol/L.
Table 3. Risk factors of cardiovascular disease estimated with Cox regression analyses
Variables Relative Risk (95% CI) p-value
Year of birth 1.07 (1.06 to 1.09) <0.001
Males 3.03 (2.57 to 3.58) <0.001
Smoking 1.94 (1.57 to 2.39) <0.001
Diabetes mellitus 1.31 (1.03 to 1.67) 0.03
Hypertension 1.14 (0.92 to 1.41) 0.2
Body mass index 1.02 (0.99 to 1.05) 0.1
Low-density lipoprotein cholesterol 0.96 (0.92 to 1.01) 0.1
High-density lipoprotein cholesterol 0.36 (0.26 to 0.48) <0.001
Triglycerides 1.22 (1.08 to 1.38) 0.002
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ABCG8 genotypes and risk of secondary cardiovascular endpoints
Coronary artery disease was the most frequent cardiovascular event: in 553 (85.3%) subjects 
it was the first event. Cerebral artery disease occurred as the first event in only 37 (5.7%) 
persons. In 58 (9.0%) patients the first event was peripheral artery disease. The relationship 
between ABCG8 genotypes and coronary heart disease is shown in Table 4. The D19H poly-
morphism was associated with increased risk of coronary heart disease, but only after adjust-
ment for year of birth, gender, smoking, diabetes, HDL cholesterol, and triglycerides levels in 
multiple Cox regression analyses (adjusted model). We found no significant relationship of 
the D19H variant with susceptibility of cerebral artery disease and peripheral artery disease 
(data not shown). Nor did we find associations between T400K polymorphism and any sec-
ondary cardiovascular endpoint.
The average (± SD) age at end of follow-up of patients without CVD was 46.5 ± 12.7 years 
and this was significantly lower than the mean age (48.4 ± 10.9 years) at onset of CVD in 
the other group. Therefore, we tested the effect of age by adjusting for age tertiles in the 
Cox regression analysis, but this did not essentially change the outcome measures (data not 
shown).
Discussion
In this large cohort study of high-risk patients with FH, we found that the D19H polymor-
phism was not associated with plasma cholesterol levels nor with total CVD risk, but there 
was evidence of an association with higher risk of coronary heart disease. We observed no 
significant association between the T400K polymorphism and plasma cholesterol levels or 
cardiovascular endpoints.
Our present analysis is the first study that examined the association between polymor-
phisms in the ABCG8 gene and risk of CVD. The important role of elevated plant sterol levels 
in humans is illustrated by sitosterolemia in which plasma levels of plant sterols are increased 
Table 4. Relative risk of cardiovascular events estimated with Cox regression analyses in 2012 individuals with FH
Crude model Adjusted model
Relative risk (95% CI) p-value Relative risk (95% CI) p-value
ABCG8 D19H polymorphism
Cardiovascular disease 1.13 (0.89 – 1.46) 0.3 1.24 (0.92 – 1.68) 0.2
Coronary heart disease 1.27 (0.98 – 1.64) 0.07 1.40 (1.03 – 1.92) 0.03
ABCG8 T400K polymorphism
Cardiovascular disease 0.88 (0.73 – 1.05) 0.2 0.87 (0.69 – 1.08) 0.2
Coronary heart disease 0.87 (0.72 – 1.06) 0.2 0.83 (0.66 – 1.05) 0.1
Crude: adjusted for year of birth, gender, and smoking; adjusted: further adjusted for diabetes, plasma HDL cholesterol and triglycerides 
concentrations.
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>50-fold due to non-function of either the ABCG5 or ABCG8 protein, leading to severe ath-
erosclerotic arterial disease at a young age.5,6 Although mutations that cause sitosterolemia 
are extremely rare, more common sequence variants in ABCG8 have been identified that 
have more subtle effects on plasma plant sterol levels as well as plasma cholesterol concen-
trations.12 In addition, several studies have reported that also in nonsitosterolemic subjects 
elevated plasma concentrations of plant sterols are associated with cardiovascular events, 
suggesting that plant sterols are atherogenic.7-10
Although the D19H polymorphism was not associated with plasma cholesterol levels in 
our FH cohort, heterozygous and homozygous carriers of this polymorphism had a slightly 
higher risk of coronary heart disease than carriers of the wild type. Previous studies have 
consistently demonstrated associations of the 19H allele with lower plasma sitosterol and 
campesterol concentrations.12,13 Hence, it was speculated that the substitution of histidine 
for aspartic acid at amino acid 19 increases the transporter function of ABCG8. The enhanced 
efflux of sterols from enterocytes to small intestinal lumen and augmented excretion of ste-
rols from the liver into the bile would eventually lead to lower plasma sterol concentrations. 
However, the effect of this amino acid substitution on ABCG8 function was never directly 
determined in an in vitro assay. Results about the relationship of the D19H polymorphism 
with plasma cholesterol levels were more contradicting: one study has found an association 
of the 19H allele with lower plasma total and LDL cholesterol levels,13 whereas other genetic 
association studies have failed to confirm this relationship.12,16
Based on the association with lower plasma plant sterol concentrations, we had a priori 
expected that carriers of the D19H variant would have had a decreased risk of cardiovascular 
events. Despite the clinical phenotype of sitosterolemia and several (relatively small) studies 
that found an association of elevated plasma plant sterol levels with CVD, other research 
groups have linked a high plant sterol content of the diet to atheroprotection. In the Asian 
diet, for example, the main protein is soy (which is rich in plant sterols), and this has been 
postulated as one of the possible explanations for the lower incidence of CVD in some Asian 
populations.28 In addition, adding plant sterols to margarine and other foods is currently used 
to optimize cardiovascular risk profile by decreasing plasma cholesterol concentrations.29
A possible explanation for the lack of a significant association in the primary endpoint total 
CVD with the D19H polymorphism is that coronary heart disease is probably a more homo-
geneous phenotype than the combined endpoint CVD. On the other hand, the minor allele 
frequency of the D19H polymorphism in our FH cohort was 6.2% and the association with 
coronary heart disease was only significant after correction for a number of cardiovascular 
risk factors. Post-hoc analyses in such small sub-populations should always be interpreted 
with caution and our observations should, therefore, be replicated in larger population-
based studies.
We found no association between the T400K polymorphism and any cardiovascular 
event nor with plasma cholesterol concentrations. Previous studies have shown that this 
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polymorphism was associated with lower sitosterol to cholesterol ratios, but these findings 
were not as consistent as for the D19H variant.12-14 In line with our observations, none of these 
studies found a significant relationship between the T400K variant and plasma cholesterol 
levels.
Although the D19H variant was associated with a slightly higher risk of coronary heart 
disease, we have to conclude that these two ABCG8 variants are not major contributors of 
CVD or coronary heart disease susceptibility in our study. The severe hypercholesterolemia 
in our patients might offer a clue as to why we observe these results. The potential beneficial 
effect of these ABCG8 polymorphisms may be partly due to lower total and LDL cholesterol 
levels.13-16 We did not observe, however, such differences; the dominant dyslipidemia of FH 
may outweigh potential beneficial effects on cholesterol metabolism. In the general popula-
tion, variants in the ABCG8 gene may be better risk predictors for cardiovascular events.
The strengths of our study are that we included a high-risk study population and that we 
carefully selected our polymorphisms. FH patients have an 8.5 times increased risk of CVD.19 
Although all FH patients have severe hypercholesterolemia, excess mortality caused by CVD 
occurs in 60% of the untreated patients whereas 40% reach a normal life span.20 Clearly sec-
ondary genetic factors and environmental factors determine CVD risk in FH.20-22 The mono-
genic background and the large variation of CVD risk offer a unique opportunity to analyze 
secondary genes involved in CVD.23 Moreover, we restricted the number of genetic variants 
(and thereby the number of null hypotheses) by selecting only the two ABCG8 polymor-
phisms that showed most consistently associations with plasma plant sterol and cholesterol 
concentrations in earlier studies among Caucasian populations.12-16
Several potential limitations of the present study have to be mentioned. All phenotypic 
data were retrospectively obtained by reviewing the patient’s medical records and certain 
information of interest, such as dietary habits and plasma plant sterol levels, were not avail-
able. Consequently, we could not assess the influence of plasma plant sterol concentrations 
as a potential intermediate trait in the relationship between ABCG8 polymorphisms and CVD 
risk. Moreover, we could not replicate our findings in a second independent study popula-
tion, because to our knowledge this is the only large FH cohort with such well-defined clinical 
endpoints. Finally, our study population consists of Caucasian individuals with FH, so these 
data cannot be generalized to other ethnic groups and the general population.
In conclusion, in this large, multicenter, cohort study amongst high-risk individuals with 
FH, we found a modest effect of the ABCG8 D19H gene variant on risk of coronary heart 
disease, but we did not observe a relationship between the ABCG8 T400K polymorphism and 
cardiovascular endpoints. Our data suggest that these two genetic variations in the ABCG8 
gene are not major contributors for differences in CVD susceptibility among FH individuals.
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Abstract
Context: Individuals with the functional ER22/23EK variant in the glucocorticoid receptor 
gene are relatively resistant to the downstream consequences of glucocorticoids. Evidence 
suggests that carriers have a more favorable cardiovascular risk profile, but the relationship 
between this ER22/23EK variant and cardiovascular disease has not been hitherto assessed.
Objective: We, therefore, determined whether carriership of the ER22/23EK improves cardio-
vascular disease risk in patients with severe hypercholesterolemia.
Design, Setting, and Participants: In a multicenter cohort study, 2024 patients with heterozy-
gous familial hypercholesterolemia, aged 18 years and older, were genotyped for the 
ER22/23EK polymorphism. Patients were identified at lipid clinics throughout the Nether-
lands between 1989 and 2002.
Main Outcome Measures: The primary outcome measure was cardiovascular disease.
Results: Seventy-six (7.8%) out of 977 men and 72 (6.9%) of 1047 women were carriers of the 
ER22/23EK variant. A total of 395 men and 247 women had a cardiovascular event. In contrast 
to expected results, we observed no significant association of the ER22/23EK variant with 
cardiovascular disease risk (men, RR 0.75, 95% CI 0.50 – 1.14, p = 0.2; women, RR 1.37, 95% 
CI 0.82 – 2.28, p = 0.2). However, we found a significant interaction between gender and the 
polymorphism on cardiovascular disease (p = 0.02).
Conclusions: In this large cohort of individuals with very high-risk of cardiovascular disease, 
the association between the functional ER22/23EK polymorphism and cardiovascular risk 
was not significant overall, though it varied significantly by gender.
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Introduction
Familial hypercholesterolemia (FH) is an autosomal dominant disorder caused by mutations 
in the low-density lipoprotein (LDL) receptor gene.1 The prevalence of heterozygotes in Cau-
casian populations averages about 1:500, positioning FH among the most common mono-
genetic disorders in man.2 Patients with FH have severely increased LDL cholesterol levels 
and a pronounced susceptibility to premature cardiovascular disease (CVD).1,2 Despite the 
monogenetic nature of this disorder, however, large variation in CVD risk is observed.3,4 Age, 
gender, smoking, body mass index (BMI), and the presence of hypertension and diabetes 
mellitus contribute to this variation of CVD risk.5,6 In addition, polymorphisms in candidate 
genes have also been shown to modulate the expression of the clinical phenotype,7-15 sup-
porting the concept that the hereditary component of CVD is determined by multiple genes, 
each explaining only a limited proportion of the risk.16 The present challenge is to identify 
those markers that improve risk prediction in FH in order to tailor preventive strategies to the 
individual risk level.
Variants in the glucocorticoid receptor gene have been associated with a plethora of 
cardiovascular risk factors.17 One of these variants consists of two linked, single nucleotide 
changes in codon 22 and 23 of exon 2. The mutation in codon 22 at nucleotide position 198 
does not result in an amino acid change (both coding for a glutamic acid (E)), whereas the 
other sequence change in codon 23 at nucleotide position 200 causes a change from argin-
ine (R) to lysine (K). Therefore, this variant has been named ER22/23EK. Upon dexamethasone 
suppression testing, carriers of the ER22/23EK variant express higher serum cortisol concen-
trations as well as a smaller decrease in cortisol levels, suggesting a relative resistance to 
glucocorticoids.18 Recently, the pathophysiological basis of this resistance was elucidated.19,20 
Alternative translation initiation occurs that results in two isoforms of the glucocorticoid 
receptor: a long (GR-A) and a short (GR-B) isoform.21 The GR-B protein has stronger gene tran-
scription activating effects.20 The ER22/23EK polymorphism affects translation, resulting in 
a shift towards the less active GR-A variant.19,20 In fact, association studies have shown that 
carriers have: (i) lower plasma total and LDL cholesterol levels; (ii) increased insulin sensitivity; 
(iii) beneficial body composition; and (iv) lower plasma C-reactive protein levels and a better 
survival.18,22,23
These findings suggest that carriers of this functional ER22/23EK variant in the glucocor-
ticoid receptor gene may have a reduced risk of CVD. Nevertheless, this relationship has not 
been assessed. In the present study, we therefore investigated the effect of this polymor-
phism on CVD in patients heterozygous for FH.
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Materials and Methods
Study design and study population
Between 1989 and 2002, Lipid Clinics throughout the Netherlands submitted blood samples 
of 9,300 patients who were clinically suspected for FH to a central laboratory for LDL receptor 
mutation analysis.6 Out of this database, we randomly selected 4,000 patients and diagnosed 
FH according to previously published criteria.6 We excluded subjects with secondary causes 
of hypercholesterolemia and those with hypercholesterolemia caused by other genetic de-
fects, such as familial defective apolipoprotein B. A total of 2,400 unrelated patients aged 
18 years and older fulfilled the diagnostic criteria for heterozygous FH. Over 99% of these 
patients were Caucasian. The Institutional Review Board of each participating hospital ap-
proved the study protocol and informed consent was obtained from all patients.
Data collection
Patients’ medical records were used to acquire information about age, gender, smoking, BMI, 
and the presence of hypertension (patients with a documented diagnosis using antihyper-
tensive medication or a systolic blood pressure >140 mmHg or a diastolic blood pressure >90 
mmHg at three consecutive office visits) and diabetes mellitus (patients using anti-diabetic 
medication or fasting plasma glucose >6.9 mmol/L). Additional information was sought from 
general practitioners and hospitals that patients had visited formerly and with questionnaires 
to ensure data completeness.
Lipid levels were determined in fasting patients not using lipid-lowering medication for at 
least 6 weeks. Total cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides 
were measured by standard methods. LDL cholesterol was calculated with the Friedewald 
formula. Forty patients had triglyceride levels > 4.5 mmol/L and in these individuals LDL-C 
concentrations were directly measured by standard methods.
CVD and CHD definitions
CVD was defined as coronary, cerebral, or peripheral artery disease using internationally ac-
cepted criteria as published before.6 Coronary heart disease (CHD) was defined by the pres-
ence of: (I) myocardial infarction, (II) percutaneous coronary intervention or other invasive 
procedures, (III) coronary artery bypass grafting, (IV) angina pectoris.
Molecular analysis
DNA was available of 2024 heterozygous FH patients for the present analyses. Genomic 
DNA was extracted from peripheral blood leukocytes according to a standard proto-
col.24 The ER22/23EK polymorphism in the glucocorticoid receptor gene was detected 
by allelic discrimination using Taqman Universal PCR master mix (Applied Biosystems, 
Foster City, USA), primers (forward: 5’AGAAGAAAACCCCAGCAGTGT-3’ and reverse: 5’-
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CAGTAGCTCCTCCTCTTAGGGTTTTA-3’), probes (Applied Biosystems), and a Taqman ABI 
Prism 7900 Sequence Detection System (Applied Biosystems). Used probes were 5’-FAM-
CACATCTCCCTTTTCCTGA-3’ and 5’-VIC-CACATCTCCCCTCTCCTGA-3’ (Applied Biosystems). 
Reaction components and amplification parameters were based on the manufacturer’s in-
structions using an annealing temperature of 60º.
Statistical analysis
All data were analyzed using SPSS for Windows software package version 11.5.0 (SPSS Inc., 
Chicago, IL, USA). Since the hormone dynamics and the risk of CVD differ considerably be-
tween men and women, we stratified our analyses by gender. As expected, the number of 
ER22/23EK homozygotes was limited; the analyses of heterozygous and homozygous carriers 
were therefore combined. Contingency tables were used with chi-square tests to compare 
observed genotype frequencies with those expected under Hardy-Weinberg equilibrium. Dif-
ferences between ER22/23EK carriers and noncarriers and men and women were tested with 
chi-square statistics for dichotomous variables or independent sample t-test for continuous 
variables. Statistical testing of triglyceride levels was performed after logarithmic transforma-
tion. We used multiple logistic regression analysis to adjust statistical tests for age.
The association between the ER22/23EK polymorphism and the occurrence of CVD and 
CHD was evaluated using a Cox proportional hazard regression analysis. The proportional 
hazards assumption was tested by drawing log minus log plots of the survival function and 
was met for all Cox proportional hazard models. Follow-up started at birth and ended at the 
first occurrence of established fatal or non-fatal CVD. Patients without CVD were censored at 
the date of the last lipid clinic visit or at the date of death attributable to other causes than 
CVD. In the primary model, we adjusted for year of birth and smoking. Additional variables, 
which had significant effects on CVD risk in univariate Cox regression analyses, were inves-
tigated in the secondary model. Young patients with the polymorphism may not have had 
the chance to express their high CVD risk. Therefore, we tested the effect of age by adjusting 
for age tertiles in the Cox regression analysis. The interaction between the ER22/23EK variant 
and gender in the total population was statistically tested in the Cox regression analysis with 
adjustment for variables that were significantly different between genders. Throughout, a 
two-tailed p value of less than 0.05 was interpreted as statistical significant.
Results
Patient characteristics
In 977 men heterozygous for FH, 76 (7.8%) individuals were heterozygous for the ER22/23EK 
polymorphism but no homozygous carriers were detected. In 1047 women heterozygous 
for FH, 70 (6.7%) were heterozygous for the ER22/23EK variant whereas 2 (0.2%) were 
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homozygous. In women with CVD, the ER22/23EK variant deviated from Hardy-Weinberg 
equilibrium (χ2 = 9.182; p = 0.002) due to the small number of homozygotes; omitting one of 
them resulted in equilibrium. The genotype distributions in the total cohort and in all other 
subgroups (Table 1) did not differ from Hardy-Weinberg equilibrium (χ2 < 1.610; P > 0.2).
Table 1. Genotype and allele frequencies for the ER22/23EK polymorphism in the glucocorticoid receptor gene
Men Women
CVD No CVD CVD No CVD
N (%) N (%) N (%) N (%)
Genotypes
Wild type 368 (93.2) 533 (91.6) 231 (93.5) 744 (93.0)
Heterozygous ER22/23EK 27 (6.8) 49 (8.4) 14 (5.7) 56 (7.0)
Homozygous ER22/23EK 0 (0.0) 0 (0.0) 2 (0.8) 0 (0.0)
Total 395 (100.0) 582 (100.0) 247 (100.0) 800 (100.0)
Alleles
Wild type allele 763 (96.6) 1115 (95.8) 476 (96.4) 1544 (96.5)
ER22/23EK allele 27 (3.4) 49 (4.2) 18 (3.6) 56 (3.5)
Total 790 (100.0) 1164 (100.0) 494 (100.0) 1600 (100.0)
Abbreviations: CVD, history of cardiovascular disease.
Table 2. Characteristics of male and female familial hypercholesterolemia patients with and without the ER22/23EK polymorphism in the 
glucocorticoid receptor gene
Men Women
Noncarriers ER22/23EK Carriers p-value* Noncarriers ER22/23EK Carriers p-value*
(n=901) (n=76) (n=975) (n=72)
Age at first lipid clinic visit 
(years)
43.6 (± 0.4) 43.3 (± 1.2) 0.8 46.2 (± 0.4) 41.5 (± 1.6) 0.006
Age at last lipid clinic visit 
(years)
48.7 (± 0.4) 47.7 ± (1.2) 0.4 51.0 (± 0.5) 47.7 ± (1.7) 0.07
Smoking, ever (%) 79.3 (± 1.4) 76.1 (± 5.1) 0.6 67.7 (± 1.6) 57.6 (± 6.1) 0.08
Hypertension (%) 8.6 (± 0.9) 6.8 (± 2.9) 0.6 10.1 (± 1.0) 8.5 (± 3.3) 0.9
Diabetes mellitus (%) 5.5 (± 0.8) 3.9 (± 2.2) 0.7 6.3 (± 0.8) 6.9 (± 3.0) 0.6
Body mass index (kg/m2) 25.5 (± 0.1) 25.7 (± 0.4) 0.5 24.8 (± 0.1) 24.3 (± 0.5) 0.4
Total cholesterol (mmol/L) 9.36 (± 0.07) 9.41 (± 0.24) 0.8 9.67 (± 0.06) 9.76 (± 0.28) 0.4
LDL cholesterol (mmol/L) 7.24 (± 0.07) 7.22 (± 0.26) 0.9 7.46 (± 0.07) 7.70 (± 0.27) 0.2
HDL cholesterol (mmol/L) 1.09 (± 0.01) 1.14 (± 0.04) 0.3 1.32 (± 0.01) 1.30 (± 0.05) 0.6
Triglycerides (mmol/L) 1.96 (± 0.03) 2.15 (± 0.11) 0.4† 1.64 (± 0.03) 1.64 (± 0.13) 0.9†
Abbreviations: LDL indicates low-density lipoprotein; HDL, high-density lipoprotein.
Values are given as means ± standard error of the mean (SEM).
SI conversion factors: to convert total cholesterol, LDL cholesterol, and HDL cholesterol to mg/dL, multiply by 38.67; for triglycerides, multiply 
by 89.15.
*Additional adjustment for age.
†Statistical testing after logarithmic transformation.
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The clinical and biochemical characteristics of carriers and noncarriers of the ER22/23EK 
polymorphism are presented in Table 2. In men, no differences existed between patients with 
and without ER22/23EK. Female carriers of ER22/23EK were 4.6 ± (SD) 1.7 years younger at 
first Lipid Clinic visit compared with women without the polymorphism (p = 0.006). Other 
variables were not significantly different between female carriers and noncarriers.
Males visited the Lipid Clinic 2.3 ± (SEM) 0.6 years earlier, were more often smokers (differ-
ence, 12.0 ± 2.1%), had a higher BMI (difference, 0.7 ± 0.2 kg/m2), lower plasma LDL cholesterol 
(difference, 0.24 ± 0.09 mmol/L) and HDL cholesterol (difference, 0.23 ± 0.02 mmol/L) levels, 
and higher plasma triglyceride concentrations (difference, 0.34 ± 0.05 mmol/L) compared 
with women; all as expected.
Risk factors for CVD
During 44.044 person years, 395 (40.4%) men had onset of CVD and a total of 247 (23.6%) 
women had their first cardiovascular event during 51.331 person years. The mean age of on-
set of CVD (± SD) was 45.7 ± 9.3 years in men and 52.8 ± 11.6 years in women.
Separate analyses of a number of variables, which may act as confounder or intermediate 
trait in the relationship between the ER22/23EK polymorphism and CVD risk, are presented 
in Table 3. In men and women, year of birth, smoking, and lower plasma HDL cholesterol con-
centrations were significantly associated with increased CVD risk. The presence of diabetes 
mellitus also contributed to an increased risk of CVD in women but not in men. Hypertension, 
BMI, plasma LDL cholesterol levels, and triglyceride concentrations were not significantly as-
sociated with CVD among men or women.
Table 3. Risk factors of cardiovascular disease in 977 men and 1047 women with familial hypercholesterolemia
Variables Men Women
Relative Risk (95% CI) p-value Relative Risk (95% CI) p-value
Year of birth 1.05 (1.04 to 1.07) <0.001 1.08 (1.06 to 1.10) <0.001
Smoking 1.56 (1.14 to 2.15) 0.006 1.53 (1.15 to 2.05) 0.004
Diabetes mellitus 1.06 (0.76 to 1.48) 0.7 1.68 (1.19 to 2.37) 0.004
Hypertension 1.32 (1.00 to 1.75) 0.05 1.10 (0.79 to 1.52) 0.6
Body mass index 1.00 (0.97 to 1.04) 0.8 1.04 (1.00 to 1.08) 0.07
LDL cholesterol 0.99 (0.92 to 1.06) 0.7 1.00 (0.93 to 1.08) 0.9
HDL cholesterol 0.53 (0.35 to 0.80) 0.002 0.47 (0.29 to 0.75) 0.001
Triglycerides 1.15 (0.99 to 1.35) 0.08* 1.02 (0.83 to 1.26) 0.8*
Abbreviations: LDL, low-density lipoprotein; HDL, high-density lipoprotein.
*Statistical testing after logarithmic transformation.
CVD and the ER22/23EK polymorphism
In the total population, we found no significant association between the ER22/23EK vari-
ant and CVD with adjustment for year of birth, gender, and smoking (RR 0.92, 95% CI 
0.67 – 1.27; p = 0.6). Unadjusted survival rates of men and women with and without the 
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ER22/23EK polymorphism are shown in Table 4. Figure 1 illustrates the association between 
the ER22/23EK polymorphism and the cumulative incidence of CVD during lifetime follow-up 
in patients with FH after adjustment for year of birth and smoking and stratified by gender. 
The ER22/23EK polymorphism was not significantly associated with CVD in either gender: 
male carriers had a 0.75 (95% CI 0.50 – 1.14; p = 0.2) times decreased risk of CVD, whereas 
female carriers had a 1.37 (95% CI 0.82 – 2.28; p = 0.2) times increased CVD risk. As shown in 
Table 5, additional adjustment of plasma HDL cholesterol concentrations in men and plasma 
HDL cholesterol concentrations and diabetes mellitus in women did not change the results. 
To test for effects of the ER22/23EK variant on CVD risk with age, we repeated the multiple 
Cox regression analyses of the primary model with additional adjustment for age tertiles. 
After this additional adjustment, the CVD risk estimates remained virtually identical in men 
(RR 0.75, 95% CI 0.49 – 1.13; p = 0.2) and in women (RR 1.41, 95% CI 0.84 – 2.35; p = 0.2).
Table 4. Cardiovascular disease free survival of patients with familial hypercholesterolemia according to the ER22/23EK polymorphism in the 
glucocorticoid receptor gene
Men Women
Noncarriers ER22/23EK Carriers Noncarriers ER22/23EK Carriers
CVD free survival*
40 years 62.9 (1.9) 63.0 (6.5) 87.1 (1.3) 85.7 (5.2)
50 years 35.2 (2.4) 43.9 (8.5) 70.1 (2.0) 63.3 (8.7)
60 years 20.5 (2.9) 31.4 (12.2) 49.2 (2.8) 41.0 (11.8)
Median survival time 54.7 56.8 69.6 66.0
Abbreviations: CVD, history of cardiovascular disease.
*Cumulative CVD free survival probability ± standard error of the mean (SEM).
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Figure 1. Cardiovascular disease hazard curve according to the ER22/23EK polymorphism in 977 men and 1047 women with heterozygous 
familial hypercholesterolemia.
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Although we found no significant relationship between the ER22/23EK variant and CVD 
overall, the effect of the polymorphism on CVD risk seemed opposite in men and women. 
Therefore, we tested the interaction between the ER22/23EK variant and gender in the total 
population using Cox regression analysis with adjustment for variables that were significantly 
different between genders (age, smoking, BMI, plasma LDL cholesterol, HDL cholesterol, and 
triglyceride levels). Indeed, the effect of the ER22/23EK variant on CVD risk was significantly 
different for men and women (p = 0.02).
CHD and the ER22/23EK polymorphism
CHD was the most frequent cardiovascular event: in 350 (88.6%) men and 200 (81.0%) women 
CHD was the first event. Cerebral artery disease occurred as the first event in only 20 (5.1%) 
men and 20 (8.1%) women; in 25 (6.3%) men and 27 (10.9%) women the first event was pe-
ripheral artery disease.
In the total population, again we observed no significant relationship between the poly-
morphism and CHD after adjustment for year of birth, gender, or smoking (RR 0.93, 95% CI 0.67 
– 1.31; p = 0.7). With adjustment for year of birth and smoking, the ER22/23EK polymorphism 
was not significantly associated with CHD in men (RR 0.72, 95% CI 0.46 – 1.12; p = 0.1) or women 
(RR 1.60, 95% CI 0.94 – 2.73; p = 0.09). Additional adjustment for additional variables resulted 
in similar risk estimates (Table 5). In line with the results for CVD, the effect of the ER22/23EK 
variant on CHD risk was significantly different between men and women (p = 0.006).
Table 5. Relative risks for cardiovascular disease and coronary heart disease according to ER22/23EK genotype
Relative Risk (95% Confidence Interval)
Genotype Univariate Model 1 Model 2 Model 3
Men CVD
Wild type 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
ER22/23EK 0.86 (0.58 – 1.27) 0.75 (0.50 – 1.14) 0.73 (0.46 – 1.17) 0.75 (0.49 – 1.13)
Women CVD
Wild type 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
ER22/23EK 1.27 (0.76 – 2.10) 1.37 (0.82 – 2.28) 1.35 (0.74 – 2.44) 1.41 (0.84 – 2.35)
Men CHD
Wild type 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
ER22/23EK 0.83 (0.55 – 1.25) 0.72 (0.46 – 1.12) 0.72 (0.44 – 1.19) 0.71 (0.46 – 1.11)
Women CHD
Wild type 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
ER22/23EK 1.45 (0.86 – 2.45) 1.60 (0.94 – 2.73) 1.62 (0.86 – 3.02) 1.64 (0.96 – 2.80)
Abbreviations: CVD, history of cardiovascular disease; CHD, coronary heart disease.
Model 1: adjusted for year of birth and smoking.
Model 2: adjusted for year of birth, smoking, and HDL cholesterol levels in men and adjusted for year of birth, smoking, HDL cholesterol levels, 
and diabetes in women.
Model 3: adjusted for year of birth, smoking, and age tertiles.
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Discussion
We hypothesized that the functional ER22/23EK variant in the glucocorticoid receptor gene 
might decrease CVD risk. In this large cohort at severely increased risk, however, the associa-
tion between the ER22/23EK variant and the occurrence of CVD or CHD was not significant 
overall. Nonetheless, in a post hoc analysis we found opposite effects of the polymorphism 
on CVD and CHD in men and women.
Exogenous as well as endogenous glucocorticoid excess in humans contributes to the de-
velopment of hypertension, dylipidemia, impaired glucose tolerance, central adiposity, and 
may imbalance thrombosis and fibrinolysis.25,26 Glucocorticoids exert their function primarily 
via binding to the cytoplasmic glucocorticoid receptor, which then transfers into the nucleus 
where it enhances or represses transcription of specific target genes.27 The ER22/23EK 
polymorphism in the glucocorticoid receptor gene results in a relative glucocorticoid resis-
tance and has been associated with a beneficial cardiovascular risk profile defined by lower 
plasma total and LDL cholesterol levels, increased insulin sensitivity, and beneficial body 
composition.18,22 In addition, carriers had lower plasma C-reactive protein levels as well as 
better overall survival.23 In our FH cohort, 7.3% of the individuals carried at least one copy 
of the variant, in concordance with genotype frequencies described in previous studies 
(5.2 – 8.9%). In contrast to expected results, we found no significant association between 
the ER22/23EK polymorphism and CVD or CHD risk. The severe hypercholesterolemia in our 
patients might offer a clue as to why we observe these results. The potential beneficial ef-
fect of this polymorphism may be partly due to lower LDL cholesterol levels.18 We did not 
observe, however, such differences; the dominant dyslipidemia of FH may outweigh poten-
tial beneficial effects on cholesterol metabolism. In the general population, variants in the 
glucocorticoid receptor gene may be better risk predictors for CVD. Alternatively, we made 
a type II error in the separate analyses of men and women: differences were not observed 
with statistical significance because of lack of power due to small numbers. The result of our 
interaction analysis between the polymorphism and gender in the total population support 
the latter alternative. Based on literature, we had a priori hypothesized that the ER22/23EK 
variant decreased CVD risk and the study was powered to detect a significant association 
between the polymorphism and cardiovascular risk in the total population.
Although we found no significant relationship between the ER22/23EK polymorphism and 
CVD or CHD overall, the influence of the genetic variant appears to be different between 
sexes. This variant has been preferentially analyzed in male individuals and most association 
studies did not analyze men and women separately. In a cohort of young-adults followed 
from the age of 13 to 36 years, the body composition in carriers of the ER22/23EK variant was 
indeed different between sexes: only male carriers were taller, leaner, and had more muscle 
strength.22 The reason for these differential effects of the ER22/23EK variant between men 
and women is yet unknown. In rodents, the hypothalamic-pituitary-adrenal axis responds to 
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variations in circulating sex steroid concentrations.28 This regulation differs between sexes: 
estrogen primarily exerts stimulatory effects on stress-induced ACTH and glucocorticoid 
release, whereas testosterone inhibits stress-related hypothalamic-pituitary-adrenal axis 
activity.28-30 As speculated previously, in a relative glucocorticoid resistance condition, as 
is the case for ER22/23EK carriers, the high circulating estrogen levels in women may an-
nul the potential beneficial effects of the ER22/23EK variant.22 Otherwise, high variability in 
the expression of genes located at the X-chromosome between men and women has been 
reported and may also account for these gender differences.31 An example of such a gene 
is Mediator subunit MED14. Garabedian and co-workers found that MED14 interacts with 
the glucocorticoid receptor and increases its transcriptional activation in a gene-specific 
manner.32,33 Interestingly, MED14 is X-linked and fails to undergo X-chromosome inactivation. 
Therefore, the researchers suggested that MED14 levels could be higher in females than in 
males, which may represent a mechanism underlying gender-specific differences in the ex-
pression of glucocorticoid receptor target genes.33 These observations support that separate 
analyses of men and women are indicated for studies on the ER22/23EK variant.
The monogenetic background but large variation in CVD risk determines the strength of 
the present study. Patients with heterozygous FH have 8.5 times increased cardiovascular 
risk.4 The atherosclerotic burden of the disorder, however, exhibits wide variation and many 
untreated FH patients experience little or no excess mortality.3 As in the general population, 
CVD in FH patients is the result of a dynamic interplay among multiple genes in addition to 
gene-environment interactions.3-5 The disorder is therefore considered to be an exemplary 
model to analyze secondary (or modifier) genes involved in CVD.
However, there are also some limitations to our association study. It depended on medical 
records, questionnaires, and information retrospectively obtained from physicians as the pri-
mary source of data. Certain information of interest, such as postmenopausal status, was not 
available. Furthermore, the influence of the ER22/23EK polymorphism on potential interme-
diate traits (e.g. dexamethasone suppression test, insulin and C-reactive protein levels, body 
composition, and hormone levels) could not be determined. Our study included patients that 
were referred to lipid clinics and this could lead to selection bias in two different ways. First, 
patients with the most detrimental genetic profiles might have died before referral, although 
we did not observe such premature deaths in a previously reported mortality analysis.3 None-
theless, we cannot exclude that polymorphisms causing early death could have been missed, 
leading to underestimation of the risk. Secondly, patients that presented themselves with 
premature symptoms of atherosclerosis are more easily referred to lipid clinics; this could 
lead to selection on CVD in our cohort study. However, we used data of a nationwide screen-
ing program and to prevent selection biases we only selected patients from the 48 larger 
outpatient lipid clinics that are characterized by clinically more diverse patient populations. 
Finally, our findings in heterozygous FH cannot be extrapolated to other populations. The 
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observed opposite effects of the ER22/23EK variant on CVD and CHD in our FH cohort should 
be validated or excluded in wider population-based studies.
In conclusion, in this large, retrospective cohort study amongst patients with heterozygous 
FH, the association between the functional ER22/23EK polymorphism and CVD risk or CHD 
risk was not significant overall, though it varied significantly by gender.
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Abstract
Introduction: Glucocorticoids contribute to the development of hypertension, dyslipidemia, 
impaired glucose tolerance, and central adiposity. Several polymorphisms within the gluco-
corticoid receptor (GR) gene have been reported to alter glucocorticoid sensitivity and have 
been associated with risk factors for cardiovascular disease (CVD). The relationship between 
these GR variants and CVD has not been investigated.
Aim of the study: We determined whether the combined four functional polymorphisms in 
the GR gene influence CVD risk in patients with severe hypercholesterolemia.
Materials and Methods: In a multicenter cohort study, 1,830 patients with heterozygous fa-
milial hypercholesterolemia, aged 18 years and older, were genotyped for the ER22/23EK, 
N363S, BclI, and GR-9β variants. Patients were identified at lipid clinics throughout the Neth-
erlands. The primary outcome measure was CVD defined as coronary, cerebral, and periph-
eral artery disease.
Results: A total of 359 (40.8%) men had onset of CVD and 224 (23.6%) women had their first 
cardiovascular event. We analyzed the combined effect of all GR variants by reconstructing 
haplotypes and using a Cox proportional hazards regression model with adjustment for year 
of birth and smoking. The most frequent haplotype (45%) consisted of the wild type alleles of 
all four polymorphisms. Compared to this haplotype, the GR-9β haplotype, with only varia-
tion at the GR-9β site, was associated with a 41% higher CVD risk (p=0.04) and the BclI haplo-
type, with only variation at the BclI site, with a 34% higher CVD risk (p=0.03) in men only. In 
women, none of the haplotypes was significantly related with CVD. We found no significant 
association of any individual GR variant with CVD risk among men and women. No statistical 
significant differences in cardiovascular risk factors were found between the GR genotype 
groups.
Conclusion: In this large cohort of individuals with very high-risk of CVD, two common hap-
lotypes in the GR gene explained a small proportion of the variation in CVD susceptibility 
among men but not among women.
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Introduction
Glucocorticoids play an important role in the pathofysiology of atherosclerosis by their con-
tribution to the development of hypertension, dyslipidemia, impaired glucose tolerance, 
and central adiposity.1,2 The effects of glucocorticoids are known to be mediated primarily 
by binding to the intracellular glucocorticoid receptor (GR), which belongs to the nuclear 
receptor family of ligand-dependent transcription factors.3 Upon ligand binding, the GR 
translocates to the nucleus where it results in a cascade of events, that eventually leads to 
the induction or repression of glucocorticoid responsive genes. 
The sensitivity to glucocorticoids varies considerably among individuals.4 The presence of 
functional DNA sequence variants within the GR gene has been shown to be partly responsi-
ble for variation in the sensitivity to glucocorticoids.5 Mutations in the GR gene are extremely 
rare and result in generalized glucocorticoid resistance syndromes.6 Several more common 
single nucleotide polymorphisms have been reported to alter glucocorticoid sensitivity more 
subtle and have been associated with cardiovascular disease (CVD) risk factors.7
Two polymorphisms in the GR gene, the N363S and BclI variants, have been associated 
with an increased sensitivity to glucocorticoids in vivo: carriers had lower cortisol levels after 
a dexamethasone suppression test.4,8 In addition, the N363S variant has shown a relationship 
with increased insulin response to exogeneous dexamethasone, higher body mass index 
(BMI), elevated plasma total cholesterol and triglyceride concentrations, and a higher fre-
quency of coronary artery disease.4,9,10 The frequent BclI polymorphism has been linked to 
higher systolic blood pressure and increased abdominal visceral obesity.11-14 
Opposite effects were found of the ER22/23EK polymorphism. Carriers of this polymor-
phism were relatively resistant to the effects of glucocorticoids, because they had higher 
cortisol levels after dexamethasone suppression test.15 Furthermore, they had lower plasma 
total and low-density lipoprotein (LDL) cholesterol concentrations, an increased insulin sen-
sitivity, a beneficial body composition at young-adult age, lower plasma C-reactive protein 
levels, and a better overall survival in the elderly.15-17 Recently, we found subtle effects of this 
polymorphism on CVD risk that varied significantly by gender.18 
The ER22/23EK variant has been previously linked to a fourth polymorphism in the GR gene, 
the GR-9β variant: the rare 22/23EK allele was only present in combination with the rare GR-
9β G-allele.19 Due to alternative splicing, two isoforms of the GR gene exists: GRα and GRβ.20 
These two forms differ in their 3’end (exon 9); GRα mRNA contains exon 9α and GRβ mRNA 
contains exon 9β. GRα can bind glucocorticoids and alter gene transcription, whereas GRβ 
does not bind hormone and is transcriptionally inactive. The GR-9β polymorphism was not 
associated with altered cortisol response to dexamethasone,19 but has been suggested to in-
fluence the immune system. The GR variant was significantly related with a higher frequency 
of rheumatoid arthritis and a decreased susceptibility to nasal colonization by Staphylococcus 
aureus, suggesting a reduced immune suppression in carriers of the GR-9β polymorphism.21,22 
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The effects of glucocorticoids on inflammation are exerted via the transrepressing pathway. 
Recently, ex vivo experiments have shown a decreased glucocorticoid transrepression in per-
sons carrying the GR-9β haplotype whereas glucocorticoid-induced transactivation was not 
significantly different.19
Although these four polymorphisms in the GR gene are associated with altered glucocor-
ticoid sensitivity and cardiovascular risk factors, their combined influence on cardiovascular 
endpoints has thus far not been investigated. In the present study, we therefore determined 
the effect of haplotypes based on these four functional polymorphisms in the GR gene on 
CVD risk in patients with heterozygous FH who have a severely increased predisposition to 
premature cardiovascular events.
Materials and methods
Study design, population, and data collection
The design, population, and data collection of this multicenter cohort study have been de-
scribed previously.23 Briefly, DNA samples of clinically suspected FH patients in The Neth-
erlands are submitted to a central laboratory for LDL receptor mutation analysis. From this 
DNA-bank database, we randomly selected 4,000 out of 9,300 patients whose DNA had been 
collected between 1989 and 2002. A total of 2,400 unrelated patients, aged 18 years and 
older, fulfilled the FH diagnostic criteria that are based on genetic and clinical information.23 
Over 99% were Caucasian. The Institutional Review Board of each participating hospital ap-
proved the study protocol and informed consent was obtained from all patients.
Information about age, gender, smoking, BMI, and the presence of hypertension and dia-
betes mellitus was collected from patients’ medical records, general practitioners, hospital 
physicians, and with questionnaires.23 Smoking was classified as ever having smoked. Body 
mass index (BMI) was calculated from height and length (kg/m2). Hypertension was defined 
as a systolic blood pressure >140 mmHg or a diastolic blood pressure >90 mmHg at three 
consecutive office visits or patients with a documented diagnosis and using antihyperten-
sive medication. Diabetes mellitus was defined as patients with fasting plasma glucose 
>6.9 mmol/L or patients using anti-diabetic medication. Lipid levels, as stated in the medi-
cal record, were determined in fasting patients not using lipid-lowering medication for at 
least 6 weeks. Total cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides 
were measured by standard methods. LDL cholesterol was calculated with the Friedewald 
formula.
CVD endpoints
Primary outcome of this study was fatal or non-fatal CVD defined as coronary, cerebral, and 
peripheral artery disease using internationally accepted criteria as published before.23
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Molecular analysis
Genomic DNA was extracted from peripheral blood leukocytes according to a standard pro-
tocol.24 Allelic discrimination was performed to genotype the patients, using Taqman Uni-
versal PCR master mix, primers, probes, and a Taqman ABI Prism 7900 Sequence Detection 
System (Applied Biosystems, Foster City, USA). Used primers and probes (Applied Biosystems) 
are shown in Table 1. Reaction components and amplification parameters were based on the 
manufacturer’s instructions using an annealing temperature of 60º.
The ER22/23EK polymorphism comprises two linked, single nucleotide variations separated 
by one base pair in exon 2. The first mutation at nucleotide position 198 is silent, changing 
codon 22 from GAG to GAA, both coding for a glutamic acid (E). The second mutation changes 
codon 23 at nucleotide position 200 from AGG to AAG, causing a change from arginine (R) 
to lysine (K). The N363S polymorphism changes codon 363 of exon 2 at nucleotide position 
1220 from AAT to AGT and results in an aspargine (N) to serine (S) amino acid change. The 
very common BclI intronic restriction fragment length polymorphism results in fragments of 
2.3 kb and 4.5 kb due to a C to G nucleotide alteration, 646 nucleotides downstream from 
exon 2. Finally, the GR-9β polymorphism is located in the 3’ untranslated region of exon 9β 
at nucleotide position 3669 and results in an A to G mutation. Successful DNA genotyping 
of the GR gene polymorphisms was possible in 2,024 patients for the ER22/23EK (G/A), 2,032 
patients for the N363S (A/G), 2,063 patients for the BclI (C/G), and 2,025 patients for the GR-9β 
(A/G). The results of the remaining patients were missing due to lack of DNA or inconclusive 
Table 1. Primer and probe sequences for polymorphisms in glucocorticoid receptor gene used in Taqman ABI Prism 7900 Sequence Detection 
System
Polymorphism Sequence (5’−3’)
ER22/23EK (G/A) Forward primer AGAAGAAAACCCCAGCAGTGT
Reverse primer CAGTAGCTCCTCCTCTTAGGGTTTTA
Probes VIC−CACATCTCCCCTCTCCTGA
FAM−CACATCTCCCTTTTCCTGA
N363S (A/G) Forward primer GTCATTCCACCAATTCCCGTTG
Reverse primer GTCAAGTTGTCATCTCCAGATCCTT
Probes VIC−ACCTATTCCAATTTTCGG
FAM−CCTATTCCAACTTTCGG
BclI (C/G) Forward primer CAGGGTTCTTGCCATAAAGTAGACA
Reverse primer GCACCATGTTGACACCAATTCC
Probes VIC−CTCTTAAAGAGATTGATCAGC
FAM−CTCTTAAAGAGATTCATCAGC
GR-9β (A/G) Forward primer TCAGACTGTAAAACCTTGTGTGGAA
Reverse primer CCAATTCGGTACAAATGTGTGGTT
Probes VIC−CTTTTATTTTTTCATTTAAATTT
FAM−TTTATTTTTTCGTTTAAATTT
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genotyping. A total number of 1,830 patients had complete GR genotypes and were used 
in haplotype analysis. There were no differences in CVD risk between subjects with total GR 
genotypes and excluded individuals.
Statistical analysis
All data were analyzed using SPSS for Windows software package version 11.5.0 (SPSS Inc., 
Chicago, IL, USA). Recently, we have reported opposite effects of the ER22/23EK polymor-
phism on CVD risk in men and women.18 Hence, we stratified all present analyses by gender. 
Differences between men and women were tested with chi-square statistics for dichotomous 
variables and independent sample t-test for continuous variables. Statistical testing of trig-
lyceride levels was performed after logarithmic transformation to normalize the distribution. 
Multiple logistic regression analysis was used to adjust statistical tests for age. Deviations of 
the genotype distribution from that expected for a population in Hardy-Weinberg equilib-
rium were tested using the chi-square test with one degree of freedom.
First, we analyzed the combined effect of all GR variants using haplotypes to obtain more 
detailed information about the genetic variation of the locus in relation with CVD. Haplo-
types of the GR were estimated with the PHASE program (version 2.1), which implements a 
Bayesian statistical method for reconstructing haplotypes from population genotype data.25 
In over 99% of the individuals, the alleles of the haplotypes could be inferred with 96-100% 
certainty.
The association between GR haplotype and CVD was evaluated using a Cox proportional 
hazards regression model. Follow-up started at birth and ended at the first occurrence of 
established fatal or non-fatal CVD. Patients without CVD were censored at the date of the last 
lipid clinic visit or at the date of death attributable to other causes than CVD. The multiple 
Cox regression model was initially adjusted for covariates that were independent of the GR 
gene haplotypes: year of birth and smoking. In addition, we performed analyses to assess the 
effect of possible confounders or intermediates in the relationship between the GR polymor-
phism and CVD by adjusting for covariates which had significant effects on CVD risk in uni-
variate Cox regression analyses. In the Cox regression analyses, persons with the haplotype 
of interest were compared to the wild type haplotype. We repeated the haplotype estimation 
and analyses, weighted for the posterior uncertainty in the haplotype assignments, using the 
haplo.glm function of haplo.stats.26,27 The haplo.glm function applied a general linear model 
to investigate the association between the haplotypes and CVD with adjustment for age and 
smoking status.
Secondly, we assessed the relationship between each GR polymorphism and the risk of 
CVD separately. All polymorphisms were assessed using a dominant, additive, or recessive 
genetic model without adjustment for covariates and the model with the highest log-likeli-
hood was used in multivariable Cox regression analysis. To examine gender-specific effects of 
GR variants on cardiovascular outcomes, we tested the interaction between each GR variant 
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and gender in the total population using Cox regression analysis with adjustment for vari-
ables that were significantly different between genders. Differences in cardiovascular risk 
factors between genotypes were tested with chi-square statistics for dichotomous variables 
and independent sample t-test or one-way ANOVA for continuous variables. For all statistical 
analyses, a P value of less than 0.05 was considered statistically significant.
Results
Patient characteristics and genotype distributions
The general characteristics of 879 men and 951 women with complete GR genotypes are 
shown in Table 2. Men visited the lipid clinic 2.2 ± (SEM) 0.6 years earlier, were more often 
smokers (difference, 12.0 ± 2.2%), had a higher BMI (difference, 0.8 ± 0.2 kg/m2), lower plasma 
total cholesterol (difference, 0.26 ± 0.10 mmol/L) and HDL cholesterol levels (difference, 0.23 
± 0.02 mmol/L), and higher plasma concentrations of triglycerides (difference, 0.33 ± 0.05 
mmol/L) compared to women.
Table 3 presents the genotype distributions for all GR gene polymorphisms. The observed 
genotype distributions were in Hardy-Weinberg equilibrium in the total population and 
among individuals with and without CVD (χ2 < 3.29; P > 0.07). Only in the subgroup of women 
with CVD, the ER22/23EK variant deviated from Hardy-Weinberg equilibrium (χ2 = 11.06; p = 
0.0009), which is probably the result of only 2 rare ER22/23EK homozygotes in our population. 
Due to this small number of rare ER22/23EK homozygotes, heterozygous and homozygous 
Table 2. Characteristics of 1,830 individuals with familial hypercholesterolemia
Men Women p-value*
(n=879) (n=951)
Age at first lipid clinic visit (years) 43.7 (± 0.4) 45.9 (± 0.4) <0.001
Age at last lipid clinic visit (years) 48.8 (± 0.4) 50.8 (± 0.5) 0.001
Smoking, ever (%) 79.1 (± 1.4) 67.2 (± 1.6) <0.001
Hypertension (%) 8.6 (± 1.0) 9.4 (± 1.0) 0.9
Diabetes mellitus (%) 5.2 (± 0.8) 6.5 (± 0.8) 0.6
Body mass index (kg/m2) 25.6 (± 0.1) 24.8 (± 0.1) <0.001
Total cholesterol (mmol/L) 9.37 (± 0.07) 9.63 (± 0.07) 0.03
LDL cholesterol (mmol/L) 7.23 (± 0.07) 7.43 (± 0.07) 0.09
HDL cholesterol (mmol/L) 1.10 (± 0.01) 1.33 (± 0.01) <0.001
Triglycerides (mmol/L) 1.96 (± 0.04) 1.64 (± 0.03) <0.001†
Abbreviations: LDL indicates low-density lipoprotein; HDL, high-density lipoprotein.
Values are given as means ± standard error of the mean (SEM).
SI conversion factors: To convert total cholesterol, LDL cholesterol, and HDL cholesterol to mg/dL, multiply by 38.67; for triglycerides, multiply 
by 89.15.
*Additional adjustment for age.
†Statistical testing after logarithmic transformation.
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carriers of the minor allele were combined for further analyses. We did not find homozygote 
N363S carriers in our population.
Table 3. Genotype distributions for all glucocorticoid receptor gene polymorphisms
Men Women
CVD No CVD CVD No CVD
N (%) N (%) N (%) N (%)
ER22/23EK
Wild type 337 (93.9) 482 (92.7) 210 (93.8) 677 (93.1)
Heterozygous ER22/23EK 22 (6.1) 38 (7.3) 12 (5.4) 50 (6.9)
Homozygous ER22/23EK 0 (0.0) 0 (0.0) 2 (0.9) 0 (0.0)
N363S
Wild type 327 (91.1) 491 (94.4) 205 (91.5) 678 (93.3)
Heterozygous N363S 32 (8.9) 29 (5.6) 19 (8.5) 49 (6.7)
Homozygous N363S 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
BclI
Wild type 139 (38.7) 232 (44.6) 87 (38.8) 299 (41.1)
Heterozygous BclI 173 (48.2) 238 (45.8) 111 (49.6) 336 (46.2)
Homozygous BclI 47 (13.1) 50 (9.6) 26 (11.6) 92 (12.7)
GR-9β
Wild type 254 (70.8) 367 (70.6) 158 (70.5) 492 (67.7)
Heterozygous GR-9β 98 (27.3) 138 (26.5) 60 (26.8) 215 (29.6)
Homozygous GR-9β 7 (1.9) 15 (2.9) 6 (2.7) 20 (2.8)
Abbreviations: CVD, history of cardiovascular disease.
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Figure 1. Schematic overview of the five most frequent haplotype alleles of the glucocorticoid receptor gene based on the four polymorphisms 
in 1,830 patients with familial hypercholesterolemia. The haplotype frequencies in the study population are depicted on the right side. Squares 
indicate the wild type alleles of the polymorphisms; circles indicate the variant alleles of the polymorphisms.
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GR haplotype and CVD
Frequencies of the five most common haplotypes of the GR gene based on the ER22/23EK, 
N363S, BclI, and GR-9β polymorphisms are presented in Figure 1. These five haplotypes cap-
tured more than 99% of the variation in the GR gene accounted for by the four polymor-
phisms. The most frequent haplotype (45%) was the haplotype with the wild type alleles of 
all four polymorphisms.
During 39,701 person years, 359 (40.8%) men had onset of CVD and a total of 224 (23.6%) 
women had their first cardiovascular event during 46,570 person years. The mean age of onset 
of CVD (± SD) was 45.8 ± 9.2 years in men and 52.9 ± 11.5 years in women. Separate analyses 
of a number of variables, which may act as confounder or intermediate trait in the relation-
ship between the GR haplotype and CVD risk, are shown in Table 4. In men and women, 
year of birth, smoking, and lower plasma HDL cholesterol concentrations were significantly 
associated with increased CVD risk. The presence of diabetes mellitus and higher BMI also 
contributed to an increased risk of CVD in women but not in men.
Table 4. Risk factors of cardiovascular disease in individuals with familial hypercholesterolemia
Variables Men Women
Relative Risk (95% CI) p-value Relative Risk (95% CI) p-value
Year of birth 1.05 (1.04 to 1.07) <0.001 1.08 (1.06 to 1.10) <0.001
Smoking 1.79 (1.25 to 2.55) 0.001 1.60 (1.17 to 2.18) 0.003
Diabetes mellitus 1.10 (0.77 to 1.57) 0.6 1.80 (1.27 to 2.57) 0.001
Hypertension 1.23 (0.91 to 1.66) 0.2 1.11 (0.78 to 1.56) 0.6
Body mass index 1.00 (0.96 to 1.04) 0.9 1.05 (1.01 to 1.10) 0.03
Total cholesterol 0.98 (0.91 to 1.06) 0.6 0.99 (0.92 to 1.07) 0.8
LDL cholesterol 0.98 (0.91 to 1.06) 0.6 0.99 (0.92 to 1.07) 0.8
HDL cholesterol 0.49 (0.32 to 0.76) 0.001 0.48 (0.30 to 0.78) 0.003
Triglycerides 1.16 (0.98 to 1.36) 0.08* 1.05 (0.85 to 1.30) 0.6*
Abbreviations: LDL, low-density lipoprotein; HDL, high-density lipoprotein.
*Statistical testing after logarithmic transformation.
Table 5. Relative risk of cardiovascular disease in men and women with familial hypercholesterolemia according to glucocorticoid receptor 
haplotype
GR haplotype Men Women
Relative Risk (95% CI) p-value Relative Risk (95% CI) p-value
wild type 1.00 ref 1.00 ref
GR-9β 1.41 (1.02 to 1.94) 0.04 1.02 (0.69 to 1.51) 0.9
BclI 1.34 (1.02 to 1.76) 0.03 1.08 (0.76 to 1.54) 0.7
N363S 1.20 (0.71 to 2.02) 0.5 1.05 (0.53 to 2.07) 0.9
ER22/23EK+GR-9β 1.19 (0.70 to 2.00) 0.5 1.03 (0.45 to 2.34) 1.0
Abbreviations: GR, glucocorticoid receptor.
Relative risks were estimated with Cox proportional hazards regression and adjusted for year of birth and smoking.
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Table 5 shows the effect of the GR gene haplotypes on CVD risk after adjustment for year of 
birth and smoking and stratified by gender. Compared to the wild type haplotype, the GR-9β 
haplotype, consisting of the mutant allele of the GR-9β polymorphism and the wild type of 
alleles of the other three polymorphisms, was associated with a 41% higher CVD risk in men 
only (p=0.04). A similar association in men was found for the BclI haplotype that consists of 
the mutant allele of the BclI polymorphism and wild types of all other polymorphisms: this 
haplotype was associated with a 34% higher risk of CVD in men (p=0.03). In women, none of 
the haplotypes was significantly related with CVD. Additional adjustment of covariates that 
had significant effects on CVD risk in univariate Cox regression analyses (plasma HDL choles-
terol concentrations in men and plasma HDL cholesterol concentrations, BMI, and diabetes 
mellitus in women) did not influence the results. The results of the analyses with haplo.stats 
were concordant.
GR polymorphisms and CVD
Table 6 shows the effect of the individual GR gene polymorphism on CVD susceptibility after 
adjustment for year of birth and smoking and stratified by gender. We found no significant 
association between any of the GR variants and risk of CVD in men or women. Additional 
adjustment of covariates did not change the results (data not shown).
Table 6. Relative risk of cardiovascular disease in 1,830 individuals with familial hypercholesterolemia
GR polymorphism Mode of inheritance Men Women
Relative Risk (95% CI) p-value Relative Risk (95% CI) p-value
ER22/23EK Dominant 0.74 (0.46 to 1.18) 0.2 1.50 (0.86 to 2.60) 0.2
N363S Dominant 1.14 (0.79 to 1.64) 0.5 1.16 (0.70 to 1.91) 0.6
BclI Recessive 1.28 (0.93 to 1.76) 0.1 0.82 (0.52 to 1.28) 0.4
GR-9β Recessive 1.19 (0.56 to 2.52) 0.7 0.95 (0.39 to 2.31) 0.9
Abbreviations: GR, glucocorticoid receptor.
Relative risks were estimated with Cox proportional hazards regression and adjusted for year of birth and smoking.
As reported previously, the effect of the ER22/23EK variant on CVD risk was opposite in men 
and women.18 The statistical interaction term between this polymorphism and gender was 
statistically significant (p = 0.02) in the total population using Cox regression analysis with 
adjustment for variables that were significantly different between genders (age, smoking, 
BMI, plasma LDL cholesterol, HDL cholesterol, and triglyceride levels). The influence of other 
GR variants on CVD susceptibility was not significantly different for men and women (N363S, 
p=0.7; BclI, p=0.2; GR-9β, p=0.7).
No statistical significant differences in general characteristics were observed between the 
GR genotype groups (data not shown), but for the following two exceptions: women with the 
ER22/23EK polymorphism visited the lipid clinic 4.7 ± (SEM) 1.8 years earlier and men with 
the N363S variant visited the lipid clinic 4.0 ± 1.4 years later.
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Discussion
In this large cohort of FH individuals with severely increased predisposition to CVD, we 
found that two common GR gene haplotypes were associated with CVD susceptibility, but 
only among men. Men with the GR-9β haplotype had a 41% higher CVD risk and men with 
the BclI haplotype had a 34% higher CVD risk compared to male carriers of the wild type 
haplotype. We did not find an association between any of the single functional GR gene poly-
morphisms with CVD risk nor with cardiovascular risk factors such as BMI, plasma lipid levels, 
or hypertension.
The strength of our study is determined by the accessibility of a large, well-documented 
cohort of individuals with a monogenic cause of hypercholesterolemia who have a 8.5 times 
increased CVD risk.28 Patients with heterozygous FH have mutations in the LDL receptor gene 
leading to plasma LDL cholesterol levels above the 95th percentile of the general popula-
tion.29 Although all individuals have severe hypercholesterolemia, CVD risk and mortality 
varies considerably and depends on both environmental and genetic factors.30,31 The effect of 
any single gene on the susceptibility for a complex disorder such as CVD is a priori expected 
to be modest. Therefore, we prefer to study the association between genetic variants with 
CVD in a population at increased risk of CVD with the resulting high power to detect potential 
small effects of the genetic variant.
This is the first study that investigated the combined influence of GR gene variants on CVD 
susceptibility by using haplotypes. Previous research focused on single nucleotide polymor-
phisms (SNPs) in the GR gene and their effects on glucocorticoid sensitivity and cardiovas-
cular risk factors.7 Across the GR gene, there is strong linkage disequilibrium of SNPs with 
neighboring polymorphisms. Genetic variation in the majority of the population can then be 
defined into a limited number of haplotypes. The advantage of a haplotype-based approach 
is its ability to detect multiple effects within the same genetic region. Surprisingly, we found 
relationships between two GR haplotypes on CVD risk, but none of the single polymorphisms 
associated with cardiovascular endpoints. These findings suggest that the effects of the BclI 
haplotype and the GR-9β haplotype on CVD susceptibility cannot be explained by the indi-
vidual BclI and GR-9β polymorphisms. Hence, it is possible that these genetic variants are in 
linkage disequilibrium with functional but yet unidentified polymorphisms that account for 
the haplotype effects.
One previous genetic study performed haplotype-analysis of the GR gene and determined 
association with postdexamethasone cortisol production.32 This study included all GR poly-
morphisms that were tested in our analyses, together with other validated SNPs spaced across 
the gene. Stevens and co-workers found a three-point haplotype of intron B polymorphisms 
that segregates with increased sensitivity to glucocorticoids, as evidenced by lower cortisol 
levels after a 0⋅25 mg dexamethasone suppression test.32 This three-marker haplotype in-
cludes the G allele of the BclI polymorphism. Since the BclI polymorphism was not associated 
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with postdexamethasone cortisol production in Stevens’ study and with CVD susceptibility 
in our study, we could speculate that one of the two other polymorphisms in intron B (the A 
allele of the intron B 33389 and the T allele of the intron B 33388) may explain the relationship 
with increased CVD risk in our population. 
The association between the GR-9β haplotype and the BclI haplotype and increased CVD 
risk was only significant in men. Previously, we already described opposite effects of the 
ER22/23EK polymorphism on CVD in men and women.18 Obviously, the hormone dynamics 
and the risk of CVD differ considerably among males and females, but the exact reason for 
these differences of GR haplotypes between gender are yet unknown. The response of the 
hypothalamic-pituitary-adrenal axis to variations in circulating sex steroid concentrations dif-
fer between sexes: estrogen primarily exerts stimulatory effects on stress-induced ACTH and 
glucocorticoid release, whereas testosterone inhibits stress-related hypothalamic-pituitary-
adrenal axis activity.33 Otherwise, high variability in the expression of genes located at the 
X-chromosome between men and women has been reported and may also account for these 
gender differences.34 Obviously, further research is warranted to acquire more information 
about the mechanisms underlying gender-specific differences in the expression of GR target 
genes but our observations support that separate analyses of men and women are indicated 
for studies on GR variants.
Our study has a number of limitations. First, data were obtained from medical records and 
some information of interest, such as body composition, plasma insulin levels and inflam-
mation markers were not known. The influence of these factors on the relationship between 
the GR variants and CVD risk could therefore not be measured. In addition, the strength of 
any association study is highly increased by confirmation of the results in a second inde-
pendent population. However, to our knowledge, this study is the only large FH cohort with 
well-defined cardiovascular endpoints. Obviously, our findings in heterozygous FH cannot 
be extrapolated to other populations and future research should establish the effect of GR 
haplotypes in other populations with increased CVD risk and in population-based studies.
In conclusion, in this large cohort study of high-risk patients with severe hypercholester-
olemia, the GR-9β and the BclI haplotype were significantly associated with increased CVD 
risk in men. This suggests that variations at the GR gene modify CVD susceptibility among 
male FH patients.
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Introduction
Heterozygous familial hypercholesterolemia (FH) is an inherited disorder of lipid metabolism, 
leading to severely elevated low-density lipoprotein (LDL) cholesterol levels and increased 
risk of cardiovascular disease (CVD).1 Despite the monogenic cause of FH, CVD susceptibility 
varies considerably and traditional risk factors account for only a minority of this variation.2-4 
In this thesis, we focussed on the identification of genetic variations at the LDL receptor locus 
as well as candidate genes outside the LDL receptor locus that could improve risk prediction 
in FH in order to tailor preventive strategies.
Variation at the LDL receptor locus
Previously, several studies in adult FH patients have assessed whether variation at the LDL re-
ceptor locus influenced lipoprotein metabolism and, consequently, cardiovascular risk. These 
studies, however, have yielded conflicting results.3,5-13 We proposed that FH children might 
be more suitable to perform genotype-phenotype studies in because of a lower chronic ex-
posure to known environmental factors that alter lipid levels and they are not selected on 
CVD. In the present thesis we tested this hypothesis by calculating the intra-class correlation 
(i.e. the variance in LDL cholesterol levels introduced by familial factors) in a pediatric and 
adult FH cohort with identified LDL receptor mutations. Familial factors explained 50.4% of 
the variance in LDL cholesterol levels among children with FH, whereas only 9.5% of the 
variance in LDL cholesterol levels was explained by family ties in untreated adult FH patients. 
This shows that children indeed share a more homogeneous environment. It supports that 
analyses of effects of LDL receptor genotypes in pediatric cohorts are more accurate. Hence, 
we examined the assumed relationship between LDL receptor genotypes and lipoproteins 
in a large pediatric cohort and the relation with the occurrence of parental CVD. The dou-
ble-mutation named N543H/2393del9 was the most frequent mutation in the cohort and 
belongs to the receptor-defective group. Interestingly, children carrying this mutation had 
a less deteriorated lipid profile and CVD was expressed to a lesser extent in their parents 
relative to parents of children with other mutations. In general, however, the variation in 
lipid profile of the children poorly explained the differences in CVD risk among the parents. 
Plasma LDL cholesterol concentrations of children with null alleles were higher compared to 
children with receptor-defective mutations, but we found no significant differences in paren-
tal CVD risk between carriers of null alleles and receptor-defective mutations. It seems that 
during life other factors become more important modulators of CVD risk in FH than the LDL 
receptor genotype. 
Another topic we addressed in this thesis was the response to statin therapy and LDL recep-
tor genotype. After diagnosis, FH patients are treated lifelong with statins to prevent CVD.14,15 
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The lipid lowering response to statin therapy shows considerable interindividual variation 
and specific LDL receptor mutations have been suggested to affect statin response.16-23 Re-
sults of previous genotype-phenotype studies, however, were conflicting and difficult to 
compare due to selection on specific founder mutations, limited numbers of patients, differ-
ent classifications of the LDL receptor mutation types, and a variety of treatment strategies 
without randomization. Therefore, we examined in the present thesis whether the type of LDL 
receptor mutation influenced the response to statin treatment in a subgroup (only children 
with genetically confirmed FH) of a randomized, placebo-controlled two-year clinical trial 
with pravastatin in FH children, aged between 8 and 18 years. The randomization was used to 
reduce the influence of confounding factors. In addition, our observations were controlled for 
placebo effects, which enabled us to determine the natural course of the specific LDL recep-
tor mutations during the two-year follow-up. Carotid intima-media thickness (IMT) was used 
to measure efficacy. IMT can be visualized with non-invasive B-mode ultrasound imaging. 
The edges of the lumen-intima and media-adventitia interfaces of the posterior artery wall 
represent the boundaries of the intima-media complex. The distance between the interfaces 
is called IMT. Carotid IMT has been accepted as a validated marker for atherosclerosis and 
future cardiovascular outcome.24-27 In this thesis, we showed that before treatment children 
with null alleles had already a significantly higher carotid IMT than receptor-defective muta-
tions, independent of their more elevated LDL cholesterol levels. Although the reduction of 
LDL cholesterol concentrations by statin treatment tended to be less in carriers of null alleles, 
we observed no significant difference in change of carotid IMT during the trial between the 
two LDL receptor genotype groups. Hence, after two-year treatment carotid IMT and lipid 
profile remained more unfavorable in children with null alleles. Our data suggest that the 
greater carotid IMT in carriers of null alleles was not solely the result of higher LDL cholesterol 
levels. Knowledge of LDL receptor genotype may therefore improve clinical decision-making: 
untreated and treated children carrying null alleles may have more pronounced atherogen-
esis that may be partially independent of their more increased LDL cholesterol levels. The risk 
of CVD is, however, a more complex endpoint.
Candidate genes of cardiovascular disease in FH
With the completion of the Human Genome Project and the availability of high through-
put molecular methods, insight into the role of genetic variations in the pathogenesis of 
atherosclerosis has increased enormously. Several candidate genes have been suggested 
to influence CVD risk in FH patients already.28-43 In this thesis we examined three additional 
candidate genes in 2,400 individuals of the GIRaFH cohort.
The first candidate gene is complement factor H (CFH). Recently, three independent ge-
nome-based studies identified the Y402H polymorphism of CFH as an important risk factor 
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of age-related macular degeneration.44-46 This disorder is a progressive late-onset disease 
affecting central vision and results in progressive damage to the macula, ultimately lead-
ing to blindness.47 Epidemiologic, genetic, and pathological evidence suggest a role for ath-
erosclerosis in the pathophysiology of macular degeneration.48 We therefore assessed the 
relationship between this common CFH variant and CVD risk. We observed that homozygous 
carriers of the Y402H polymorphism in CFH were protected against CVD in our FH population. 
This finding emphasizes the involvement of the complement system in the pathophysiol-
ogy of atherogenesis. Atherosclerosis is characterized by a strong inflammatory component 
and activation of the complement system could be an important link between inflammation 
and atherosclerosis.49,50 CFH plays a critical role in the protection of the host cells and tissues 
from damage by complement activation.51 The localization of CFH, C-reactive protein, and 
proteoglycans in the superficial layer of the arterial intima suggests that CFH may protect 
the arterial wall from excess complement activation.52 The Y402H polymorphism in the CFH 
gene is located within binding sites for heparin and C-reactive protein. The replacement of 
tyrosine for histidine at position 402 in exon 9 may alter the binding properties and could 
affect the level of inflammation, thereby influencing atherosclerosis.53 Our finding is in total 
contrast with observations in macular degeneration that found increased risk of this disease 
in carriers of the CFH variant. We hypothesized that differences in angiogenesis may be a 
possible explanation for the opposite effects of the Y402H polymorphism in CVD and macu-
lar degeneration. Insufficient collateral blood vessel formation increases the burden of CVD, 
whereas neovascularisation clearly increases the severity of macular degeneration. Although 
speculative, CFH could be involved in the process of neovascularisation. To date, three studies 
have been conducted on potential associations between the Y402H polymorphism and CVD 
but with conflicting results.54-56 This inconsistency may be partly due to heterogeneity in the 
cardiovascular phenotype, variations in population and study design, and because previous 
studies were underpowered. However, the CFH variant was associated with an increased risk 
of myocardial infarction in participants of the Rotterdam Study, a prospective population-
based study among men and women aged 55 years and over.56 We could not entirely explain 
the discrepancy in their and our results by differences in cardiovascular phenotype, age, and 
lipid concentrations. Obviously, future research is warranted to acquire more detailed char-
acterization of the CFH gene and to establish the functional consequences of the CFH Y402H 
variant and its impact on complement activation, neovascularisation, and complex diseases 
such as macular degeneration and atherosclerosis.
The second candidate gene is the adenosine triphosphate binding cassette (ABC) G8, 
which is involved in plant sterol metabolism. The important role of plant sterols in human 
is illustrated by sitosterolemia in which plasma levels of plant sterols are increased >50-fold 
due to mutations in the ABCG8 gene, leading to severe atherosclerotic arterial disease at a 
young age.57,58 Elevated plant sterol concentrations were also associated with cardiovascular 
events in several small studies among nonsitosterolemic individuals, thereby suggesting that 
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plant sterols are atherogenic.59-63 ABCG8 actively prevents accumulation of plant sterols by 
effluxing sterols from enterocytes to small intestinal lumen and promoting the excretion of 
sterols from the liver into the bile.64 Two polymorphisms in ABCG8 (D19H and T400K) have 
been shown to influence both plant sterols and cholesterol levels but their relation with CVD 
susceptibility was never assessed.65-67 In the GIRaFH study, we found that the D19H polymor-
phism was not associated with plasma cholesterol levels nor with total CVD risk, but there was 
an association with higher risk of coronary heart disease. Based on the association with lower 
plant sterol concentrations, we had a priori expected that carriers of the D19H variant would 
have had a decreased risk of cardiovascular events.65,66 Plasma plant sterol levels were not 
available in our cohort and could not be obtained because of its retrospective design. There 
is, however, controversy about the influence of plant sterols on atherosclerosis, because a 
high plant sterol content of the diet has been previously related with atheroprotection.68,69 
In the Asian diet, for example, the main protein is soy (which is rich in plant sterols), and this 
has been postulated as one of the possible explanations for the lower incidence of CVD in 
some Asian populations.68 In addition, adding plant sterols to margarine and other foods is 
currently a therapy to optimize cardiovascular risk profile by decreasing plasma cholesterol 
concentrations.69 The unfavorable effect of the D19H polymorphism could be restricted to 
coronary heart disease in our study since this is probably a more homogeneous phenotype 
than total CVD. The T400K polymorphism resulted in significant higher plasma HDL choles-
terol levels, but we found no association with cardiovascular endpoints. These data suggest 
that the two genetic variations in ABCG8 analyzed in this thesis are not major contributors for 
differences in CVD susceptibility among FH patients.
The third candidate gene is the glucocorticoid receptor (GR). The GR mediates the effects 
of glucocorticoids.70 Glucocorticoids play an important role in the pathofysiology of athero-
sclerosis by their contribution to the development of hypertension, dylipidemia, impaired 
glucose tolerance, and central adiposity.71 The sensitivity to glucocorticoids, however, varies 
considerably among individuals.72 Several functional genetic variants within the GR gene have 
been associated with variation in glucocorticoid sensitivity and cardiovascular risk factors.73 
In this thesis, we first studied the ER22/23EK polymorphism of GR. Carriers of the ER22/23EK 
variant were suggested to be relative resistant to glucocorticoids, because they had higher 
serum cortisol concentrations and a smaller decrease in cortisol levels after dexamethasone 
suppression testing.74 In previous studies, this polymorphism has been associated with a 
beneficial cardiovascular risk profile defined by lower plasma total and LDL cholesterol levels, 
increased insulin sensitivity, a beneficial body composition, lower C-reactive protein levels, 
and a better overall survival.74-76 Hence, we hypothesized that this functional ER22/23EK vari-
ant in the GR gene might decrease CVD risk. We found, however, that the association between 
the ER22/23EK variant and the occurrence of CVD was not significant overall. In separate 
analyses of men and women, however, we found opposite effects of the polymorphism on 
CVD. This variant has been preferentially analyzed in male individuals and most association 
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studies did not analyze men and women separately. In a cohort of young-adults followed 
from the age of 13 to 36 years, the body composition in carriers of the ER22/23EK variant 
was different between sexes: only male carriers were taller, leaner, and had more muscle 
strength.75 The reason for these differential effects of the ER22/23EK variant between men 
and women is yet unknown. Differing responses of the hypothalamic-pituitary-adrenal axis 
to variations in circulating sex steroid concentrations have been proposed as a possible ex-
planation. Soon after the publication of these findings, other investigators reported that the 
ER22/23EK polymorphism was only present in combination with another polymorphism: the 
GR-9β variant.77 This observation prompted us to examine the effect of this GR variant in our 
FH population. In addition, we analyzed the N363S and BclI polymorphisms in GR, which have 
been previously associated with an increased sensitivity to glucocorticoids and an increased 
cardiovascular risk profile.78-84 Individual analyses of these functional polymorphisms in the 
GIRaFH cohort revealed no significant association with CVD in men nor women. In this thesis, 
we also analyzed the combined effect of the GR variants using haplotypes to obtain more 
detailed information about the genetic variation at the locus in relation with CVD. As already 
observed by other research groups, we found that the ER22/23EK, N363S, and BclI polymor-
phisms never occurred on the same allele and ER22/23EK carriers always carried the GR-9β as 
well. Furthermore, the GR-9β also never occurred with the N363S and BclI polymorphisms on 
one allele. In women, none of the haplotypes was significantly related with CVD. In men, the 
GR-9β haplotype (consisting of the mutant allele of the GR-9β polymorphism and the wild 
type alleles of the other three polymorphisms) was associated with an increased CVD risk. A 
similar increased association with CVD in men was found for the BclI haplotype (that consists 
of the mutant allele of the BclI polymorphism and wild types of all other polymorphisms). We 
concluded that common functional variants in the GR gene explained a small proportion of 
the variation in CVD risk among FH men.
Limitations of genetic association studies
The initial enthusiasm about genetic association studies is partially tempered because pub-
lished positive associations could frequently not be replicated in subsequent studies. This 
inconsistency among genetic association studies may be due to false positive results, false 
negative results or true variability in association among different populations (Box 1).85-89 Sev-
eral limitations of genetic association studies will be discussed in more detail.
The most likely reason for failure of replication is a false-positive result due to multiple 
testing (type I error), publication bias, and small sample size.85,89 When none of the genetic 
variants are related to CVD, 1 out of 20 will show significant association at a p-value equal to 
or below 0.05 by chance alone. There are a number of methods used to deal with multiple 
testing problems. In the classical approach for correcting p-values, the nominal p-value is 
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multiplied by the number of hypotheses tested (Bonferroni correction). However, this correc-
tion is too conservative, because many true positive associations between genetic variants 
and phenotypes may not become significant. In the Bayesian method, the threshold p-value 
for declaring success takes into account the a priori probability that a particular genetic vari-
ant is truly associated with the phenotype. This approach allows calculation of the posterior 
probability that an association is genuine based on pre-test estimates, but the method gives 
rise to analytic problems. There is clear consensus that no available statistical method can 
effectively distinguish between true-positives and false-positives in genetic association 
studies.
Another potential source of variable findings among genetic association studies is false 
negative results because subsequent studies are underpowered (type II error). This difficulty 
is heightened by the winner’s curse phenomenon, in which the initial reported effect size 
is almost always an overestimation of the true effect of the genetic marker.90,91 Therefore, 
replication studies should be powered to detect effect sizes that are a bit smaller than the 
initial effect size reported and thus need to include larger numbers of patients to achieve 
statistical significance.
Of course true variation in association between the populations of two different studies 
may exist. If a genetic variant’s influence on CVD risk is only manifest on a certain genetic 
or environmental background, then differences in genetic and environmental factors could 
account for irreproducibility. The strong genetic background in FH patients (leading to se-
vere hypercholesterolemia) could modify the association between a genetic marker and CVD 
susceptibility; this may explain discrepant results in FH populations and population-based 
Box 1. Causes of irreproducibility of genetic association studies.
•	 False positive studies
 multiple testing
 publication bias
 small sample size
 population stratification
 genotyping error
•	 False negative studies
 small sample size
 failure to consider that initial effect size is overestimation of true effect size
 inconsistent phenotype
•	 True variation in association between populations
 variation in linkage disequilibrium between the SNP being studied and the true causal 
variant among populations
 population-specific gene-gene or gene-environmental interactions
 population admixture
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studies. True heterogeneity between the populations may also exist if there is variation in 
linkage disequilibrium between the SNP being studied and the true causal variant among 
populations. Historical recombination between the tested and the causal variant could 
be different in populations leading to variation in the strength of an association between 
populations.
Finally, the success of genetic studies highly depends on the characterization of the phe-
notype of interest.89 For example, myocardial infarction can be arbitrarily defined as a history 
of myocardial infarction based on questionnaires or can be assessed according to rigorous 
and reproducible criteria such as classical symptoms >15 min with specific electrocardio-
graphic abnormalities and/or elevated cardiac enzymes >2 times the upper limit of normal 
as we did in the GIRaFH study. The first phenotype is likely to include heterogeneity in cause 
and disease course and may confound genetic analyses. Therefore, precision of the study 
phenotype is of key importance in genetic association studies.
Future perspectives: genetic association studies
In general, to detect a significant correlation between a specific genetic marker and CVD 
susceptibility effectively, the association must be strong and the allele of interest must occur 
with relatively high frequency. Rare genetic markers with strong effects on CVD susceptibility 
and common genetic markers with weaker associations to the phenotype are both difficult to 
identify and polygenic involvement may cause inconsistent results among genetic studies.92 
Candidate gene studies comprise mainly common genetic variants with a relatively small 
effect on the phenotype. Simple association studies of SNPs in the general population are 
not likely to identify new genes in which rare variants have a strong effect on the phenotype 
in a few individuals; case-control studies in high-risk populations such as FH may be a power-
ful alternative to detect these. Genotyping FH individuals at the extremes of the phenotype 
distribution can increase statistical power of a genetic association study. For example, the 
genotypes of FH patients with severe premature onset of CVD symptoms can be compared 
with older FH patients who did not experience CVD during life. This study design will improve 
the power to detect rare variants with relatively large effects.
Highly significant associations with a plausible biological mechanism are most convincing. 
A reported association will gain evidence by replication of the association with the same 
allele, the same phenotype, and the same direction of the effect in independent population 
samples. The genes that determine the susceptibility to CVD in FH should be tested in other 
high-risk populations (diabetes mellitus, hypertension) and in the general population also. 
This type of replication in populations without FH serves another purpose: generalization of 
the findings. On the one hand, a monogenic background and large variation of CVD risk in FH 
offer a unique opportunity to identify genes that are generally involved in CVD. On the other 
Ch
ap
te
r 8
116
hand, their expression may be context dependent and restricted to severe hypercholester-
olemia and other high-risk disorders.
Ultimately, results could be combined in a meta-analysis to give a reliable estimation of the 
effect of gene variation on CVD susceptibility in FH.91 Meta-analyses, however, are not devoid 
of potential biases, because most are conducted on highly heterogeneous studies according 
to size and phenotype and because publication bias against studies with negative results 
may lead to overestimation of the true effect. Another possibility to increase statistical power 
to detect candidate genes is multicenter, international collaborations for collecting large 
FH populations. Investigators can routinely bank DNA and clinical data of well-phenotyped 
FH patients in anticipation of large-scale genomic analyses to determine the association of 
gene(s) with CVD risk.
Future perspectives: genome wide association studies
Multiple genes generally act through complex networks involving gene-gene and gene-
environment interactions. Accordingly, each gene explains only a limited proportion of the 
CVD risk, thereby making it difficult to explicitly study one gene. A genomic strategy that 
analyzes genes on the entire genome may be more informative and more efficiently than 
the candidate gene approach that focuses on selected genes.86 Two main strategies are 
used to identify potential candidate genes in genomic studies: genetic-linkage analyses and 
genome wide association studies.89 Linkage studies in families are useful in analyzing the 
entire genome to identify chromosomal regions that may harbor genes responsible for CVD. 
The linkage method has been extremely successful in dissecting Mendelian disorders, but 
analytic problems occur when 3 or more loci are involved. Genome wide association studies 
can be used to determine the effect of thousands of genetic variants simultaneously on oc-
currence of CVD. Such genomic studies are based on hypothesis-free methods in which no 
pre-selection of genes is made based on inference about a potential relationship with CVD.
In a recent gene centric study, a large collection of SNPs that were selected on potentially 
affecting protein function of expression were tested in multiple populations.93 A total of 4 
gene variants were associated with myocardial infarction. These 4 genes were not related 
before with myocardial infarction. This illustrates the potential for genomic association stud-
ies in the search for novel insights into CVD pathogenesis. Especially, because the genomic 
coverage of novel gene-chips, containing 500-550K SNPs, is much better. False positive find-
ings were largely eliminated by the multistage design; replication in multiple independently 
recruited, large populations was performed to reduce the false discovery rate.
No genome wide association studies on CVD risk in FH have been reported so far. As a 
consequence of the recent progress in genome wide association scans and with the lower-
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ing of genotyping costs, abundant genetic association studies and eventually genome wide 
association studies will be conducted among FH populations in the next years.
Prognostic model
The incorporation of new genetic risk factors in a prognostic model that gives an accurate 
estimation of a FH individual’s CVD risk will be the next challenging step towards more per-
sonalized preventive medicine. Prognostic models in FH can be developed using multiple 
regression analysis of a data set containing genetic and clinical information of individual FH 
patients. The development of such a prognostic model would ideally take place in a very 
large database to accurately estimate regression coefficients. In practice, this ideal is seldom 
achieved because the data sets of individual patient data are often relatively small. Recently, 
a new statistical method was described that combines univariable regression results from 
the medical literature (for example from meta-analyses) with univariable and multivariable 
results from the data set containing individual patient data.94 This ‘adaptation method’ was 
shown to benefit from the incorporation of literature data evidenced by a better model per-
formance and less variability of the regression coefficients when compared with models that 
use individual patient data only. This method offers interesting opportunities to optimally 
combine the results of a large number of studies in the development of a prognostic model. 
Finally, the prognostic model should be validated in independent FH populations to assess 
its overall performance and optimize the model when needed. Although findings may be 
generalized to other populations, relevant post-test probabilities will only be attained when 
genetic panels have extremely high discriminative ability or when pre-test probabilities are 
high.
Conclusion
In conclusion, children with FH provide a better model to perform genotype-phenotype 
analyses than FH adults. LDL receptor genotype may guide treatment strategies in future, 
because selection of null alleles identifies children with FH who may have more pronounced 
atherogenesis and who may benefit by more aggressive as well as earlier lipid lowering treat-
ment. The risk of CVD among adults with FH is, however, a more complex endpoint. With 
the exception of rare mild LDL receptor mutations, the specific LDL receptor mutation pro-
vides limited prognostic information over and above the untreated LDL cholesterol level and 
general CVD risk profile. The Y402H polymorphism of CFH is strongly related with decreased 
CVD risk in FH whereas variation at the GR locus was associated with increased CVD suscep-
tibility among FH men. At present, however, there is no strong evidence to test individual 
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polymorphisms in routine clinical practice to improve risk prediction in FH in order to tailor 
preventive strategies to the individual risk level. With the availability of large-scale sequenc-
ing and the ability to measure genotypes at thousands of loci simultaneously, however, we 
expect that the creation of a genetic fingerprint of CVD risk in FH is feasible in the coming 
years. The challenge remains to link genetic data and clinical information to refine individual-
ized approaches to CVD care in FH patients.
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Summary
Familial hypercholesterolemia (FH) is a common inherited disorder of lipid metabolism 
caused by mutations in the low-density lipoprotein (LDL) receptor gene. FH is characterized 
by elevated plasma LDL cholesterol levels, tendinous xanthomas, and premature cardiovas-
cular disease (CVD).
As introduced in chapter 1, CVD susceptibility in heterozygous FH varies considerably and 
depends only partially on the traditional cardiovascular risk factors. Modifier genes have 
been suggested to influence the susceptibility to CVD in FH. The aim of this thesis was to 
identify genetic factors that could potentially enhance the ability of clinicians to identify FH 
individuals with severely increased CVD risk, who will most likely benefit from targeted thera-
peutic intervention. First, we focused on genetic variants in the LDL receptor gene (chapter 2 
and 3). Secondly, we analyzed the effects of candidate genes outside the LDL receptor locus 
(chapter 4 to 7).
In chapter 2 we first established that children with FH provide a better model than adults 
to analyze the relation between the LDL receptor genotype and lipid levels. Subsequently, we 
investigated the role of variations at the LDL receptor locus on lipid levels and parental CVD 
risk in 645 children with FH. In these children, null alleles were clearly associated with more 
elevated LDL cholesterol levels compared to receptor-defective mutations. However, CVD 
risk in the parents was not significantly different between carriers of null alleles and receptor-
defective mutations. Hence, the variation in lipid profile of the children poorly explained the 
differences in CVD risk among parents. The N543H/2393del9 mutation was the most frequent 
LDL receptor variant in the cohort. Interestingly, this specific mutation was clearly associated 
with a less deteriorated lipid profile and the parents had less often CVD relative to parents 
with other mutations.
In chapter 3 we assessed the relationship between LDL receptor genotype and response to 
statin treatment in children with genetically confirmed FH using carotid intima-media thick-
ness (IMT) to measure efficacy. All children participated in a randomized, placebo-controlled, 
double-blind, two-year trial with pravastatin. At baseline, children with null alleles had higher 
LDL cholesterol levels and a greater carotid IMT compared to children with receptor-defective 
mutations. Although the reduction of LDL cholesterol levels by pravastatin treatment tended 
to be less in carriers of null alleles, we observed no significant difference in change of carotid 
IMT during the trial between the two LDL receptor genotype groups. After two-year treat-
ment, however, carotid IMT and lipid profile continued to be more unfavorable in children 
with null alleles. Selection of null alleles identifies children with more pronounced athero-
genesis who may benefit by more aggressive as well as earlier lipid lowering treatment.
In chapter 4 we describe the role of the Y402H polymorphism of complement factor H (CFH) 
in CVD. This polymorphism has been strongly and consistently related with increased risk of 
age-related macular degeneration, an atherosclerosis-related phenotype. We hypothesized 
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that the Y402H variant is also related to CVD susceptibility. Therefore we investigated this 
polymorphism in the GIRaFH-study (Genetic Identification of Risk Factors in Familial Hyper-
cholesterolemia), a Dutch cohort of 2400 unrelated FH patients, aged 18 years and older, 
who were identified at lipid clinics throughout the Netherlands between 1989 and 2002. Ho-
mozygous carriers of the Y402H polymorphism had a 2-fold decreased risk of CVD relative to 
heterozygous carriers and noncarriers. Adjustment for clinically relevant cardiovascular risk 
factors and age effects did not influence this association. We also analyzed the risk of coro-
nary, cerebral, and peripheral events separately and found similar decreased relative risks in 
homozygous Y402H carriers. These results suggest that the CFH gene is a modifier gene of 
CVD among patients with FH.
In chapter 5 we investigated a second candidate gene named ABCG8 because of its asso-
ciation with plasma plant sterol levels. High plasma concentrations of plant sterols have been 
suggested to increase CVD risk. In the GIRaFH-study, we examined associations between the 
D19H and T400K polymorphisms in the ABCG8 gene and cardiovascular events. The D19H 
variant was not associated with plasma cholesterol levels nor with total CVD risk, but there 
was evidence of an association with higher risk of coronary heart disease after adjustment 
for all cardiovascular risk factors. We observed no significant relationship between the T400K 
polymorphism and plasma cholesterol levels or cardiovascular endpoints. These data sug-
gest that these two genetic variations in the ABCG8 gene are not major contributors for dif-
ferences in CVD risk among patients with FH.
In chapter 6 we describe a third candidate gene of CVD: the glucocorticoid receptor (GR) 
gene. Glucocorticoids influence atherosclerosis by their contribution to the development 
of hypertension, dylipidemia, impaired glucose tolerance, and central adiposity. Glucocor-
ticoids exert their function primarily via binding to the GR. In this chapter we focused on the 
functional ER22/23EK polymorphism in the GR gene. Individuals with this polymorphism are 
relatively resistant to the downstream consequences of glucocorticoids and they have a more 
favorable cardiovascular risk profile. We determined whether carriership of the ER22/23EK 
improves CVD suceptibility in the GIRaFH-study. In contrast to expected results, we observed 
no significant association of the ER22/23EK variant with CVD risk. In addition, no differences 
existed in cardiovascular risk factors between patients with and without ER22/23EK. How-
ever, in a post hoc analysis we found opposite effects of the polymorphism on CVD in men 
and women.
In chapter 7 we studied the combined effect of the ER22/23EK variant and several other 
functional polymorphisms within the GR gene (N363S, BclI, and GR-9β) on CVD risk in the 
same FH population. We analyzed the combined effect of all GR variants by reconstructing 
haplotypes. Men with the GR-9β haplotype (only variation at the GR-9β site) and the BclI 
haplotype (only variation at the BclI site) had a higher CVD risk compared to male carriers 
of the wild type haplotype (wild type alleles of all four polymorphisms). In women, none of 
the haplotypes was significantly related with CVD. We did not find an association between 
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any of the single functional GR gene polymorphisms with CVD risk nor with cardiovascular 
risk factors such as body mass index, plasma lipid levels, or hypertension. Thus two common 
haplotypes in the GR gene explained a small proportion of the variation in CVD susceptibility 
among FH men.
Chapter 8 contains a general discussion in which the main findings of this thesis are put 
into a broader perspective. We also discuss the limitations and potential pitfalls when con-
ducting candidate gene studies and developing individual prognostic models. Finally, we 
conclude that LDL receptor genotype may guide treatment strategies in future, but it is not 
a major determinant of CVD risk in patients with FH. Although there is no strong evidence 
to test individual polymorphisms in routine clinical practice to improve risk prediction in FH 
in order to tailor preventive strategies to the individual risk level, the CFH gene and GR gene 
appear modifier genes of CVD in FH individuals.
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Familiaire hypercholesterolemie (FH) is een vaak voorkomende erfelijke aandoening van het 
lipiden metabolisme welke wordt veroorzaakt door mutaties in de low-density lipoprotein 
(LDL) receptor gen. FH wordt gekenmerkt door verhoogde plasma LDL cholesterol waarden, 
peesxanthomen en premature hart-en vaatziekten (HVZ).
Zoals geïntroduceerd in hoofdstuk 1 is het cardiovasculaire risico in patiënten met 
heterozygote FH zeer variabel en dit kan slechts gedeeltelijk worden verklaard door de tradi-
tionele risicofactoren. Zogenoemde modificerende genen zouden het cardiovasculaire risico 
in FH kunnen beïnvloeden. Het doel van dit proefschrift was het identificeren van genetische 
factoren welke de clinicus kunnen helpen om FH personen met het hoogste cardiovasculaire 
risico te onderscheiden die baat hebben bij agressieve, individuele therapeutische behandel-
ing. In eerste instantie hebben we ons gericht op genetische varianten in het LDL receptor 
gen (hoofdstuk 2 en 3). Hierna hebben we de effecten van enkele kandidaat-genen buiten 
het LDL receptor locus onderzocht (hoofdstuk 4 tot 7).
In hoofdstuk 2 hebben we eerst aangetoond dat kinderen met FH meer geschikt zijn dan 
volwassenen om fenotype studies van het lipidenmetabolisme in te verrichten. Vervolgens 
hebben we de rol van variaties in het LDL receptor locus onderzocht op cholesterol waarden 
van 645 kinderen met FH en op het cardiovasculaire risico van hun ouders. In deze kinderen 
waren nul allelen duidelijk geassocieerd met hogere LDL cholesterol waarden dan recep-
tordefectieve mutaties. Echter het risico van HVZ in de ouders was niet significant verschil-
lend tussen dragers van nul allelen en receptordefectieve mutaties. De variatie in het lipiden 
profiel bij de kinderen verklaart dus slecht de verschillen in HVZ risico bij de ouders. De 
N543H/2393del9 mutatie was de meest frequente LDL receptor mutatie in het cohort. Deze 
specifieke mutatie was duidelijk geassocieerd met een minder ongunstig lipiden profiel en 
de ouders hadden minder HVZ in vergelijking met de ouders van andere mutaties.
In hoofdstuk 3 hebben we de relatie tussen het LDL receptor genotype en het effect van 
statine behandeling in kinderen met genetisch bewezen FH onderzocht door het meten van 
de intima-media thickness (IMT) in de carotiden. Alle kinderen hadden deelgenomen aan een 
gerandomiseerd, placebogecontroleerd, dubbelblind, tweejarig geneesmiddelen onderzoek 
met pravastatine. Bij de start van het onderzoek hadden kinderen met nul allelen hogere 
LDL cholesterol waarden en een dikkere IMT dan kinderen met receptordefectieve mutaties. 
Hoewel de LDL cholesterol daling door pravastatine minder leek in dragers van nul allelen 
vonden we geen significante verschillen in IMT verandering tijdens het onderzoek tussen 
de twee LDL receptor genotypes. Na twee jaar behandeling bleven IMT en het lipiden pro-
fiel echter meer ongunstig in kinderen met nul allelen. Selectie van nul allelen identificeert 
kinderen met meer uitgesproken atherosclerose en zij zouden baat kunnen hebben bij een 
agressievere en ook eerdere cholesterol verlagende behandeling.
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In hoofdstuk 4 beschrijven we de rol van het Y402H polymorfisme in complement factor 
H (CFH) in HVZ. Dit polymorfisme is sterk en consequent geassocieerd met een verhoogd 
risico op leeftijdsgerelateerde maculadegeneratie, een atherosclerose-gerelateerd fenotype. 
Wij veronderstelden dat de Y402H variant ook geassocieerd is met het cardiovasculaire risico. 
Vandaar dat we dit polymorfisme hebben onderzocht in de GIRaFH studie (Genetische Iden-
tificatie van Risicofactoren in Familiaire Hypercholesterolemie), een cohort van 2400 niet-
gerelateerde FH patiënten, 18 jaar en ouder, die werden geïdentificeerd in lipiden klinieken 
uit geheel Nederland tussen 1989 en 2002. Homozygote dragers van het Y402H polymorfisme 
hadden juist een sterk verlaagd cardiovasculair risico in vergelijking met heterozygote drag-
ers en niet-dragers. Correctie voor klinisch relevante risicofactoren en leeftijdseffecten kon 
deze associatie niet beïnvloeden. We hebben coronaire, cerebrale en perifere vasculaire ziek-
ten ook apart geanalyseerd en vonden vergelijkbare verlaagde relatieve risico’s in homozy-
gote Y402H dragers. Deze bevindingen suggereren dat het CFH gen een modificerend gen is 
voor HVZ in patiënten met FH.
In hoofdstuk 5 hebben we een tweede kandidaat gen, ABCG8, onderzocht vanwege de as-
sociatie van dit gen met plasma plantsterolen. Hoge plasma concentraties van plantsterolen 
zouden het cardiovasculaire risico mogelijk kunnen verhogen. In de GIRaFH studie hebben 
we de associatie tussen de D19H en T400K polymorfismes in het ABCG8 gen en HVZ onder-
zocht. De D19H variant was niet geassocieerd met cholesterol waarden noch met het totale 
cardiovasculaire risico, maar er waren aanwijzingen voor een hoger risico op coronaire hartz-
iekten na correctie voor andere risicofactoren. We vonden echter geen significante relatie 
tussen het T400K polymorfisme en cholesterol waarden of cardiovasculaire eindpunten. 
Deze data suggereren dat de twee genetische variaties in het ABCG8 gen geen belangrijk 
aandeel hebben in het cardiovasculaire risico van patiënten met FH.
In hoofdstuk 6 beschrijven we een derde kandidaat gen voor HVZ: het glucocorticoïd recep-
tor (GR) gen. Glucocorticoïden beïnvloeden atherosclerose door hun bijdrage aan de ontwik-
keling van hypertensie, dyslipidemie, gestoorde glucose tolerantie en centrale adipositas. 
Glucocorticoïden oefenen hun functie voornamelijk uit door binding aan de glucocorticoïd 
receptor. In dit hoofdstuk hebben we ons geconcentreerd op het functionele ER22/23EK 
polymorfisme in het GR gen. Individuen met dit polymorfisme zijn relatief resistent voor de 
nadelige effecten van glucocorticoïden en zij hebben een gunstiger cardiovasculair risico-
profiel. Wij hebben in de GIRaFH studie geanalyseerd of het ER22/23EK polymorfisme het 
cardiovasculaire risico in FH patiënten verlaagd. In tegenstelling tot de verwachte resultaten 
vonden we geen significante relatie tussen de ER22/23EK variant en HVZ. Ook waren er geen 
verschillen in cardiovasculaire risicofactoren tussen personen met en zonder het ER22/23EK 
polymorfisme. Echter in een post hoc analyse zagen we tegengestelde effecten van het poly-
morfisme op HVZ in mannen en vrouwen.
In hoofdstuk 7 bestuderen we het gecombineerde effect van de ER22/223EK variant 
en enkele andere functionele polymorfismes in het GR gen (N363S, BclI en GR-9β) op het 
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cardiovasculaire risico in dezelfde FH populatie. We analyseerden het gecombineerde effect 
van alle GR varianten door haplotypes te reconstrueren. Mannen met het GR-9β haplotype 
(enige variatie op de GR-9β plaats) en het BclI haplotype (enige variatie op de BclI plaats) 
hadden een hoger risico op HVZ dan mannen met het wild type haplotype (wild type al-
lelen van alle 4 de polymorfismes). In vrouwen was geen van de GR haplotypes significant 
geassocieerd met HVZ. We vonden geen relatie tussen één van de enkele functionele GR 
gen polymorfismes met HVZ risico noch met cardiovasculaire risicofactoren zoals body mass 
index, lipiden waarden of hypertensie. Wij concluderen dat twee veel voorkomende haplo-
types in het GR gen een klein deel van de variatie in het cardiovasculaire risico in mannen 
met FH verklaren.
Hoofdstuk 8 bevat een algemene discussie waarin de belangrijkste bevindingen van dit 
proefschrift in een breder perspectief worden gezet. We bespreken ook de beperkingen en 
mogelijke valkuilen wanneer kandidaat gen studies worden verricht en individuele prognos-
tische modellen worden gemaakt. Ten slotte concluderen we dat het LDL receptor genotype 
een leidraad kan zijn voor behandelingsstrategieën in de toekomst, maar dat het geen be-
langrijke determinant is van het cardiovasculaire risico in FH patiënten. Momenteel is er geen 
bewijs om individuele polymorfismes in de praktijk te testen om de risicovoorspelling in FH 
te verbeteren en preventieve strategieën naar een individueel niveau te tillen, maar het CFH 
en GR gen lijken modificerende genen van HVZ in patiënten met FH.
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Dr. G.M. Dallinga-Thie, beste Geesje, onnoemelijk veel dank ben ik je verschuldigd voor 
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slagen en je enorme aandeel in het beoordelen van alle manuscripten hebben een positieve 
stempel gedrukt op mijn promotieperiode. Ik vind het ontzettend jammer dat je het Erasmus 
MC hebt verlaten en ik hoop dat we in de toekomst kunnen blijven samenwerken.
Alle co-auteurs: dr. A. Wiegman, Jessica Rodenburg, Barbara Hutten, Liesbeth van Rossum, 
Prof. dr. S.W.J. Lamberts, Simon Mooijaart, Prof. Dr. R.G.J. Westendorp, dr. P. Martin van Hagen 
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en dr. J. Plat, veel dank voor de tijd die jullie hebben vrijgemaakt voor alle besprekingen en 
hulp bij het schrijven van de manuscripten.
Mijn (oud-)collega’s bij Andro Medical Research (Andromed):
Dr. J.J.C. Jonker en mw. A.Damen, beste Jan en Anneke, ons onderzoek had nooit kunnen 
plaatsvinden zonder jullie steun. Bijna de helft van mijn promotietijd heb ik met veel plezier 
bij jullie geneesmiddelen onderzoeksbedrijf gewerkt. Ik wist niet dat er zoveel kwam kijken 
bij een ‘multicenter, placebo-controlled, double-blind, randomized’ trial. Ieder clinicus zou 
eigenlijk een trial moeten uitvoeren om de resultaten ervan goed te kunnen interpreteren. 
Ook al is het eindproduct niet terug te vinden in het boekje, ik had de ervaring niet willen 
missen.
Alle artsen, verpleegkundigen, secretaresses en andere betrokkenen bij Andromed, be-
dankt voor de fijne tijd. Ondanks alle wisselingen bleef de team-spirit bestaan.
Mijn maatjes in het onderzoek:
Joost Rutten, Adrienne Zandbergen en Nathalie van der Velde, ik wist niet hoe gezellig 
onderzoek kon zijn totdat ik bij jullie op de kamer kwam. Samen zwoegen maakt tegenslagen 
draaglijker en overwinningen veel leuker. Thanks voor jullie steun en wijze raad tijdens de 
thee- en koffieuurtjes. Zonder de aanwezigheid van Nathalie had ik nooit al die avonden en 
weekenden in het ziekenhuis achter mijn bureautje kunnen werken. Joost, bedankt dat jij 
mijn paranimf wilt zijn!
Jeroen van der Net, mijn andere paranimf, een betere opvolger had ik me niet kunnen wen-
sen. Ik heb grote bewondering voor je doorzettingsvermogen. Jij bent absoluut een aanwinst 
voor de groep. Jouw hulp in het laatste gedeelte van mijn onderzoek was van onschatbare 
waarde. Ik ben blij dat je op de promotiedag naast me staat.
Annette Galema-Boers en Hannie Dusault, kamergenoten van het eerste moment, wat is 
er veel veranderd sinds het begin van ons Lipidengroepje. Als vasculair verpleegkundige en 
genetic-field werker hebben jullie allebei van een enorme uitdaging een groot succes kun-
nen maken. Ik zal jullie steun en gezelligheid nooit vergeten. Mandy van Hoek, als studente 
begonnen op de afdeling en inmiddels bezig met je eigen promotieonderzoek. Kort hebben 
we samen op de kamer gezeten en elke keer verbaasde je me weer met je kordate aanpak en 
zelfstandigheid bij de opzet en uitwerking van je studies. Ik weet zeker dat we nog veel van je 
zullen horen. Alle andere kamergenoten die ik in mijn rondreis op de vasculaire afdeling heb 
verzameld: Anke, Sarah, Arnold, Simone en Bart, bedankt voor alle gezelligheid. En natuurlijk 
Marjolein de Vlaming niet te vergeten: jouw hulp op de Lipidenpolikliniek was onmisbaar. 
Janneke Langendonk, ik ken niemand die zo enthousiast elke ochtend kan fitnessen tijdens 
een congres; dank voor de begeleiding op de Lipidenpolikliniek. Leonie van der Zee, zonder 
jouw hulp bij het genotyperen van de GIRaFH populatie was ik nu nog bezig: bedankt!
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Franka, Simone, Hong-Chau en Marianne, ik ben blij dat ik zulke fantastische vriendinnen 
aan de geneeskunde studie heb overgehouden. Tijdens onze etentjes kon ik altijd weer bij-
tanken. Onze vakanties zal ik nooit vergeten (en dan met name niet de scones in Stratford-
upon-Avon, autopech tijdens een sneeuwstorm in het Atlasgebergte, ons afspraakje voor de 
dierentuin op Sumatra en die superweek met zijn allen in New York).
Mandy, Ingrid, Iris, Ludeke, Jilles en Marion, ook al zien we elkaar niet meer zo frequent als 
op de middelbare school, jullie vriendschap is voor het leven.
Al mijn collega’s in het Erasmus MC en het MCRZ ben ik dankbaar voor hun geduld wanneer 
in crisistijd een beroep werd gedaan op een luisterend oor. De laatste tijd is er een nieuwe 
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Mijn ouders, schoonouders en familie ben ik enorm dankbaar voor hun steun en geduld. 
Pap en mam, jullie hebben je kinderen een gezonde hoeveelheid doorzettingsvermogen en 
verantwoordelijkheidsgevoel meegegeven; zonder jullie hulp waren we nooit zover geko-
men. Katrien, mijn zussie en beste vriendin, de afgelopen jaren heb ik de mooiste momenten 
maar ook het grootste verdriet met je mogen delen. Ik ben enorm trots dat wij peetouders 
mochten zijn van jullie twee zoons. Lieve Gijs, jij bent altijd in mijn hart.
Tenslotte wil ik Bastiaan bedanken, na al die jaren ben je me nog steeds niet zat. Jouw 
nuchtere kijk op de zaken hebben me vaak geholpen problemen in het onderzoek te rela-
tiveren. Op jouw liefde kon ik altijd rekenen en ik hoop dat we samen een mooie toekomst 
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